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Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models contain 
specific expressions for processes on the causal path between drug administration and 
response. These models include expressions to describe a) blood pharmacokinetics in 
blood or plasma, b) biophase distribution, c) kinetics or target binding, d) transduction 
and e) homeostatic feedback mechanisms. 
Previously, the PK-PD correlations of the high efficacy μ-opioid receptor agonists 
alfentanil, fentanyl and sufentanil have been investigated using quantitative EEG 
parameters as pharmacodynamic endpoint. In these investigations, the hysteresis 
observed for fentanyl and sufentanil was described with an effect-compartment 
model. Furthermore, by simulation it was shown that, in mechanistic terms, the in vivo 
concentration-effect relationships could be explained on the basis of the operational 
model of agonism, under the assumption of considerable receptor reserve. A limitation 
of this analysis was however, that all investigated opioids behaved as full agonists. 
Moreover, complexities at the level of blood-brain barrier (BBB) distribution had not 
been taken into account.
The main focus of the research in this thesis is on mechanism-based PK-PD modelling 
of the EEG effects of opioids with special emphasis on 1) the biophase distribution 
kinetics, which is mainly determined by BBB transport, and 2) interaction with the 
μ-opioid receptor in the brain as determinants of the time course of the pharmacological 
effect. To this end, a wide range of opioids with different binding characteristics and 
intrinsic activities should be investigated. The impact of biophase distribution should 
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The objective of pharmacokinetic-pharmacodynamic (PK-PD) modelling is the 
characterisation and prediction of the time course of drug effects in vivo under 
physiological and pathological conditions (Breimer & Danhof 1997). 
1.1  Classical/empirical approach
Classical PK-PD models consist of three components: (1) a pharmacokinetic 
model describing the time-course of drug concentration in blood or plasma, (2) a 
pharmacodynamic model describing the relation between the observed effect and the 
(predicted) drug concentration and (3) a link model to account for the often observed 
delay between blood/plasma concentration and effect.
1.1.1 Pharmacokinetic models
In PK-PD modelling, compartmental models are most commonly used to describe 
the time course of the drug concentration in blood/plasma. In these models 
drug disposition is characterised as the transfer of drug between interconnected 
hypothetical compartments, which serves to mimic the drug absorption, distribution 
and elimination processes. A limitation of this approach is that, although useful for 
descriptive purposes, it is not truly mechanistic. As a result, it is of limited value for 
extrapolation and prediction (i.e. interspecies scaling). 
1.1.2 Pharmacodynamic models
Pharmacodynamic models describe the relationship between blood or plasma 
concentration and effect. The most general pharmacodynamic model is the sigmoid 
Emax model. This model is mathematically expressed by the Hill equation (Hill 1910) 
according to:
in which E0 is the no-drug response (baseline), α is the maximum response (intrinsic 
activity), EC50 is the concentration at which 50% of the maximum effect is reached 
(potency) and nH is a factor expressing the slope of the sigmoid relationship. A limitation 
of the Hill equation is that it is not a mechanistic model. Specifically, the model does not 
provide insight in the factors which determine the shape and the location of the drug 
concentration-effect relationship. In this respect, it is important that drug concentration-
effect relationships are determined by a combination of drug-specific properties (affinity 
and intrinsic efficacy) and biological system-specific characteristics such as receptor 
density and the efficiency of receptor-effector coupling (van der Graaf & Danhof 1997), 
as is illustrated in figure 1. An important factor is that the system-specific properties 




processes like disease, age, chronic treatment and by other drugs. This may explain 
differences in drug-concentration-effect relationships between biological systems (i.e. 
species) and individuals (inter-individual variability). Moreover, the parameters of the 
sigmoid Emax model are “mixed” parameters; potency of a drug is determined by both 
affinity and efficacy and the intrinsic activity is a function of both compound (intrinsic 
efficacy) and system (receptor density and signal transduction) characteristics. This 
complicates the prediction of in vivo drug concentration-effect relationships on the 
basis of information from in vitro bio-assays.
1.1.3 Link models
For many drugs the relationship between blood/plasma concentration and 
pharmacological effect is not direct. Often a delay in pharmacological effect (hysteresis) 
is observed, which can be caused by time dependencies at the level of a) pharmacokinetics 
and b) pharmacodynamics. To account for delays between drug concentration and 
response, Segre introduced the concept of a “hypothetical effect compartment” (Segre 
1968). Sheiner and co-workers were the first to formalize this concept into a model to 
describe hysteresis caused by distribution to the biophase (Holford & Sheiner 1982; 
Sheiner et al. 1979). With the effect compartment model the assumption is made that the 
rate of onset and offset of the drug effect is governed by the rate of drug distribution 
to the hypothetical “effect-site” (Sheiner et al. 1979). This effect-compartment is then 
linked to the blood concentrations with the rate constant k1e for transport to the effect-
site and the rate constant for drug loss keo. The effect-site distribution is considered to 
be symmetrical under the assumption that in equilibrium the effect-site concentration 
equals the blood concentration, where k1e is equal to keo. 
1.2 New approach – distinction between determinants of in vivo effects
At present there is a clear trend towards the development and application of mechanism-
Figure 1: The pharmacodynamics of a drug (potency, intrinsic activity and Hill factor) are dependent on both drug 
(affinity	and	intrinsic	efficacy)	and	system-related	properties.	These	system	related	properties	can	be	influenced	




based PK-PD models. Mechanism-based PK-PD models differ from the classical 
empirical descriptive models in that they contain specific expressions to characterise 
the processes on the causal path between drug administration and effect. These 
models should contain expressions for a) blood/plasma pharmacokinetics, b) biophase 
distribution c) kinetics of target binding, d) transduction and e) homeostatic feedback 
mechanisms (Danhof et al.  2005). A schematic diagram of drug action in vivo with the 
major determinants is shown in figure 2.
1.2.1 Blood/plasma pharmacokinetics
To improve the prediction of pharmacokinetics, especially with regard to the 
extrapolation between species and the understanding of inter-individual variability, 
the concept of physiologically-based pharmacokinetic (PBPK) modelling has been 
proposed (Rowland et al. 2004). PBPK models are based on physiological principles and 
typically contain specific expressions for physiological variables such as blood flow 
to specific organs, binding to plasma proteins and/or tissue components and liver 
enzyme activity.
1.2.2 Biophase distribution
The concentration at the site of action (the biophase) is an important determinant of the 
drug effect in vivo. For drugs acting at extracellular targets, physicochemical properties 
(e.g. molecular size) and binding to plasma proteins and other blood constituents can 
restrict distribution to the biophase. Moreover, for drugs acting at intracellular targets 
and at targets in tissues that are protected by specific barriers (e.g. the brain), the 
distribution into the biophase can be influenced by the functionality of transporters. 
At present, these mechanisms are usually not taken into consideration when modelling 
biophase distribution kinetics. Yet, this is important since complexities at the level 
of biophase distribution may affect the derived shape of the concentration-effect 
relationship (Mandema et al. 1991; Visser et al. 2002b). Moreover, it may complicate the 
in vitro to in vivo extrapolation of parameters characterising the binding affinity of a 
drug to a specific target (Zuideveld et al. 2004). Another important consideration in 
relation to biophase distribution is whether it is indeed the free drug concentration 
Figure 2: Schematic diagram of drug action in 
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that drives the intensity of the pharmacological response. For a number of drugs (i.e. 
benzodiazepines, synthetic opioids) this seems to be the case (Cox et al. 1998; Mandema 
et al. 1991). However, there is still limited experimental evidence that the “free drug 
hypothesis” is valid under all circumstances. Particularly for drugs with a high affinity 
to their biological target and for drugs, which are transported by active transport 
mechanisms to the site of action, the biophase distribution may be non-restrictive.
In general, biophase distribution is dependent on both perfusion and distribution 
processes. Distribution processes include 1) passive diffusion and 2) transporter-
mediated transport. Passive membrane diffusion is dependent on filtration (paracellular 
transport) and diffusion (transcellular transport), which can both be influenced by 
binding of the compound to proteins or other blood constituents.  The main focus of 
this thesis is on the mechanisms of biophase distribution and this will be discussed in 
a separate section.
1.2.3 Kinetics of target binding
At the effect-site in the brain, the relationship between the concentration and 
the pharmacological effect is dependent on target interaction kinetics and signal 
transduction. Typically, when analysing concentration-effect relationships of a range 
of compounds in a given biological system, a single unique transducer function 
determines the effect and observed differences in concentration-effect relations are 
related to differences in receptor interaction kinetics in terms of target affinity and 
intrinsic efficacy. 
In recent years, there has been considerable interest in the incorporation of receptor 
theory in PK-PD modelling for the prediction of in vivo concentration-effect relationships 
(van der Graaf & Danhof 1997). This is important since this enables a separation between 
drug-specific and biological-specific properties as determinants of the concentration-
effect relationships. Modern receptor theory is based on the concept of the occupancy 
theory as first proposed by Clark (1937). This theory was further refined to describe 
the effects of partial agonists (Ariens 1954; Stephenson 1956) and receptor reserve 
(Furchgott 1966). Black and Leff have proposed the operational model of agonism to 
describe the relationship between drug concentration, receptor interaction and response 
(Black & Leff 1983). This model consists of two hyperbolic functions to describe the 
concentration-receptor occupancy and the receptor occupancy-response relationship, 
respectively, according to:
where Em is the maximum effect achievable in the system, KA is the agonist dissociation 
equilibrium constant, n is the slope index for the occupancy-effect relationship and τ is 




where R0 is the total number of available receptors and KE is the concentration of the 
drug-receptor complex required to produce half-maximal effect. The drug-specific 
properties, the intrinsic activity (α) and the potency (EC50) can than be derived with the 
following equations:
Recently, the principles of receptor theory have been successfully applied in the PK-
PD analysis of neuroactive steroids (Visser et al. 2002a), benzodiazepines (Tuk et al. 
1999; 2003; Visser et al. 2001), adenosine A1 receptor agonists (van der Graaf et al. 1997) 
and 5-HT1A receptor agonists (Zuideveld et al. 2004). PK-PD analysis on the basis of the 
operational model of agonism of the concentration-effect relationships of adenosine A1 
receptor agonists (van der Graaf et al. 1997) and 5-HT1A receptor agonists (Zuideveld et 
al. 2004) have shown that a distinction can be made between drug-related and system-
related parameters. For the adenosine A1 receptor agonists a good correlation was 
found between the in vivo pKA and the in vitro pKi and between the in vivo efficacy 
parameter τ and the in vitro GTP shift. In contrast, for the 5-HT1A receptor agonists a 
poor correlation was found between the in vivo pKA and the in vitro pKi, whereas a good 
correlation was found between in vivo efficacy parameter τ and the in vitro GTP shift. 
This poor correlation between in vivo pKA and in vitro pKi could in part be explained by 
differences in blood-brain distribution of the 5-HT1A receptor agonists.
1.2.4 Signal transduction
Within the context of PK-PD modelling, transduction is defined as the cascade of 
processes that govern the time course of the pharmacological response in vivo following 
drug-induced target activation.
In addition to biophase distribution, time-dependent processes like the synthesis or 
degradation rate of an endogenous compound can explain hysteresis. To link this time 
delay between blood/plasma concentration and effect, a family of four physiological 
indirect response models have been proposed (Dayneka et al. 1993), which are based on 
the following differential equation:







in time, kin is the zero-order rate constant for production of the physiological entity 
and kout is the first-order rate constant for its loss. These models have been applied to 
describe the time-courses of a wide array of different drugs (Jusko & Ko 1994), although 
these models are often not properly validated. 
A recent development has been the incorporation of dynamic system analysis to 
describe complex in vivo transduction processes (Zuideveld et al. 2001; 2004). 
1.2.5 Homeostatic feedback mechanisms
The time course of the pharmacological response is often influenced by in vivo 
homeostatic feedback mechanisms, which may be operative. Such mechanisms may 
explain observations such as complex pharmacological effect vs time profiles. Recently, 
a model has been developed to describe the complex effect vs time profiles of the 
hypothermic response following the administration of 5-HT1A receptor agonists to rats 
(Zuideveld et al. 2001; 2004). This model describes the hypothermic effect based on the 
concept of a set-point and general physiological response model.
2. BIOPHASE DISTRIBUTION OF CNS DRUGS
CNS active drugs have to pass the blood-brain barrier (BBB) to reach their target in the 
brain to be able to exert their pharmacological effect. This often results in biophase 
kinetics which are substantially different from plasma pharmacokinetics since BBB 
transport and brain distribution is often neither instantaneous nor complete (Welty 
et al. 1993).
2.1 Blood-brain barrier
2.1.1 Blood-brain barrier morphology
The BBB is situated at the interface between blood and brain and its main functions 
are (1) to maintain homeostasis in the brain (Abbott & Romero 1996), (2) selective 
transport of essential compounds like amino acids and glucose and (3) metabolism 
and modification of substances before entering the brain, for example proteins and 
peptides (de Boer & Breimer 1992). The BBB is primarily formed by brain capillary 
endothelial cells (BCEC) (de Boer & Breimer 1992; Rubin & Staddon 1999), although 
cells like astrocytes, pericytes and neuronal cells also play an important role in the 
function of the BBB (Pardridge 1991). The BCECs are distinctly different from peripheral 
endothelial cells in functional and morphological aspects (Bradbury 1993; de Boer et 
al. 2003). The most specific feature is the presence of tight junctions which prevents 
paracellular transport of hydrophilic compounds (Brightman & Reese 1969). Moreover, 
the BCECs express numerous influx and efflux transporters (de Boer et al. 2003; Golden 




Transport across the BBB can be divided into passive and active transport processes (de 
Lange & Danhof 2002). Passive transport of compounds across the BBB is dependent on 
physicochemical properties, such as lipophilicity, degree of ionisation and number of 
hydrogen bonds (van Bree et al. 1988). Passive transport (diffusion) across the BBB can 
either be permeability-limited or cerebral blood flow limited. Permeability-limited BBB 
transport is applicable for the more hydrophilic drugs that depend on the paracellular 
route for exchange between blood and brain. This route is restricted by the above-
mentioned presence of tight junctions. Lipophilic, small and non-charged drugs more 
easily diffuse via the transcellular route and in such case blood-flow will mainly 
determine the transport rate. Active transport can be divided into carrier mediated 
transport, receptor mediated transport and endocytosis (de Boer et al. 2003). A schematic 
diagram of the transport processes across the BBB is shown in figure 3.
2.1.3 P-Glycoprotein
An important efflux transporter expressed at the luminal face of the BBB is P-glycoprotein 
(Pgp) (Cordon-Cardo et al. 1989). Pgp is a member of the adenosine triphosphate-binding 
cassette (ABC) super family and is encoded by the multidrug resistance gene (MDR1) 
(Thiebaut et al. 1987). Pgp is a 170 kDa glycosylated membrane protein that consists of 
an integral membrane protein with twelve putative transmembrane α-helical domains 
and an energy-coupling domain localized at the cytoplasmatic side of the membrane 
(Fath & Kolter 1993; Pigeon & Silver 1994). The proposed function of Pgp is mainly to 
protect the brain from exogenous toxins, to excrete metabolites and furthermore to 
transport hormones from the brain to the periphery (Borst & Schinkel 1996; Karssen 
et al. 2001). The use of in vitro cell systems comprising of MDCK or LLC-PK1 cells 
transfected with the human MDR1 gene and MDR1a(-/-) (Pgp knock-out) mice (Schinkel 
et al. 1994) has clarified the impact of this efflux transporter on brain concentrations of 
many drugs including dexamethasone, domperidone, indinavir, digoxin, vinblastine, 
sparfloxacin, amitryptyline and cyclosporin (de Lange et al. 2000; de Lange & Danhof 
Figure 3:	Schematic	diagram	of	substrate	flux	through	the	BBB,	indicating	factors	and	processes	that	determine	
net	brain	uptake.	Uptake	and	efflux	transporters	are	illustrated	on	the	luminal	membrane	of	the	endothelial	cells	
for illustrative purposes only (Golden and Pollack, 2003)
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2002; Kim et al. 1998; Meijer et al. 1998; Schinkel et al. 1995; Schinkel et al. 1996; Uhr et 
al. 2000; van der Sandt et al. 2001b). Alternatively, co-administration of Pgp inhibitors 
such as GF120918 (Hyafil et al. 1993) and SDZ-PSC 833 (Desrayaud et al. 1998; Mayer 
et al. 1997) can change drug distribution into the brain. For example, for the 5-HT1A 
receptor agonist flesinoxan it was shown that a 5 to 6 fold increase in Cmax and AUC was 
observed in brain pharmacokinetics when co-infused with the Pgp inhibitor SDZ-PSC 
833 (van der Sandt et al. 2001a).
2.2 Distribution processes within the brain
The brain cannot be considered a homogeneous tissue, because it is composed of many 
anatomical structures with different characteristics (Collins & Dedrick 1983; Gross et 
al. 1986). In general, the main compartments are the brain extracellular fluid (ECF), the 
intracellular space (ICS) and the brain cerebrospinal fluid (CSF). After passage of the 
BBB, a drug enters the brain ECF and may thereafter distribute into brain ICS and the 
CSF (de Lange & Danhof 2002; Walker et al. 2000; Wong et al. 1993). Brain intracellular 
distribution is, in general, quantitatively more profound for the more lipophilic drugs 
and as a consequence the brain ECF concentrations will be relatively lower. 
The interplay between the kinetics of BBB transport and intracellular distribution 
determines the time to equilibrium between plasma and biophase kinetics (Liu et al. 
2005). With regard to the brain ECF concentrations, active transport out of the brain 
decreases whereas brain tissue binding increases the time to equilibrium. It should 
be noted that other than BBB transport, active transporters may also play a role in 
the intracellular distribution in the brain as indicated by localisation and functional 
expression of Pgp and MRP in the brain parenchyma (Lee et al. 2001).
2.3 Intracerebral microdialysis
Intracerebral microdialysis is very valuable technique for characeterisation of brain 
distribution kinetics, since it allows the determination of the free drug in the ECF as 
a function of time. It involves the implantation of a microdialysis probe into tissue, 
for example a specific region of the brain. The probe, consisting of a hollow tube and 
a semi-permeable membrane, is constantly perfused with a physiological solution. 
During perfusion, compounds that are small enough to traverse the membrane will 
diffuse from higher to lower concentration into the dialysate (Benveniste & Huttemeier 
1990; de Lange et al. 1999a). 
An important aspect of microdialysis is the recovery of the microdialysis probe. The 
dialysate concentrations do not equal the real ECF concentrations, because of the 
existence of a constant flow of the perfusion fluid. At early stages of microdialysis 
research, the in vitro recovery was used to calculate the ECF concentrations. However, 
in vivo, several tissue processes influence the recovery (Bungay et al. 1990) and therefore 
in vivo recovery methods have been developed including retrodialysis, no-net-flux and 
the dynamic-no-net-flux (Bouw & Hammarlund-Udenaes 1998; de Lange et al. 1997; 
1999a; 1999b; 2000; Olson & Justice, Jr. 1993). Many CNS active drugs have their target 
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at extracellular recognition sites and therefore the ECF concentrations are most closely 
related to the biophase concentrations.
3.  BRAIN AND BIOPHASE DISTRIBUTION MODELS
For PK-PD modelling, often only blood/plasma and effect data are available. In this 
case, a hypothetical effect-compartment is commonly applied to describe the biophase 
distribution kinetics. Recently, important progress has been made with the development 
of the technique of intracerebral microdialysis. It has been demonstrated that the 
mechanisms of brain distribution kinetics can be investigated in detail in vivo using 
this technique. It is proposed that this may provide novel insights in the mechanisms 
of the biophase distribution kinetics of CNS active drugs. 
3.1. Brain distribution models
Recently, pharmacokinetic models have been developed that allow integrated 
analysis of microdialysis data which means that recovery calculations are included 
into the models (Schaddelee et al. 2004; Tunblad et al. 2004). In addition, population 
pharmacokinetic modelling of the microdialysis data has provided insight into the BBB 
transport characteristics of several drugs. These drugs include adenosine A1 receptor 
agonists (Schaddelee et al. 2004), gabapentin (Wang & Welty 1996), norfloxacin (Chenel 
et al. 2004), fluvoxamine (Geldof et al. 2007) and opioids, which will be discussed in a 
separate section. 
3.1.1 Application to adenosine A1 receptor agonists
Schaddelee and co-workers have proposed a population pharmacokinetic model for 
estimation of the brain distribution clearance of the synthetic adenosine A1 receptor 
agonists, 2’dCPA and MCPA. The model consisted of three compartments for description 
of the time course of the concentration in blood in combination with three compartments 
for the brain ECF concentrations (figure 4). 
The mass balance in the brain compartments is described with the following differential 
equations:
Where A1 represents the amount in the central blood compartment, A4 – A6 represent 






transport rate constants from compartment m to compartment n. The rate constants 
were related to the inter-compartmental clearances (Q) and compartment volume (V) 
according to the following equations:
Low distribution clearances into the brain (Q4) were found, 1.6 ± 0.3 μl/min and 1.9 ± 
0.4 μl/min for 2’dCPA and MCPA, respectively, which were consistent with the results 
from in vitro tests. Furthermore, a slow elimination from the brain compartment was 
observed, indicating that the duration of the CNS effect might be much longer than 
expected on the basis of the terminal half-life in blood.
3.1.2 Application to the 5-HT1A receptor agonist fluvoxamine
The pharmacokinetics of the 5-HT1A receptor agonist fluvoxamine, were described by 
simultaneous analysis of plasma, brain ECF and total brain concentrations on the basis 
of a more physiologically-based pharmacokinetic model. A three compartment model 
was used to describe the pharmacokinetics in plasma. The brain model to describe both 
brain ECF and total brain concentrations considers the brain to be composed of two 
areas (figure 5) and was based on the models proposed by Upton and co-workers (2000). 
The first area is the perfusion compartment, considered to be in direct contact with the 
blood flow and in which mass exchange is perfusion limited (shallow perfusion-limited 
compartment). The second area is the diffusion limited brain ECF compartment (deep 
brain compartment) in which the concentration is equal to the measured fluvoxamine 
ECF concentration. This compartment is poorly perfused and distribution is diffusion 
(10)
(11)
Figure 4: The population pharmacokinetic model for synthetic adenosine A1 receptor agonists as proposed 
by Schaddelee and co-workers (2003). The model consists of three compartments to describe the blood 
pharmacokinetics (grey) and three compartments to describe the brain pharmacokinetics (black). Abbreviations: 
V= volume of distribution, Q = intercompartmental clearance and CL = body clearance.
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limited. Fluvoxamine is not able to enter this compartment directly by perfusion, but 
only indirectly from the shallow perfusion-limited compartment by diffusion or active 
transport processes.
In this model, the BBB is located between the perfusion and ECF compartment. The mass 
balance in the brain is determined by both the perfusion and the ECF compartment 
according to the following equations:
where ASP is the amount of morphine in the shallow perfusion-limited compartment, 
QB is the effective blood perfusion rate, Cin is the concentration entering the perfusion 
compartment en Cout is the concentration leaving the perfusion compartment. NSP-DB 
is the net mass exchange between the shallow perfusion-limited and the deep brain 
compartment and ADB is the amount of fluvoxamine in the deep brain compartment and 
can include both passive and active transport processes. In case of fluvoxamine, mass 
exchange between the perfusion and ECF compartment consisted of passive diffusion 
and an active saturable efflux process, resulting in the following relation:
in which kdiff is the diffusion rate constant between the shallow perfusion-limited and 








described	by	a	passive	diffusion	term	and	an	active	saturable	efflux	process.	Abbreviations:	kin is the rate constant 
into the shallow perfusion compartment, kout is the rate constant out of shallow perfusion compartment; kdiff is the 
diffusion rate constant between the shallow perfusion-limited and the deep brain compartment; Nmax	is	the	maximal	




is the maximal active removal flux and C50 is the fluvoxamine concentration in the deep 
brain compartment at which 50% of saturation of the active removal flux is reached. 
Under the assumption that rapid equilibrium between fluvoxamine concentrations 
in the shallow perfusion-limited and the deep brain compartment is reached, the 
relationship between both compartments can be described as follows:
The total amount of fluvoxamine in the brain can be described by:
in which AT represents the total amount of fluvoxamine in the brain. The concentration 
entering the perfusion compartment (Cin) is assumed to be equal to the plasma 
concentration (Cplasma), whereas the concentration leaving the perfusion compartment 
is determined by the partition coefficient (P) between fluvoxamine in blood and the 
concentration in the shallow perfusion-limited compartment (CSP).
When aggregating the perfusion rates, partition coefficient and brain distribution 
volume to the rate constants kin and kout, the differential equation for the total fluvoxamine 
in the brain can be described by:
in which CT is the total fluvoxamine concentration in the brain. The relationships 
between the total brain concentrations and both compartments could be derived on the 
basis of the partition coefficients for the shallow perfusion-limited and the deep brain 
compartment.
It was shown that the proposed model could accurately describe the plasma and brain 
pharmacokinetics of fluvoxamine. Active saturable efflux could be identified, although 
it remains unclear what transporter at the BBB is involved in the active efflux of 
fluvoxamine. 
3.2 Biophase distribution models
In PK-PD investigations, the biophase distribution kinetics is often described by a 1-
compartment biophase distribution model, also known as the effect-compartment 
model. With the effect compartment model, the assumption is made that the rate of 
onset and offset of the drug effect is governed by the rate of drug distribution to the 
hypothetical “effect-site” (Sheiner et al. 1979). This effect-compartment is then linked to 
the blood/plasma concentrations with the rate constant for transport to the biophase k1e 
and the rate constant for drug loss keo. The rate of change of the drug concentration in 






Where Cb represents the blood/plasma concentration and Ce represents the effect-site 
concentration. Under the assumption that in equilibrium the effect-site concentration 
equals the blood/plasma concentration, this equation can be simplified to:
However, more complex biophase distribution models have also been proposed. For 
example, for the neuroactive steroid alphaxolone the value of keo was concentration 
dependent (Visser et al. 2002b). In addition, Mandema and co-workers have reported 
two equilibration rate constants for the EEG effects of heptabarbital and have shown 
that the equilibration kinetics of amobarbital were best described with a bi-exponential 
equilibration function instead of a simple first-order mono-exponential equilibration 
model (Mandema & Danhof 1990; Mandema et al. 1991).
Recently, Chenel and co-workers have simultaneously investigated central nervous 
system distribution and the PK-PD relationship of the EEG effects of norfloxacin (2004). 
For this purpose, the combined EEG/microdialysis technique has been used. It was 
shown that the extensive time delay between EEG effect and plasma concentration of 
norfloxacin could be best described with an effect compartment model. However, this 
delay could not be accounted for by restricted BBB transport. Presumably, the drug 
concentration in brain ECF is not representative for the effect-site concentration of 
norfloxacin. In contrast, for morphine 80% and for morphine-6-glucuronide 50% of the 
delay in anti-nociceptive effect could be explained by restricted transport across the 
BBB (Bouw et al. 2000; 2001).
4. PHARMACOKINETIC-PHARMACODYNAMIC MODELLING OF OPIOIDS
4.1 Biophase distribution kinetics of opioids
For the analysis of the PK-PD correlations of opioids, modelling of complex biophase 
distribution kinetics is important, given the (potential) interaction with active 
transporters and the wide range in lipophilicity. In previous investigations, morphine 
and loperamide have been identified as Pgp substrates in two in vitro models, comprising 
of either BCECs or LLC-PK1:MDR1 cells, and in in vivo models, in rats and mice 
(Henthorn et al. 1999; Letrent et al. 1998; 1999a; 1999b; Mahar Doan et al. 2002; Schinkel 
et al. 1995; 1996). Alfentanil and sufentanil were not identified as Pgp substrates within 
the abovementioned investigations in in vitro models, whereas inconsistencies have 





brain perfusion studies have indicated a minimal contribution of Pgp mediated efflux 
as it was found that the brain uptake of fentanyl was only marginally increased (1.2 
fold) in MDR1a (-/-) mice when compared to MDR1a (+/+) mice (Dagenais et al. 2004). 
Nalbuphine, a semi-synthetic opioid analgesic, was also found to be a Pgp substrate in 
an MDCKII-MDR1 cell-system (Mahar Doan et al. 2002).
The BBB transport characteristics of morphine and its metabolites have been studied in 
great detail using intracerebral microdialysis (Bouw et al. 2000; 2001; Xie et al. 2000). The 
brain pharmacokinetics of morphine, morphine-3-glucuronide (M3G) and morphine-
6-glucuronide (M6G) were best described with a two compartment brain distribution 
model. The half-life of morphine in the brain was 44 ± 11 minutes for a dose of 10 mg/kg 
and was dependent on dose. For M3G and M6G the half-life in the brain was around 70 
and 60 minutes, respectively. The brain-to-plasma concentration ratios were 0.28, 0.11 
and 0.27 for morphine, M3G and M6G, respectively. All ratios are below 1 indicating 
that these compounds are actively removed at the BBB. Furthermore, PK-PD studies in 
rats have revealed that after oral pre-treatment with the specific Pgp inhibitor GF120918, 
the anti-nociceptive effect of morphine was prolonged due to its prolonged half-life in 
the brain (Letrent et al. 1998; 1999a). Tunblad and co-workers investigated the influence 
of probenecid on the BBB transport of morphine and found that in the presence of 
probenecid the steady state brain-to-plasma ratio was increased from 0.29 to 0.39 and 
that the morphine half-life in the brain increased from 58 to 115 min (2004). In addition, 
probenecid also decreased the systemic clearance of morphine and decreased the 
formation of M3G. M3G is also identified as a substrate for the probenecid-sensitive 
transporters (Xie et al. 2000). 
In contrast, intracerebral microdialysis studies with the highly lipophilic opioid codeine 
have shown that a distributional equilibrium is reached rapidly with equal unbound 
concentrations in blood and brain and without dose dependency (Xie & Hammarlund-
Udenaes 1998).
4.2 EEG as a biomarker for opioid receptor activation
Detailed characterisation of the role of biophase distribution kinetics in PK-PD 
investigations requires the availability of high density pharmacodynamic data. In this 
respect, quantitative analysis of drug effects on the electroencephalogram (EEG) yields 
attractive biomarkers, which are continuous, sensitive and reproducible (Dingemanse 
et al. 1988). Another advantage is that EEG effect measurements can be obtained in 
both laboratory animals and humans which enables interspecies extrapolation of the 
pharmacodynamics. On the basis of spectral analysis, the EEG can be subdivided into 
five distinct frequency bands: delta (0.5-4.5 Hz), theta (3.5-8 Hz), alpha (8-12 Hz), beta 
(12-30 Hz) and gamma (30->70 Hz) (Faulkner et al. 1999). Frequencies ranging from below 
1 Hz up to around 12 Hz (delta – alpha bands) are readily observable in recordings from 
subjects during sleep, sedation or relaxed wakefulness. Higher frequencies from 12 Hz 
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to >70 Hz (beta – gamma bands) can also be seen, but at much lower amplitudes during 
intense mental activity and following sensory stimulation (Visser 2003).
Quantitative EEG parameters have been widely used as a pharmacodynamic endpoint 
in pre-clinical and clinical investigations on the PK-PD correlations of a variety of CNS 
active drugs. This includes barbiturates (Ebling et al. 1991), benzodiazepines (Mandema, 
et al. 1991a; 1991b; 1992b), neurosteroids (Visser et al. 2002a) and baclofen (Mandema et al. 
1992a). It has also been shown that the synthetic opioid alfentanil, which is frequently 
used in anesthesia, produces a progressive slowing of the EEG with a pre-dominant 
increase in the delta frequency band (0.5-4.5 Hz) of the EEG power spectrum in both 
animals (Cox et al. 1997; Mandema & Wada 1995; Wauquier et al. 1988; Young & Khazan 
1984) and humans (Scott et al. 1985; Wauquier et al. 1984; Young & Khazan 1984). After 
administration of alfentanil the EEG profile changes from high-frequency and low-
amplitude to low-frequency and high-amplitude as is illustrated in figure 6.
4.3 Pharmacokinetic-pharmacodynamic modelling of the EEG effects of opioids
Previously, Cox and co-workers investigated the PK-PD correlations of the EEG 
effects of synthetic opioids alfentanil, fentanyl and sufentanil after intravenous 
administration in rats (1998). In these investigations, hysteresis was observed between 
the pharmacokinetics in blood and the pharmacodynamics for fentanyl and sufentanil 
whereas a direct correlation was observed for alfentanil. The hysteresis was described 
with the effect compartment model (equation 9), resulting in keo values of 0.32 min–1 
(t1/2,keo = 2.2 min) and 0.17 min-1 (t1/2,keo = 4.2 min) for fentanyl and sufentanil, respectively. 
The pharmacodynamics was described using the sigmoid Emax model (equation 1). The 
interaction at the opioid m receptor was determined in vitro on the basis of displacement 
of [3H]-naloxone binding in washed rat brain membranes. The value of the ‘sodium 
shift’, being the ratio between affinities in the presence and the absence of sodium 
Figure 6: Typical EEG changes in rats upon alfentanil administrations. After administration of alfentanil, a 




chloride, was used as a measure of in vitro efficacy. Combination with the in vitro receptor 
binding characteristics showed that the in vivo concentration-effect relationships could 
be explained by the operational model of agonism according to Black and Leff (equation 
2) under the assumption of a considerable receptor reserve (Cox et al. 1998). 
The operational model of agonism has subsequently been used to explain the functional 
adaptation observed upon repeated administration of the selective m-opioid receptor 
agonist, alfentanil. It was proposed that the ~2-fold decrease in potency observed 
following repeated administration of alfentanil can be explained by a ~40% decrease 
in the efficacy parameter of the operational model of agonism, t, which includes both 
receptor density and coupling efficiency (Cox et al. 1998).
Garrido and co-workers further investigated the concept of receptor reserve for 
the full m-opioid agonist, alfentanil, in vivo by pre-treatment with the irreversible m 
antagonist, β-funaltrexamine (β-FNA) (2000). After pre-treatment with β-FNA the in 
vivo concentration-effect relationship of alfentanil was steeper and shifted to higher 
concentrations. Analysis with the operational model of agonism revealed that the 
observed changes could be explained by a 70-80% reduction in the alfentanil efficacy. 
This was consistent with the 40-60% reduction in the number of μ-opioid binding sites 
in the brain, as determined in an in vitro binding assay.
However, so far only simulations have been performed to investigate the role of 
μ-opioid receptor interaction kinetics. A complication in this analysis was however, 
that all investigated opioids behaved as full agonists. 
5. CONCLUSIONS
In conclusion, to be able to develop a mechanism-based PK-PD model for opioids, a 
wide range of opioids should be investigated with different binding affinities and 
intrinsic activities. Moreover, potential complexities caused by interactions with specific 
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1.  GENERAL OBJECTIVES AND BACKGROUND 
The objective of the research described in this thesis was the development of a 
mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) model for the electro-
encephalogram (EEG) effects of opioids. The central effects of opioids are determined 
by four main processes: (1) blood/plasma pharmacokinetics, (2) biophase distribution, 
which is mainly determined by blood-brain barrier (BBB) transport, (3) receptor 
interaction kinetics and (4) signal transduction. Under the assumption that within a 
single species the signal transduction mechanisms are equal for all opioids, the focus of 
this thesis was to characterise the role of biophase distribution and receptor interaction 
kinetics on the pharmacokinetic-pharmacodynamic (PK-PD) relationships of opioids. 
In the investigations described in this thesis, a panel of opioids with a wide range 
of pharmacological and physicochemical properties was used. These drugs were 
specifically selected because of their (partial) agonistic properties at the μ-opioid 
receptor. The change in the delta frequency band (0.5-4.5 Hz) of the EEG was used 
as a pharmacodynamic endpoint because it is a sensitive and continuous measure 
of the central effects of opioids (Dingemanse et al. 1988). Previously, the EEG effects 
of the opioids alfentanil, fentanyl and sufentanil have been investigated. In these 
investigations, PK-PD analysis was performed with the effect compartment model, 
to account for hysteresis between the blood concentration and effect. This analysis 
showed that these opioids all behaved as high efficacy agonists albeit that differences 
in potency and hysteresis were observed (Cox et al. 1998). 
To identify a mechanism-based PK-PD model, morphine, nalbuphine and butorphanol 
were included as model drugs. Morphine is the classical agonist of the μ-opioid receptor 
(Dhawan et al. 1996) and its biophase distribution is known to be complex, because of 
the interaction with the efflux transporters at the BBB, such as P-glycoprotein (Pgp) 
at the BBB (Henthorn et al. 1999; Letrent et al. 1998; 1999a;. 1999b; Mahar Doan et al. 
2002; Schinkel et al. 1995; 1996). Nalbuphine and butorphanol are structurally related 
to morphine and have previously been identified as partial agonists in vivo (Emmerson 
et al. 1996). Nalbuphine was identified as a Pgp substrate in vitro (Mahar Doan et al., 
2002). So far little is known about the biophase distribution kinetics of nalbuphine and 
butorphanol.
2.  CHARACTERISATION OF THE ROLE OF BIOPHASE DISTRIBUTION
The main objective of the research described in section 2 was the characterisation of 
the role of biophase distribution in the PK-PD relationships of the selected opioids. 
Restricted transport across the BBB can be a critical factor in the PK-PD relationships of 
opioids. Apart from restricted paracellular diffusion by the presence of tight junctions 
between the endothelial cells of the BBB, active transport mechanisms may play an 
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important role, especially for Pgp-mediated efflux. 
For the investigation of the PK-PD relationships of morphine, butorphanol and 
nalbuphine and the characterisation of BBB transport of morphine, first a sensitive HPLC 
method was developed to analyse blood and brain microdialysate concentrations. The 
method consisted of a liquid-liquid extraction with ethyl acetate of the blood samples 
followed by injection on an HPLC system coupled to electrochemical detection. The 
development and validation of this method is discussed in chapter 3. The microdialysate 
samples were injected without sample pre-treatment. The sample pre-treatment of 
blood samples was dependent on the compound. For morphine, an alkaline extraction 
was sufficient whereas for nalbuphine and butorphanol both and acidic and alkaline 
extraction were required. The mobile phase was a mixture of 0.1 M sodium phosphate 
buffer, methanol and octane-sulfonic acid with ratio and pH depending on compound 
and matrix. The limits of quantification in blood samples were 25, 50 and 25 ng/mL for 
nalbuphine, butorphanol and morphine, respectively and 0.5 ng/mL for morphine in 
microdialysate samples. Based on sample volume, sensitivity and reproducibility, these 
assays proved to be suitable for PK-PD studies.
Next, the membrane transport characteristics of opioids were investigated in vitro. 
The focus was on the relative contribution of passive permeability and Pgp-mediated 
efflux. The studies were conducted in an in vitro cell system using monolayers of either 
the MDCK:MDR1 cells, which were transfected with the MDR1 gene encoding for 
human P-glycoprotein (Pgp), or LLC-PK1:MDR1a cells, which were transfected with 
the MDR1a gene encoding for rodent Pgp (chapter 4). The interaction of the opioids 
with Pgp was determined a) indirectly by investigating the inhibition of Pgp-mediated 
efflux of 3H-digoxin and b) directly by a substrate assessment study. In the latter study, 
the transport of opioids in the presence and absence of the potent and specific Pgp 
inhibitor GF120918 (Hyafil et al. 1993) was determined. The passive permeability, 
as reflected by the Papp, of the different opioids was determined in the presence of 
GF120918. In addition, regression analysis was performed to investigate the relationships 
between the physico-chemical properties and the Papp values. These studies have 
shown that the influence of Pgp on membrane transport is highly dependent on the 
passive permeability. Alfentanil, fentanyl and sufentanil have affinity for Pgp but the 
contribution of Pgp mediated transport to the overall transport rate is minimal because 
of the high passive permeability rates (>500 nm/sec). In contrast, Pgp has a significant 
influence on the transport of morphine, presumably because the passive permeability 
is very low (16 nm/sec).
For morphine, the role of biophase distribution kinetics in the PK-PD correlation 
was investigated using a novel combined EEG/microdialysis technique that allows 
simultaneous characterisation of both the brain extracellular fluid (ECF) concentration 
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and the EEG effect. In these investigations a wide dose range was investigated (4 to 40 
mg/kg). The influence of Pgp was investigated by co-infusion of GF120918.
In chapter 5, the relative contributions of passive and active transport mechanisms 
of morphine across the BBB in vivo were determined in a quantitative manner upon 
intravenous administration of two distinct doses of morphine, 4 and 40 mg/kg. Complex 
brain distribution kinetics was observed in these investigations. Specifically, analysis 
of the brain microdialysate concentrations showed non-linear distribution kinetics in 
brain ECF with increasing dose and a distinct effect of Pgp inhibition by GF120918. To 
describe the complex brain distribution kinetics, a one compartment brain distribution 
model was developed, with separate expressions for passive diffusion, active saturable 
influx and active efflux. This active efflux component could be partly reduced by co-
infusion with GF120918. 
 
The focus of chapter 6 was on the influence of biophase distribution and Pgp interaction 
on the EEG effects of morphine and to compare the biophase distribution kinetics for the 
EEG with the kinetics of morphine distribution to the brain ECF. Profound hysteresis 
was observed between blood concentrations and EEG effect. To describe the biophase 
distribution kinetics of morphine, an extended-catenary biophase distribution model 
was proposed. This model consists of two sequential compartments (a transfer and 
an effect compartment) and two rate constants; the k1e which describes the transport 
through the transfer compartment and the keo, which describes the loss from the effect 
compartment. Co-infusion of GF120918 only influenced the keo and different values 
were found for k1e and keo. The observation that GF120918 affects the efflux of morphine 
is consistent with the observations on the distribution in brain ECF. The predicted 
morphine biophase concentration-time profiles, however were distinctly different from 
the brain ECF concentration-time profiles as estimated by intracerebral microdialysis.
3.  PHARMACOKINETIC-PHARMACODYNAMIC MODELLING OF THE 
EEG EFFECTS OF OPIOIDS
In section 3 the PK-PD relationships of the whole set of opioids were evaluated on the 
basis of model discrimination. For the biophase distribution kinetics, two different 
models were investigated for each opioid (chapter 7): (1) the one-compartment biophase 
distribution model and (2) the extended-catenary biophase distribution model as 
proposed for morphine in chapter 6. Both symmetrical and a-symmetrical transport 
to the biophase was investigated. It was shown that only morphine displays complex 
biophase distribution kinetics, since the biophase distribution of the other opioids 
were best described with the one-compartment distribution model. Interestingly, a 
statistically significant correlation was observed between the values of k1e and the in 
vitro passive permeability. It could be concluded that the relative contribution of passive 
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permeability and the interaction with transporters determines the complex biophase 
distribution of opioids.
In addition, the link between the in vivo concentration effect-relationships and the 
interaction at the μ-opioid receptor was investigated (chapter 8). The predicted 
biophase concentrations were used to analyse the concentration-effect relationships 
simultaneously with the empirical Emax model. Further analysis of the pharmacodynamic 
data was performed on the basis of the operational model of agonism as proposed by 
Black and Leff (1983) with the values of the system maximum Em (123 μV) and n (1.44) 
constrained to the values of alfentanil which displayed the highest intrinsic activity. 
Between the opioids, wide differences in both in vivo affinity and intrinsic efficacy were 
observed. When the estimated in vivo pKA values were correlated with the in vitro pKi 
values, indications for two distinct subpopulations were obtained. In addition, a poor 
correlation was observed between the in vitro Na/GTP-shift and the in vivo log τ. These 
observations might be explained by 1) the involvement of active transport processes in 
distribution from blood to brain, 2) the existence of μ-opioid receptor subtypes and 3) 
the interaction with other types of opioid receptors. 
4.  SUMMARY, CONCLUSIONS AND PERSPECTIVES
To conclude this thesis, in section 4 (chapter 9) the results of the separate studies are 
reviewed and discussed and perspectives for future research are presented.
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Chapter 3
HIGH-PERFORMANCE LIquID CHROMATOGRAPHY 
OF NALBuPHINE, BuTORPHANOL AND MORPHINE 
IN BLOOD AND BRAIN MICRODIALYSATE SAMPLES: 
APPLICATION TO PHARMACOKINETIC-




A rapid and sensitive assay for quantification of nalbuphine, butorphanol and morphine 
in blood (50μl) and brain microdialysate (~40μl) samples was developed. Blood samples 
were extracted with ethyl acetate. Analysis was performed with high performance 
liquid chromatography coupled to an electrochemical detector. The mobile phase was 
a mixture of 0.1M sodium phosphate buffer, methanol and octane-sulfonic acid with 
ratio and pH depending on compound and matrix. The limits of quantification in 
blood samples were 25, 50 and 25 ng/ml for nalbuphine, butorphanol and morphine, 
respectively and 0.5 ng/ml for morphine in microdialysate samples. Based on sample 
volume, sensitivity and reproducibility, these assays are particularly suitable for 
pharmacokinetic-pharmacodynamic studies in rodents.
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INTRODUCTION
Opioids are widely used in clinical anaesthesia, analgesia and treatment of drug abuse. 
For example, the natural opioid morphine, the semi-synthetic nalbuphine and the 
synthetic butorphanol are used in analgesia, whereas the synthetic opioids alfentanil, 
fentanyl, sufentanil and remifentanil have been developed for use in anaesthesia. 
However, optimal dosing for these drugs is difficult, due to the development of 
tolerance, risk of addiction and side effects like respiratory depression.
At present there is a considerable interest in the development of μ-opioid receptor partial 
agonists, since these compounds in theory have a much-improved selectivity of action. A 
mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) approach can provide 
insight into factors that determine pharmacodynamic behaviour of μ-opioid receptor 
agonists in vivo by distinction between drug and biological system characteristics (van 
der Graaf & Danhof 1997). Recently, the effects of the opioids alfentanil, fentanyl and 
sufentanil have been studied in vivo in a chronically instrumented rat model, using 
the amplitude in the 0.5-4.5 Hz frequency band of the electroencephalogram (EEG) 
as a pharmacodynamic endpoint (Cox et al. 1998). On the basis of mechanism-based 
PK-PD analysis, it was shown that these opioids all behave as full agonists in vivo. 
Subsequently, the model has been successfully applied to characterise the in vivo 
pharmacodynamic properties of the novel synthetic opioid remifentanil and its active 
metabolite GR90291 (Cox et al. 1999), showing that they also behave as full agonists at 
the μ-opioid receptor. Current research on the PK-PD correlations of opioids focuses on 
nalbuphine, butorphanol and morphine (figure 1). 
Nalbuphine and butorphanol were selected because they behave as partial agonists at 
the μ-opioid receptor (Cherny 1996; Emmerson et al. 1996; Garner et al. 1997; Pallasch & 
Gill 1985). An important feature of morphine is that blood-brain barrier (BBB) transport 
is a major determinant of its in vivo effect (Bouw et al. 2000). 
To be able to study the PK-PD correlations of nalbuphine, butorphanol and morphine 
in the rat EEG model a convenient, rapid and sensitive analytical assay should be 
developed for the analysis of concentrations in small blood samples. In addition, for 
morphine the free concentrations in brain microdialysate should be obtained to get 
insight into the BBB transport, but because of the small sample volume and the low 
concentrations a highly sensitive HPLC method is required (Benveniste & Huttemeier 
1990; Bouw et al. 2000; de Lange et al. 1999). 
Figure 1: Chemical structures of the opioids morphine (A), nalbuphine (B) and butorphanol (C)
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Several methods of analysis have been reported for nalbuphine, butorphanol and 
morphine. These methods include radio-immunoassay and HPLC combined with 
electrochemical, ultraviolet or fluorescence detection (Pittman et al. 1980; Willey 
et al. 1994). More recently, analysis methods with gas chromatography and liquid 
chromatography coupled to mass-spectrometric detection have been developed 
(Grinstead 1991; Kanazawa et al. 1998; Volk et al. 1996). These methods are exceptionally 
robust and sensitive, but the access to the instrumentation is often limited.
For the analysis of nalbuphine, the published reports focus on HPLC with electrochemical 
detection (Aitkenhead et al. 1988; Nicolle et al. 1995; 1997), but these methods require 
relatively large sample volumes (500 μl). In addition, for analysis of morphine and its 
metabolites often HPLC analysis with electrochemical and fluorescence detection is 
described for detection of morphine, the metabolite morphine-6-glucoride (M6G) and 
morphine-3-glucoronide (M3G), respectively (Drost et al. 1984; Joel et al. 2002; Liaw 
et al. 1998; Svensson 1986). However, for most assays relatively large plasma volumes 
are required (1 ml) which precludes application in pre-clinical animal investigations. 
Therefore, a rapid and highly sensitive HPLC assay was developed which requires only 
small blood samples (50 – 200 μl) to quantify nalbuphine, butorphanol, morphine. This 
assay was also able to quantify morphine concentrations in microdialysate samples (20 
– 60 μl). 
EXPERIMENTAL
Materials
Morphine hydrochloride was purchased from Pharmachemie (Haarlem, The 
Netherlands), nalbuphine hydrochloride and nalorphine hydrochloride were purchased 
from Sigma Aldrich (Zwijndrecht, The Netherlands) and butorphanol tartrate was 
purchased from Sigma Aldrich (St. Louis, MI, USA). Millipore water (resistivity 18.2 
MW.cm) was obtained from a Milli-Q® PF Plus system (Millipore B.V., Amsterdam, The 
Netherlands). Methanol (HPLC grade) was obtained from Biosolve BV (Valkenswaard, 
The Netherlands). Ethyl acetate was purchased from Fischer Scientific (‘s Hertogenbosch, 
The Netherlands) and distilled prior to use. All other chemicals were of analytical grade 
(Baker, Deventer, The Netherlands).
General instrumentation
The HPLC system consisted of an LC-10AD HPLC pump (Shimadzu, ‘s Hertogenbosch, 
The Netherlands), a Waters 717 plus autosampler (Waters, Etten-Leur, The Netherlands), 
a pulse damper (Antec Leyden, Zoeterwoude, The Netherlands) and a digital 
electrochemical amperometric detector (DECADE, software version 3.02, Antec Leyden, 
The Netherlands). The electrochemical detector consisted of a VT-03 electrochemical 
flow cell combined with a 25 μm spacer and an in situ Ag/AgCl (ISAAC) reference 
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electrode operating in the DC mode. For morphine analysis, a standard Ag/AgCl 
reference electrode, filled with a saturated KCl solution was used. Data acquisition 
and processing was performed using the Empower® data-acquisition software (Waters, 
Etten-Leur, The Netherlands).
Extraction procedure for blood samples
For determination of nalbuphine and butorphanol blood concentrations, 50 μl of internal 
standard solution (butorphanol for nalbuphine analysis and vice versa) was added to 
hemolysed blood samples (50 – 200 μl blood + 400 μl Millipore water) in glass centrifuge 
tubes. Next, 500 μl of 1.7 mM phosphoric acid (pH 2.3) and 3 ml of ethyl acetate were 
added and the mixture was vortexed for 5 min. After centrifugation for 10 min at 4000 
rpm, the organic layer was discarded and 500 μl of a 0.15 M carbonate buffer (pH 11) 
supplemented with EDTA (2.7 mM) was added. Next, 5 ml of ethyl acetate was added 
and the mixture was vortexed for 5 min. After centrifugation (10 min at 4000 rpm), the 
organic layer was transferred into a clean glass tube and evaporated to dryness under 
reduced pressure on a vacuum vortex evaporator (Buchler Instruments, Fort Lee, NJ, 
USA) at 37°C. The residue was dissolved in 100 μl mobile phase of which 10 – 75 μl was 
injected into the HPLC system.
For determination of morphine blood concentrations, 50 μl of internal standard 
solution (nalorphine) was added to hemolysed blood samples (50 – 200 μl blood + 400 μl 
Millipore water) in glass centrifuge tubes. Next 500 μl 0.15 M carbonate buffer (pH 11) 
supplemented with EDTA (2.7 mM) and 5 ml of ethyl acetate was added and the mixture 
was vortexed for 5 min. After centrifugation (10 min at 4000 rpm), the organic layer was 
transferred into a clean tube and evaporated to dryness under reduced pressure on a 
vacuum vortex evaporator at 37°C. The residue was dissolved in 100 μl mobile phase of 
which 10 – 75 μl was injected into the HPLC system.
Analysis of nalbuphine, butorphanol and morphine concentrations in blood samples
Chromatography of blood samples was performed on an Ultrasphere® C18 5 μm column 
(4.6 mm I.D. x 150 mm) (Alltech, Breda, The Netherlands) equipped with a refill guard 
column (2 mm I.D. x 20 mm) (Upchurch Scientific, Oak Harbor, WA, USA), packed with 
C18 (particle size 20-40 μm) (Alltech, Breda, The Netherlands), at a constant temperature 
of 30 °C. 
The mobile phase was a mixture of 0.1 M sodium phosphate buffer (pH 5.5) and 
methanol (65:35, v/v) for nalbuphine and butorphanol, whereas for morphine a mixture 
of 0.1 M sodium phosphate buffer (pH 4) and methanol (75:25, v/v). All mobile phases 
were supplemented with a total concentration 20 mg/l EDTA (sodium salt). The mobile 
phase for nalbuphine and butorphanol also contained 5 mM KCl whereas for morphine 
analysis 2 mM octane-sulfonic acid was added. Mobile phase solvents were filtered 
through a 0.2 μm nylon filter (Alltech, Breda, The Netherlands), mixed and degassed 
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continuously with helium. The flow rate was set at 1 ml/min. The optimal working 
potential for nalbuphine, butorphanol and morphine were +0.85 V, +0.85 V and +0.75 V, 
respectively, as determined by a voltammogram and sensitivity plot.
Analysis of morphine concentrations in brain microdialysate samples
For analysis of morphine brain microdialysate concentrations, 2 μl of internal standard 
(nalorphine) solution was added per 5 μl of sample. The samples were injected into 
the HPLC system without further sample pre-treatment. Chromatography of brain 
microdialysate samples was performed on a Ultrasphere® C18 column (2 mm I.D. x 150 
mm) (Alltech, Breda, The Netherlands) at a constant temperature of 35 °C. The mobile 
phase was a mixture of 0.1 M sodium phosphate buffer (pH 2.5) and methanol (75:25, 
v/v), supplemented with 20 mg/L EDTA (sodium salt) and 10 mM octane-sulfonicacid. 
Mobile phase solvents were filtered through a 0.2 μm nylon filter, mixed and degassed 
continuously with helium. The flow rate was set at 0.2 ml/min. The optimal working 
potential for morphine was +0.80 V, as determined by a voltammogram and sensitivity 
plot.
Reagents and standard solutions
For analysis of blood samples, the stock solutions of nalbuphine, butorphanol, morphine 
and nalorphine were prepared at a concentration of 1 mg/ml (free base) in Millipore 
water. The stock solutions were diluted with Millipore water to obtain calibration 
solutions (range 25 – 10000 ng/ml). Internal standard solutions were prepared 
by dilution of the stock solutions to a concentration of 250, 2500 and 500 ng/ml for 
nalbuphine, butorphanol and nalorphine, respectively.
For analysis of brain microdialysate samples, a stock solution of morphine was 
prepared at a concentration of 1 mg/ml (free base) in microdialysis perfusion fluid. 
Internal standard solution was prepared by dilution of the stock solution to 500 ng/ml 
nalorphine in perfusion fluid. Microdialysis perfusion fluid comprised of phosphate 
buffer (2 mM, pH 7.4) containing 145 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 
1.0 mM magnesium, 150 mM chloride and 0.2 mM ascorbate (Moghaddam & Bunney 
1989). The stock solutions were stored at –20 °C up to three months. The assay solutions 
were stored at 4 °C up to four weeks.
Calibration and validation
On each day of blood sample analysis, a 10-point calibration curve was prepared by 
spiking 50 μl of blood hemolysed in 400 μl water with 50 μl of calibration solution and 
50 μl of the internal standard solution. For analysis of brain microdialysates, a 10-point 
calibration curve was prepared with 40 μl of calibration solutions in perfusion fluid and 
16 μl of internal standard solution in Millipore water.
Samples were processed as described above and peak ratios of nalbuphine-butorphanol, 
butorphanol-nalbuphine or morphine-nalorphine were calculated. Calibration curves 
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were constructed by weighted linear regression [weight factor = 1/ (peak height ratio)2] 
according to the method implemented in the data-acquisition program Empower®.
Quality control samples of fixed concentrations were prepared to determine intra- and 
inter-assay variability. Extraction yields were determined by comparing the peak ratios 
after extraction from blood with the peak ratios of not-extracted standards.
Pharmacokinetic-pharmacodynamic study in rats
Chronically instrumented male Wistar rats, weighing 250 – 300 g were used in the 
experiments. Nine days before the experiment, seven cortical EEG electrodes were 
implanted into the skull. A number of rats used for the morphine studies were implanted 
with four cortical EEG electrodes and a CMA/12 microdialysis guide (Aurora Borealis 
Control, Schoonebeek, The Netherlands) which was replaced by the microdialysis probe 
(CMA/12, 4 mm) 24 hours before the experiment. Two days before the experiments 
three cannulas were implanted for drug administration and serial blood sampling. Two 
cannulas were implanted in the right jugular vein for opioid and midazolam infusion 
and one cannula was implanted in the left femoral artery to collect blood samples. 
The surgical procedures were performed under anaesthesia of 0.1 mg/kg Domitor® 
(intramuscular injection, 1 mg/ml medetomidine hydrochloride, Pfizer, Capelle aan 
de IJssel, The Netherlands) and 1 mg/kg Ketanest® (subcutaneous injection, 50 mg/ml 
ketamine base, Parke Davis, Hoofddorp, The Netherlands). After surgery, rats received 
a single dose of ampicilline trihydrate (0.6 ml/kg of a 200 mg/ml solution, A.U.V., Cuijk, 
The Netherlands). 
At the day of the experiment, the rats received an intravenous infusion of midazolam 
(5.5 mg/kg/h) and either nalbuphine (10 mg/kg in 10 min), butorphanol (10 mg/kg in 
10 min) or morphine (4 mg/kg in 10 min). Midazolam was administered continuously 
to prevent opioid induced seizures (Cox et al. 1997). To reach steady state rapidly, 
midazolam was administered with a Wagner infusion (Wagner 1974). The midazolam 
infusion was started 30 min before opioid infusion. A total number between 15 and 20 
arterial blood samples were collected over a period of 4 hours at fixed time intervals 
and immediately hemolysed in Millipore water. The samples were stored at – 20°C until 
analysis.
During the experiment, the EEG was recorded continuously. After off-line fast Fourier 
transformation using the data analysis software Spike2 version 4.60, (Cambridge 
Electronic Design limited, Cambridge, UK), the absolute amplitude in the delta-
frequency range in 5 s epochs were averaged over 1 min intervals.
The pharmacokinetics of nalbuphine, butorphanol and morphine were quantified 
for each individual rat using the least squares minimisation algorithm (weight = 1/(y 
predicted)2) of the WinNonlin Pro package V.1.5 (Pharsight Corporation, Mountain View, 
CA, USA). For nalbuphine, butorphanol and morphine a standard two-compartment 
model (Gibaldi & Perrier 1982) best described the concentration-time profile by the 





The sample pre-treatment by liquid-liquid extraction provided a good sample clean up 
as shown in figure 2. For nalbuphine and butorphanol a two-step extraction procedure 
was required because of interfering peaks, whereas for morphine a one-step extraction 
was sufficient (figure 3).
Retention times for nalbuphine and butorphanol were 6 and 11 min, respectively with 
a mobile phase containing 35 % methanol and 65 % 0.1 M phosphate buffer pH 5.5. 
Retention times for morphine and internal standard nalorphine were 5 and 11 min, 
Figure 2:	Chromatograms	of	an	extract	of	blank	blood	spiked	with	nalbuphine	(250	ng/ml)	and	butorphanol	(2500	
ng/ml)(A), blank blood spiked with either internal standard nalbuphine (250 ng/ml) or internal standard butorphanol 
(2500 ng/ml) (B and D) and blood obtained from a rat at 12 min after start of an infusion of 10 mg/kg butorphanol 
in 10 min (concentration 1931 ng/ml)(C) or after having received and infusion of 10 mg/kg nalbuphine in 10 min 
(concentration 1955 ng/ml)(E).
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respectively with a mobile phase containing 25% methanol, 75 % 0.1 M phosphate 
buffer pH 4 and 2 mM octane-sulfonicacid. For the analysis of morphine, the mobile 
phase was adjusted because morphine did not have enough retention on the column 
with the conditions used for nalbuphine and butorphanol. To improve retention, 2 mM 
octane-sulfonic acid was added as an ion-pair. The pH was adjusted to improve the 
peak shape. 
Table 1 summarises the recovery after extraction, the accuracy and reproducibility of 
the analysis. For nalbuphine, butorphanol and morphine intra- and inter-assay were less 
than 20 % in the concentration range of 25–10000 ng/ml. The weighted linear regression 
equations (mean ± SEM) for nalbuphine (N=9), butorphanol (N=5) and morphine (N=15) 
were y = (1.212 ± 0.055)x + (-7.195 ± 2.394), y = (0.0020 ± 0.0003)x + (-0.0629 ± 0.0127) and 
y = (0.0011 ± 0.0001)x + (-0.0045 ± 0.0015), respectively. Corresponding coefficients of 
correlation were (0.978 ± 0.003), (0.993 ± 0.001) and (0.996 ± 0.001), indicating the linearity 
of the methods. Using 50 μl blood, the limit of detection for nalbuphine, butorphanol 
and morphine was 25, 50 and 25 ng/ml (signal to noise ratio = 3), respectively. The main 
difference of the methods described here and the methods described in the literature 
is the sample size. All methods are described for studies in humans or relatively large 
laboratory animals (dogs, pigs, rabbits), whereas the method described here was 
especially for application to studies in small laboratory animals (rats). For example, for 
the analysis of nalbuphine Nicolle and co-workers (1995; 1997) used plasma samples 
Figure 3:	 Chromatograms	 of	 an	 extract	 of	 blank	 blood	 spiked	 with	 internal	 standard	 nalorphine	 (500	 ng/ml)	
(A), blank blood spiked with morphine (1000 ng/ml) and internal standard nalorphine (500 ng/ml) (B) and blood 




of 500 μl whereas in our studies blood samples of 50-200 μl were used. When whole 
blood samples are used for drug analysis, more samples can be collected from a subject 
and therefore more information about the individual pharmacokinetic profiles can be 
obtained. Another advantage of our method is that one general method is applicable 
for three opioids. Nalbuphine and butorphanol samples can be analysed with the 
same HPLC-conditions and sample pre-treatment, whereas for morphine only slight 
modifications are required.
For morphine administration, drug concentrations were also determination in brain 
microdialysate. No sample pre-treatment was required to clean up the samples as is 
shown in figure 4. The weighted linear regression equation (mean ± SEM) for morphine 
(N=9) was y = (16.644 ± 0.269)x + (-6.484 ± 0.565) and corresponding coefficient of 
correlation was (0.994 ± 0.001), indicating the linearity of the method. Using 40 μl 
microdialysate, the limit of detection for morphine was 0.5 ng/ml (signal to noise 
ratio = 3). 
Added Recovery Intra-assay Inter-assay
(ng/ml) (N=3) (N=3) (N=5)
Found Cv Accuracy Found Cv Accuracy
(ng/ml) (%) (%) (ng/ml) (%) (%)
N 100 67±2 - - - - - -
250 - 265±17 11 106 263±12 13 105
1000 71±5 - - - - - -
2500 - 2553±28 1.9 102 2936±80 7 117
10000 78±4 - - - - - -
B 100 64±14 - - - - - -
250 - 248±6 4.7 99 213±10 10 86
1000 85±8 - - - - - -
2500 - 2530±51 3.5 101 2550±62 5 102
10000 80±8 - - - - - -
M 250 62±4 239±5 4.4 96 257±5 6 103
3000 58±4 2630±97 8.2 88 3268±82 9 109
Table 1: Validation of the determination of nalbuphine (N), butorphanol (B) and morphine (M): recovery, intra-
assay	and	inter-assay	variability,	coefficients	of	variation	and	accuracy.	Results	are	expressed	as	mean	±	SEM.
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Study in rats
Figure 5a and 5b show representative blood concentration-time profiles for an 
intravenous administration of 10 mg/kg nalbuphine in 10 min and 10 mg/kg 
butorphanol in 10 min. The values for clearance, volume of distribution at steady state 
and terminal half-life were estimated for each individual rat (table 2). 
Figure 5c shows a representative blood and brain microdialysate concentration-time 
profile for an intravenous infusion of 4 mg/kg morphine in 10 min. To emphasise 
the application to PK-PD studies, figure 5 also shows the time-course of the change 
in amplitude of the delta-frequency band (0.5 - 4.5 Hz) of the EEG during and after 
administration of nalbuphine, butorphanol or morphine. Combination of both the detailed 
concentration-time and effect-time relationship revealed a complex concentration-effect 
relationship, which is currently being investigated by PK-PD modelling.
Compound Dose (mg/kg) N Cl (ml/min) vdss (ml) Elimination 
half life (min)
Nalbuphine 10 8 38.7 ± 3.3 1917 ± 385 56.0 ± 7.0
Butorphanol 10 6 22.8 ± 3.3 1242 ± 193 62.4 ± 14.0
Morphine 4 14 24.1 ± 2.1 881 ± 117 44.1 ± 4.7
Table 2: Average pharmacokinetic parameter estimates (Mean ± SEM) obtained with a two-compartment 
pharmacokinetic model for nalbuphine, butorphanol and morphine after a 10-min intravenous infusion.
Figure 4: Chromatograms of blank microdialysate spiked with internal standard nalorphine (500 ng/ml) 
(A), microdialysate spiked with morphine (10 ng/ml) and internal standard nalorphine (500 ng/ml) (B) and a 
microdialysate fraction obtained from a rat 40-60 min after the start of an infusion of 4 mg/kg morphine in 10 min 




A simple and sensitive HPLC method has been developed for the analysis of nalbuphine, 
butorphanol and morphine in biological samples. The short duration of the analysis, the 
sample size, the sensitivity, the reproducibility and the simplicity of the methods used 
make these assays particularly useful for PK-PD studies in small laboratory animals in 
which large numbers of samples have to be analysed. 
In combination with the EEG measurements, concentration-effect profiles can be 
obtained in individual rats, which can then be used for quantitative analysis of µ-
opioid receptor mediated responses in vivo. The analysis of the brain microdialysate 
concentrations of morphine allows the characterisation of the BBB transport of morphine 
and its influence on the concentration-effect relationships.
ACKNOWLEDGEMENTS
The authors wish to acknowledge the technical assistance of Andrea Rosier, Dennis de 
Mik and Susanne Bos-van Maastricht. The described work was financially supported 
by GlaxoSmithKline, United Kingdom. 
Figure 5:	 Typical	 blood	 concentration-time	 profiles	 (filled	 circles,	 left	 ordinate)	 and	 EEG	 amplitudes	 in	 delta-
frequency range versus time (grey solid line, right ordinate) in rats following intravenous infusion of 10 mg/kg 
nalbuphine (A), 10 mg/kg butorphanol (B) or 4 mg/kg morphine (C) in 10 min. Panel C also shows the brain 
microdialysate	concentration-time	profile	of	morphine	(dotted	line).	The	solid	line	represents	the	best	description	
of the plasma concentrations according to a two-compartment pharmacokinetic model.
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Chapter 4
MEMBRANE TRANSPORT OF OPIOIDS:
RELATIVE CONTRIBUTION OF P-GLYCOPROTEIN





Restricted transport across the blood-brain barrier (BBB) can be a critical factor in 
the development of mechanism-based pharmacokinetic/pharmacodynamic (PK-
PD) models for the central effects of opioids. In this study, the P-glycoprotein (Pgp) 
interaction and the apparent transmembrane passive permeability rates (Papp) of a wide 
range of opioids were investigated, This was performed in vitro, using monolayers of 
MDCK:MDR1 and LLC-PK1:MDR1a cells. The opioids alfentanil, fentanyl, sufentanil, 
loperamide and morphine were able to inhibit Pgp mediated efflux of 3H-digoxin in 
MDCK:MDR1 and LLC-PK1:MDR1a cells, whereas no inhibition was observed for 
butorphanol, nalbuphine, and the morphine metabolites M3G and M6G. Moreover, 
active transport by Pgp was found for loperamide and morphine. The Papp values 
were determined in the presence of the Pgp inhibitor GF120918. High transmembrane 
passive permeability rates (>500 nm/sec) were found for alfentanil, fentanyl, sufentanil 
and butorphanol, whereas the permeability rates of loperamide (206 nm/sec), 
nalbuphine (156 nm/sec) and morphine (16 nm/sec) were relatively low. It is concluded 
that the contributions of both Pgp mediated transport and transmembrane passive 
permeability rates  are of importance for the influence of BBB transport on the PK-
PD relationships of opioids. Alfentanil, fentanyl, sufentanil and butorphanol have high 
passive permeability rates and the relative contribution of Pgp mediated transport, if 
any, is therefore considered as not significant. In contrast, nalbuphine, morphine and 
loperamide have low passive permeabilities and therefore the net transmembrane 
transport is significantly influenced by Pgp mediated transport. 
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INTRODUCTION
The objective of pharmacokinetic-pharmacodynamic (PK-PD) modelling is the prediction 
of the time course of drug effects under physiological and pathological conditions 
(Breimer & Danhof 1997). At present there is a clear trend towards the development 
and application of mechanism-based PK-PD models. Mechanism-based PK-PD models 
differ from empirical descriptive models in that they contain specific expressions to 
characterise the processes on the causal path between drug administration and effect. 
These processes include 1) biophase distribution, 2) target site activation, 3) transduction 
and 4) the influence of in vivo homeostatic feedback mechanisms (Danhof et al. 2005). 
An important feature of PK-PD models is further the strict distinction between drug 
and system specific characteristics (van der Graaf & Danhof 1997). Our interest is to 
develop a mechanism-based PK-PD model for the central effects of opioids. In these 
investigations alfentanil, fentanyl, sufentanil, nalbuphine, butorphanol, morphine and 
loperamide (figure 1) are used as model drugs, because they differ widely in affinity 
and intrinsic efficacy at the μ-opioid receptor. 
To determine the complex in vivo concentration-effect relationships of these opioids, the 
transport across the blood-brain barrier (BBB) needs to be taken into consideration.
Recently, the effects of the opioids alfentanil, fentanyl and sufentanil have been 
studied in vivo in a chronically instrumented rat model, using the amplitude in the 
0.5-4.5 Hz frequency band of the electroencephalogram (EEG) as a pharmacodynamic 
endpoint (Cox et al. 1998). However, the role of BBB transport as a mechanism for 
the observed hysteresis of these opioids has so far not been explored in detail. This 
is important since active transporters at the BBB may influence both the rate and 
extent of transport into the brain, and thereby the estimation of the parameters in 
the complex PK-PD relationships of centrally acting drugs (de Lange et al. 2005). 




Transport across the BBB can be divided into passive and active transport processes (de 
Lange & Danhof 2002). Passive transport of compounds across the BBB is dependent 
on physicochemical properties, such as lipophilicity, degree of ionisation and number 
of hydrogen bonds (van Bree et al. 1988). Active transport can be divided into carrier 
mediated transport, receptor mediated transport and endocytosis (de Boer et al. 2003). 
Several transporters are present at the BBB to transport endogenous compounds such 
as amino acids, glucose etc. An important efflux transporter expressed at the luminal 
face of the BBB is P-glycoprotein (Pgp). Pgp is a member of the adenosine triphosphate-
binding cassette super family and is encoded by the multidrug resistance gene (MDR1) 
(Thiebaut et al. 1987). This transporter has been shown to have an important influence 
on the BBB transport of a wide range of drugs (de Lange & Danhof 2002; Schinkel et al. 
1995; Schinkel et al. 1996). 
In previous investigations, morphine and loperamide have been identified as Pgp 
substrates in both in vitro models, comprising of either brain capillary endothelial 
cells or LLC-PK1:MDR1 cells, and in vivo models, in rats and mice (Wandel et al. 2002, 
Letrent et al. 1999b; Mahar Doan et al. 2002; Schinkel et al. 1995, 1996). Furthermore, 
PK-PD studies in rats have revealed that after oral pre-treatment with the specific Pgp 
inhibitor GF120918, the anti-nociceptive effect of morphine was prolonged due to its 
prolonged half-life in the brain (Letrent et al. 1998, 1999a). Alfentanil and sufentanil 
were not identified as Pgp substrates within the abovementioned investigations in in 
vitro models, whereas inconsistencies have been reported for fentanyl (Henthorn et 
al. 1999; Wandel et al. 2002). In addition, for fentanyl, in situ brain perfusion studies 
indicated Pgp mediated efflux as it was found that the brain uptake of fentanyl is 
slightly increased (1.2 fold) in MDR1a (-/-) mice when compared to MDR1a (+/+) mice 
(Dagenais et al. 2004; Mahar Doan et al. 2002; Schinkel et al. 1995, 1996). Nalbuphine, a 
semi-synthetic opioid analgesic, was also found to be a Pgp substrate in a MDCKII-
MDR1 cell-system (Mahar Doan et al. 2002), whereas to our knowledge so far no studies 
have performed on butorphanol. 
The aim of the present study was to identify the membrane transport characteristics 
with respect to the relative contribution of Pgp mediated (efflux) transport and passive 
transmembrane permeability rate (Papp), for a series of opioids including alfentanil, 
fentanyl, sufentanil, nalbuphine, butorphanol, morphine and loperamide. The 
chemical structures of these opioids are shown in figure 1. The opioids were tested in 
an in vitro cell system, comprising of monolayers of MDCKII:MDR1 or LLC-PK1:MDR1a 
cells. Regression analysis was used to investigate the relationships between Papp and 
physicochemical properties of the opioids. These properties included polar surface 
area, lipophilicity (cLogP) and the predicted BBB permeability based on the number 
of hydrogen donors and acceptors, according to the Abraham equation (Abraham et 
al. 1994).
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MATERIALS AND METHODS
Materials
Fentanyl citrate, morphine sulphate, nalbuphine hydrochloride, butorphanol tartrate, 
loperamide hydrochloride, morphine-3-glucuronide, morphine-6-glucuronide and 
lucifer yellow were obtained from Sigma Aldrich (United Kingdom). Alfentanil 
hydrochloride and sufentanil citrate were kindly provided by Janssen Pharmaceutica 
(Beerse, Belgium). GF120918 and SB-243213 were supplied by GlaxoSmithKline. 3H-
amprenavir (specific activity 0.13 Ci/mmol), 3H-digoxin (specific activity 37 Ci/mmol) 
and 3H-loperamide (specific activity 10 Ci/mmol) were obtained from Amersham. 
The stock solutions of the opioids and GF120918 were prepared in DMSO (Sigma Aldrich, 
United Kingdom). The GSK internal standard solution was prepared in ammonium 
acetate/methanol (50/50 v/v). The lucifer yellow solution was prepared in Millipore 
water (18.2MW.cm). All other chemicals were of analytical grade.
All cell-culture reagents were obtained from Invitrogen (United Kingdom). BD Falcon™ 
HTS 24-Multiwell Inserts (24-well, 0.31 cm2, 0.1 μm pore size) were obtained from 
Becton-Dickinson (United Kingdom).
Cell lines
MDCKII:MDR1; Madine Darby Canine Kidney type II cells transfected with the human 
MDR1 gene (MDCKII:MDR1) were cultured in DMEM – glutamax media, formulated 
with D-glucose (4.5 g/l),  L-alanyl-glutamine and phenol red and supplemented with 
penicillin (10000 U/ml)-streptomycin (10000 μg/ml) and 10% (v/v) fetal calf serum at 
37 °C and 5% CO2. Cells were trypsinised every 4 days. For the studies, the cells were 
seeded onto BD Falcon™ HTS 24-Multiwell Inserts at a seeding density of 50000 cells/
well and grown for 3 days in DMEM full media. 
LLC-PK1:MDR1a; Porcine kidney epithelial cells transfected with the mouse MDR1a 
gene (LLC-PK1:MDR1a) were cultured in M199 media, formulated with Earle’s salts, 
L-glutamine, phenol red and sodium bicarbonate (2.2 g/L) and supplemented with 
penicillin (10000 U/ml)-streptomycin (10000 μg/ml) and 10% (v/v) fetal calf serum at 
37 °C and 5% CO2. The cells were trypsinised every 4 days and sub-cultured in M199 
media containing 2 mM vincristine as a selection agent. For the studies, the cells were 
seeded onto BD Falcon™ HTS 24-Multiwell Inserts at a seeding density of 75000 cells/
well and grown for 3 days in M199 media without the selection agent vincristine. 
General experimental procedures on transmembrane transport studies
Transport experiments were performed using monolayers of both the MDCKII:MDR1 
and the LLC-PK1:MDR1a cells. As an integrity check, prior to the experiment, the 
trans-epithelial electrical resistance (TEER) of each monolayer was measured with an 
EVOMTM voltohmmeter (World Precision Instruments, Stevenage, United Kingdom). 
The experiments were performed in transport buffer consisting of DMEM containing 
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25 mM HEPES without phenol red and sodium pyruvate. The experiments were started 
with pre-incubation of the monolayers for 15 min at 37°C with transport buffer to which 
either the Pgp inhibitor GF120818 or the vehicle (0.5% DMSO) was added. After the 
pre-incubation period, the transport buffer was removed and the test solutions were 
added. All test solutions were prepared from stock solutions, that were prepared in 
100% DMSO (opioids at 100 mM; GF120918 at 2 mM). To prepare the test solutions, the 
stock solutions were diluted further with transportbuffer. The test solutions ultimately 
contained 0.5% DMSO. The monolayers were incubated with the test solutions for a test 
period of 90 min at 37°C under continuous shaking. All experiments were performed 
automatically using the robotic TECANTM genesis workstation (TECAN, Reading, 
United Kingdom). 
The reference drugs for membrane integrity towards paracellular transport (lucifer 
yellow, 10 μM) and for Pgp-efflux functionality (amprenavir, 3 μM) were included in 
each experiment to test the integrity and quality of the monolayer. Lucifer yellow was 
added to each well, whereas amprenavir was only added to two wells as a positive 
control. After the test period of 90 min, 100 μl samples were collected to be analysed on 
the concentrations of the references lucifer yellow and amprenavir, as well as the test 
compound. 
Inhibition of Pgp mediated efflux of 3H-digoxin, the “3H-digoxin transport inhibition factor”  
The experiments on inhibition of Pgp mediated transport by either the Pgp inhibitor 
GF120918 or by the seven selected opioids were performed in duplicate using monolayers 
of both the MDCKII:MDR1 and the LLC-PK1:MDR1a cells. Transport measurements 
were performed in basolateral-to-apical direction (b→a). This would correspond to BBB 
transport in the direction from brain into blood (efflux).
In addition to alfentanil, fentanyl, sufentanil, nalbuphine, butorphanol, morphine and 
loperamide, the morphine metabolites, morphine-3-glucoronide (M3G) and morphine-
6-glucoronide (M6G) were also included in these studies. Stock solutions of opioids 
(100 mM) and GF120918 (2 mM) were prepared. The monolayers were pre-incubated 
with transport buffer containing either GF120918 (2 μM) or opioid (100 μM) at both 
the basolateral and apical side. At time = 0, the experiment was started by addition 
of 3H-digoxin (3 μM) for testing the inhibitory action of the opioids and the morphine 
metabolites. As a positive control 3H-amprenavir was added to two of the wells and 
lucifer yellow was added to all the wells to check for monolayer integrity. The 3H-
digoxin transport inhibition factor was calculated (see data analysis).
Pgp substrate assessment studies; the “Pgp substrate efflux ratio”  
Pgp substrate assessment studies were performed in duplicate using monolayers of the 
MDCKII:MDR1 cells. Transport experiments were performed both into the apical-to-
basolateral (a→b) as the basolateral-to-apical (b→a) direction. The stock solutions of the 
opioids contained final concentrations of 3 mM in DMSO. The pre-incubation solutions 
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contained vehicle (0.5% DMSO) or GF120918 (2 μM in 0.5% DMSO) in transport buffer. 
The test solutions contained vehicle (0.5% DMSO) or GF120918 (2 μM), lucifer yellow 
and one of the opioids (3 μM) or amprenavir (3 μM). The “Pgp substrate efflux ratio” 
was calculated (see data analysis).
Sample analysis
3H-amprenavir, 3H-loperamide and 3H-digoxin samples were dried down at 37°C 
and analysed with a Topcount NXT™ microplate scintillation counter (Perkin Elmer, 
Beaconsfield, United Kingdom), 2 min per sample.
Alfentanil, fentanyl, sufentanil and butorphanol were analysed by dual high-
performance liquid chromatography with tandem mass spectrometry (HPLC-LC/MS/
MS). The system consisted of an API-365 (Applied Biosystems, Warrington, United 
Kingdom) LC/MS/MS employing positive ion turbospray ionisation with a CTC HTS 
PAL autosampler (CTC Analytics, Hitchin, United Kingdom). HPLC was conducted on 
a 50 mm x 2.1 mm HyPURITY column (ThermoHypersil, Runcorn, United Kingdom) 
at a flow rate of 0.8 ml/min and a split ratio of 1:2. The mobile phase consisted of two 
solvents: (A) 10 mM ammonium acetate pH 4 and (B) 100% acetonitrile. The gradient 
profile was set at 0 min on 80% A and 20% B, at 1 min on 0% A and 100% B and at 1.1 min 
on 80% A and 20% B. The total run time was 1.5 min. Data acquisition was performed 
with PE Sciex version 1.1 (Applied Biosystems, Warrington, United Kingdom) and data 
were reported as the ratio of test compound peak area over internal standard peak 
area. 
Nalbuphine and morphine samples were analysed by high performance liquid 
chromatography with electrochemical detection (HPLC-ECD) as described previously 
(Groenendaal et al. 2005 – chapter 3). Briefly, the nalbuphine samples were transferred 
into glass tubes and the internal standard butorphanol (50 μl, 2500 ng/ml) was 
added. The samples were acidified with phosphoric acid (0.15 mM, pH 2.3, 500 μl) and 
extracted with 3 ml of ethyl acetate. After extraction, the organic layer was discarded. 
Subsequently, the samples were alkalinised with carbonate buffer (0.15 mM, pH 11, 500 
μl) and extracted with 5 ml of ethyl acetate. The organic layer was transferred into clean 
glass tubes and evaporated to dryness under reduced pressure at 37 °C. For morphine 
samples, only the alkaline extraction with carbonate buffer and ethyl acetate was 
performed. The HPLC system consisted of an LC-10AD HPLC pump (Shimadzu, Kyoto, 
Japan), a Waters 717 plus autosampler (Waters, Milford, MA, USA), a pulse damper 
(Antec Leyden, Rijnsburg, The Netherlands) and a digital electrochemical amperometric 
detector (DECADE, software version 3.02) from Antec Leyden. The electrochemical 
detector consisted of a VT-03 electrochemical flow cell combined with a 25 μm spacer 
and an Ag/AgCl reference electrode operating in the DC mode at a temperature of 
30 °C, set at a voltage of 0.85V and 0.75V for nalbuphine and morphine, respectively. 
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Chromatography was performed on C18 ODS Ultrasphere 5 μm column (4.6 mm I.D. x 
150 mm) (Alltech, Breda, The Netherlands) equipped with a refill guard column. The 
mobile phase was a mixture of 0.1 M phosphate buffer (pH 5.5) and methanol (65:35, 
v/v) for nalbuphine and butorphanol and a mixture of 0.1 M phosphate buffer (pH 4) 
and methanol (75:25, v/v) for morphine and contained a total concentration of 5 mM 
KCl and 20 mg/l EDTA. The mobile phase for morphine also contained 2.0 mM octane-
sulfonic acid. The flow rate was set at 1 ml/min. Data acquisition and processing was 
performed using the Empower integration software (Waters, Milford, MA, USA).
The lucifer yellow samples were analysed by a Polarstar® fluorescence microplate 
reader with λex=430 nm and λem=538 nm (BMG-Labtech, Aylesbury, United Kingdom).
Data analysis
For the Pgp inhibition studies, the amount of 3H-digoxin transported from the basolateral 
to apical (b→a, “brain to blood”) side of both monolayers of the MDCKII:MDR1 and 
the LLC-PK1:MDR1a was calculated in the presence and absence of either the vehicle, 
the Pgp inhibitor GF120918 or the opioid. The 3H-digoxin transport inhibition factor 
was calculated as the amount of 3H-digoxin transported from b→a in the presence of 
the opioid or GF120918, respectively, divided by the amount of 3H-digoxin transported 
from b→a in the presence of the vehicle (control).
For the Pgp substrate assessment studies, the Pgp substrate efflux ratio was calculated 
by the amount of opioid or the Pgp substrate 3H-amprenavir as the positive control being 
transported from basolateral to apical (b→a) side, divided by the amount of opioid or 
3H-amprenavir transported from apical to basolateral (a→b) side of the MDCKII:MDR1 
monolayer. Involvement of Pgp mediated efflux was considered significant for values 
of the Pgp substrate efflux ratio >1.5 (Mahar Doan et al. 2002). 
To exclude potential contributions of other transporters to this Pgp substrate efflux 
ratio, experiments were also performed in the presence of the Pgp inhibitor GF120918, 
for which this substrate efflux ratio should decease to 1, if the asymmetrical membrane 
transport of the opioid was indeed only caused by Pgp.
The transmembrane passive permeability rate; the “Papp” values
The apparent transmembrane passive permeability rate Papp (nm/sec) of the compounds 
was calculated using the equation:
where VD and VR are the donor (basolateral) and receiver (apical) chamber volumes 
(cm3) respectively, A is the area of the monolayer (cm2), t is the time after the start of 
the experiments (s), CR(t) is the drug concentration in the receiver (apical) chamber and 
(1)
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is described by equation 2:
where describes the average concentration of the compound on both sides of the 
monolayer, VD and VR are the donor (basolateral) and receiver (apical) chamber volumes 
(cm3) and CD(t) and CR(t) are the donor (basolateral) and receiver (apical) concentrations 
at time t (Tran et al. 2004; 2005). This calculation of Papp takes into account the loss of 
drug from the donor compartment, which results in a better estimation of the Papp.
In all studies, the 3H-amprenavir substrate efflux ratios, the apparent transmembrane 
passive permeability rate of lucifer yellow and the mass balance values were used as 
controls for the quality (integrity and Pgp functionality) of each monolayer.  
The mass balance was calculated with the following equation:
where %MB is the mass balance, Art is the drug amount in receiver chamber at time (t), 
Adt is the drug amount in donor chamber at time (t) and Ad0 is the drug amount in the 
donor chamber at t=0.
The data from experiments were only included when the value for the Pgp substrate 
efflux ratio of 3H-amprenavir was > 16, the value of the transmembrane passive 
apparent permeability rate of lucifer yellow < 50 nm/sec and the value for the mass 
balance > 70 %.
It should be noted that for nalbuphine literature values were used (Mahar Doan et al. 
2002). The nalbuphine efflux ratio was determined at a donor concentration of 10 μM. 
The Pgp substrate efflux ratio for morphine was calculated at a donor concentration of 
100 μM only, as at other concentrations no receiver concentrations were detectable. The 
apparent permeability rate for morphine was calculated at a donor concentration 100 
μM, but without GF120918 and a→b.
Quantitative structure activity relationships – physico-chemical relationships
The Log octanol/water partition coefficients (cLogP) and molar refractivity values (CMR) 
were calculated using Daylight Software v4.71/82 (Daylight Chemical Information 
Systems Inc., Irvine, CA). Polar surface areas (PSA) were calculated according to Ertl 
and co-workers (Ertl et al. 2000). An in silico  predictor of passive BBB transport was also 






where LogBB is the logarithm of the blood-brain concentration ratio and R2, πH2, αH2, βH2 
and Vx are defined as the excess molar refractivity, dipolarity/polarisability, hydrogen 
bond acidity, hydrogen bond basicity and the solute McGowan volume, respectively, as 
described by Platts (Platts et al. 1999).
Statistical analysis
The data obtained from the studies on the inhibition of Pgp mediated efflux of 3H-
digoxin (the 3H-digoxin transport inhibition factor) and on the Pgp substrate efflux 
ratio were analysed using an unpaired Student’s t-test (two-tailed) or one-way analysis 
of variance (ANOVA) (Graphpad Instat®, version 3.00). A value of p<0.05 was considered 
a significant difference. Linear regression analysis of the Papp, cLogP, PSA and LogBB 
values was performed using S-plus (version 6.0 professional, release 1, Insightful 
corporation, USA) without a weight factor at a confidence level of 0.95. All data are 
expressed as mean ± SEM, unless indicated otherwise. Each experiment was performed 
in duplicate in at least three separate experiments. 
RESULTS
Opioid inhibition of Pgp mediated efflux of 3H-digoxin –“the 3H-digoxin transport 
inhibition factor”
The inhibitory properties of the seven selected opioids and the morphine metabolites 
M3G and M6G were studied in MDCKII:MDR1 and LLC-PK1:MDR1a cells. Transport 
of 3H-digoxin from the basolateral to the apical side of the monolayers was measured 
in the presence of vehicle, 2 mM GF120918 or 100 mM of the opioids. The results are 
shown in figure 2.
Alfentanil, fentanyl, sufentanil, morphine and loperamide were able to inhibit 
the Pgp mediated 3H-digoxin transport in both cell-lines. In contrast, nalbuphine 
and butorphanol, M3G and M6G could not. According to the 3H-digoxin transport 
inhibition factor, a ranking can be made. For the opioids the ranking (strong to weak) 
is as follows: fentanyl, sufentanil, loperamide, alfentanil, morphine and nalbuphine / 
butorphanol. This ranking was similar for both cell-lines. Furthermore, the inhibition 
of Pgp mediated efflux of 3H-digoxin by the opioids was significantly weaker than by 
the Pgp inhibitor GF120918.
Pgp substrate assessment – “the Pgp substrate efflux ratio”
The next step was to determine the Pgp substrate efflux ratio of  the opioids in the 
monolayers of the MDCKII:MDR1 cells. The results are shown in figure 3. No 
statistically significant differences were found in the Pgp substrate efflux ratios for 
alfentanil, fentanyl, sufentanil and butorphanol in the presence or absence of GF120918. 
For loperamide, a Pgp substrate efflux ratio of 4 was found. This efflux ratio decreased 
to 1.0 in the presence of GF120918, indicating that the asymmetrical transport was 
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Figure 3:	Assessment	of	opioid	transport	by	Pgp.	The	Pgp	substrate	efflux	ratios	for	the	tested	opioids,	using	the	





opioid in MDCK:MDR1 (solid bars) and LLC-PK1:MDR1a cells (striped bars). The 3H-digoxin	transport	inhibition	




caused by Pgp solely. For morphine and nalbuphine the concentrations in the receiving 
compartment were below the limit of quantification of the assay when using the donor 
concentration of 3 μM. Therefore, the values obtained at a donor concentration of 10 or 
100 μM for nalbuphine and morphine were used, respectively.
Apparent transmembrane passive permeability rates; the Papp values 
The Papp values of the opioids were calculated on the basis of the amount transported 
across the monolayer over time (nm/s), in both directions, in the presence of GF120918. 
The results are shown in figure 4. 
Papp values > 500 nm/s were found for alfentanil, fentanyl, sufentanil and butorphanol, 
whereas the Papp values of nalbuphine and loperamide were 156 and 206 nm/s, 
respectively. For morphine, the Papp value was 11 nm/s, indicating that almost no 
morphine is transported across the monolayer within the experimental period of 90 
min.
Quantitative structure activity relationships: physico-chemical relationships
The values of Papp, cLogP, LogBB, PSA and CMR are listed in table 1. Regression analysis 
was performed to investigate the possible correlations between the apparent permeability 
and the physico-chemical properties of the selected opioids. Linear regression was 
performed with the Papp and LogPapp values, but no significant correlations were found. 
However, the LogPapp values gave slightly better correlations (figure 5). 
Figure 4: Calculated apparent transmembrane passive permeability rate values of the opioids across the MDCK:
MDR1	monolayer,	as	determined	at	a	donor	concentration	of	3μM	of	the	opioid	in	the	presence	of	the	Pgp	inhibitor	
GF120918. For nalbuphine literature values were used (Mahar Doan et al. 2002).
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DISCUSSION
The main objective of these studies was to characterise the membrane transport 
characteristics of the opioids alfentanil, fentanyl, sufentanil, nalbuphine, butorphanol, 
morphine and loperamide. The focus was on the relative contributions of the passive 
membrane permeability rates and Pgp mediated active transport as mechanisms that 
determine the overall membrane passage. This is important for the development of a 
mechanism-based PK-PD model for the central effects of opioids, since opioids have 




PSA CMRR2 πH2 α
H
2 βH2 vx LogBB
Alfentanil 416.6 2.1 2.58 3.02 0 2.04 3.26 0.277 85.5 11.5
Fentanyl 336.5 3.6 2.08 2.21 0 1.23 2.84 0.886 23.6 10.4
Sufentanil 386.6 3.6 2.07 2.26 0 1.49 3.11 0.932 32.8 11.3
Nalbuphine 357.5 1.4 2.34 1.91 0.81 2.08 2.62 -0.247 73.2 9.6
Butorphanol 327.5 3.7 2.02 1.7 0.8 1.48 2.61 0.253 43.7 9.5
Morphine 285.4 0.6 2.1 1.68 0.55 1.76 2.06 -0.28 52.9 7.7
Loperamide 477.1 4.7 2.85 2.98 0.35 2.11 3.77 0.566 43.8 14.1
Table 1: Physicochemical properties of opioids
Abbreviations: Mw – molecular weight, cLogP – calculated LogP value, which is indicative for lipophilicity, R2, pH2, 
αH2, βH2 and Vx – descriptors for Abraham equation, LogBB = BBB transport on basis of Abraham equation PSA = 
polar surface area (Å), and CMR = calculated molecular refractivity, which is indicative for size of molecule.




Large differences were found between the opioids in the values for passive 
transmembrane permeability rates (Papp) and for the interaction with Pgp. The results 
show that the contribution of Pgp mediated transport should be taken into account for 
opioids with a low passive transmembrane permeability rate, whereas for opioids with 
a high passive permeability rate no significant contribution of Pgp mediated transport 
on membrane passage is to be expected. 
The biophase kinetics of a CNS drug is an important determinant in the time course 
and intensity of its CNS effects. Apart from plasma pharmacokinetics, the mechanisms 
that determine CNS biophase kinetics include the rate and extent of BBB transport, and 
the kinetics of distribution and elimination within the brain. Transport across the BBB 
can be divided into passive and active transport processes (de Lange & Danhof 2002). 
Active transport processes are mediated by transporters, such as the Pgp, which has 
been shown to be an important efflux transporter at the BBB for many drugs. Therefore, 
the relative contribution of Pgp on overall BBB membrane transport is of interest. Our 
approach was to characterise the contribution of Pgp mediated transport, relative to 
passive membrane diffusion, on the overall membrane transport. Investigations were 
performed for the whole set of opioids, using a robust in vitro system composed of 
monolayers of Pgp-expressing cells. Monolayers of both MDCKII-MDR1 (transfected 
with the human MDR1 gene that encodes for Pgp) and of LLC-PK1:MDR1a cells 
(transfected with the mouse MDR1a gene) were used in these studies. These cell 
systems were chosen because of their very tight junction, which is similar to brain 
endothelia cells. If significant differences in Pgp mediated transport by the human and 
rodent gene products would be identified, these findings could be used to improve 
interspecies extrapolation of PK-PD relationships.
A number of in vitro studies has been performed with monolayers of LLC-PK1:MDR1 
cells. However, these studies mainly focussed on morphine, loperamide and fentanyl 
(Schinkel et al. 1995, 1996; Wandel et al. 2002). Nalbuphine was only investigated 
once (Mahar Doan et al. 2002), whereas butorphanol has never been tested for Pgp 
interaction. For our ultimate goal, which is the development of a mechanistic PK-PD 
model for opioids, it was necessary to test all the selected opioids for Pgp interaction in 
the same experimental design. Moreover, unlike in previous studies, here the relative 
contribution of Pgp mediated efflux relative to the passive membrane transport 
component was explicitely addressed. 
The inhibition of Pgp mediated efflux of 3H-digoxin by the opioid (the 3H-digoxin 
inhibition factor) was determined at a concentration of 100 μM of the opioid or 3 μM 
GF120918. The transport of 3H-digoxin was measured from basolateral to apical direction 
(what would correspond with brain efflux). Efflux ratios were not calculated because 
the transport from apical to basolateral was very low and therefore the variability 
was between the wells was very high when efflux ratios were used. Inhibition of 
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Pgp mediated transport of 3H-digoxin was found for alfentanil, fentanyl, sufentanil 
and loperamide, in accordance with the results found by Wandel and co-workers 
(Wandel et al. 2002). Interestingly, in our experiments morphine was identified as a Pgp 
inhibitor. In contrast, Wandel and co-workers (2002) did not show an inhibition of Pgp 
mediated efflux of 3H-digoxin when using a 5-fold lower morphine concentration. This 
indicates that the interaction of morphine and Pgp is relatively weak. No inhibition 
of Pgp mediated efflux of 3H-digoxin was found for nalbuphine, butorphanol and the 
morphine metabolites M3G and M6G. GF120918 inhibited the 3H-digoxin efflux to 
20%. Interestingly, the 3H-digoxin transport ratio could not be completely inhibited by 
GF120918 although GF120918 is a very potent Pgp inhibitor. This indicates that other 
transporters might be involved in the efflux of 3H-digoxin. In general, identical results 
were obtained using either the MDCKII:MDR1 or the LLC-PK1:MDR1a monolayers, 
though the variability in the LLC-PK1:MDR1a cells was a little higer. Taken together, 
these inhibition studies show that Pgp could influence the membrane transport 
characteristics of alfentanil, fentanyl, sufentanil, morphine and loperamide. 
The Pgp substrate efflux ratio was determined for all opioids. For alfentanil, fentanyl 
and sufentanil no Pgp mediated transport could be found, in accordance with literature 
(Wandel et al.  2002). For loperamide a Pgp efflux ratio value of 4 was found, confirming 
that loperamide is a strong Pgp substrate (Schinkel et al. 1995, 1996; Wandel et al. 2002). 
For morphine and nalbuphine, the Pgp substrate efflux ratio was initially determined 
at a donor concentration of 3 μM. Under these conditions the concentrations in the 
acceptor phase were below the limit of quantification of the assay. Therefore, morphine 
has been investigated at a donor concentration of 100 μM and was clearly detected as 
Pgp substrate (with an efflux ratio of 4). For nalbuphine, literature values were included 
(Mahar Doan et al. 2002) to calculate a Pgp substrate efflux ratio value of 2. This would 
indicate that nalbuphine is a substrate for Pgp, while an absence of inhibition of Pgp 
mediated transport of 3H-digoxin by nalbuphine was found. This apparent contradiction 
might be explained by the existence of several Pgp binding sites (Martin et al. 2000). 
The Papp values of <50, 50-250, >250 nm/sec were considered as low, moderate and 
high, respectively. Thus, for morphine a low permeability was found; for loperamide 
and nalbuphine a moderate permeability, and for alfentanil, fentanyl, sufentanil and 
butorphanol a high permeability. For alfentanil, fentanyl and sufentanil the high 
Papp values explain why these opioids could not be identified as Pgp substrates. The 
potential contribution of Pgp mediated transport to the overall membrane transport is 
too low to be detected, and therefore not of any significance. In contrast, for loperamide 
and morphine, the Papp values were very low, which means that their Pgp mediated 
transport is of more much relevance in the overall membrane passage. To summarise, 
these results emphasise that the passive transmembrane permeability rates should be 
considered when investigating the impact of Pgp interaction on membrane transport. 
80
CHAPTER 4
Our interest was to predict the impact of BBB transport on the in vivo PK-PD relationships 
of opioids. In the current experiment in vitro cell systems have been used, made up from 
kidney epithelium cells, for its robustness. For an extrapolation of the results found in 
this study to the in vivo BBB transport characteristics it should be realised that the BBB 
is comprised of brain capillary endothelial cells, which may differ from the kidney 
epithelial cells used in this study in terms of membrane characteristics and paracellular 
spaces, while also the functionality of Pgp may differ. Such differences may explain 
why fentanyl, in a study using an in vitro cell-system comprising of brain capillary 
endothelial cells, could be identified as a borderline Pgp substrate (Henthorn et al. 
1999). However, though small quantitative differences may exist between epithelial and 
endothelial membranes, the investigation of a whole set of opioids in a similar set-up 
will provide useful information on transport characteristics, which can be related to 
the differences observed in the in vivo PK-PD relationships. Therefore, based on the 
Papp values, it is to be expected that for morphine, loperamide and nalbuphine, passive 
transport across the BBB membrane plays a role in the PK-PD relation of centrally 
mediated effects. For alfentanil, fentanyl, sufentanil and butorphanol, a significant 
influence of BBB transport can be excluded. However, biophase pharmacokinetic 
processes like distribution within the brain should still be considered (Liu et al. 2005).
Based on the results presented here, a role of Pgp and BBB transport is expected in 
vivo for loperamide, morphine and potentially nalbuphine. Previously, the distribution 
of 3H-loperamide has been investigated in MDR1a wild-type and knock-out mice. A 
13.5 times higher concentration of 3H-loperamide was found in the brain of knock-out 
mice compared with the wild-type (Schinkel et al. 1996). For morphine, Letrent and 
co-workers showed that the anti-nociceptive effect in rats was prolonged after oral 
administration of GF120918, due to its prolonged half-life of in the brain (Letrent et al. 
1998, 1999a). For fentanyl, in MDR1a wild-type and knock-out mice it was shown that 
Pgp has a very small effect on the distribution and the anti-nociceptive effect  (Dagenais 
et al. 2004;Thompson et al. 2000). However, it should be noted that variability in the anti-
nociceptive data is relatively high and that the influence of Pgp on pharmacokinetics in 
blood and plasma was not considered in this study. For alfentanil, fentanyl, sufentanil 
and butorphanol no significant influence of Pgp and BBB transport on their central 
effects is expected.
In the last years, several in silico methods have been developed to predict passive 
BBB transport on the basis of physico-chemical properties, as reviewed by Clark 
and Norinder (Clark 2003; Norinder & Haeberlein 2002). These methods include the 
relationship between polar surface area and BBB penetration (Clark 1999; Kelder et al. 
1999; Norinder & Haeberlein 2002; van de Waterbeemd et al. 1998). Abraham and co-
workers have developed an in silico method that predicts passive BBB transport on the 
basis of several descriptors, including excess molar refraction, dipolarity/polarisability, 
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hydrogen bonding and size of the molecule (Abraham et al. 1994). Recently, it has been 
found that the dynamic polar surface area (non-linear) and logBB as calculated by the 
Abraham equation (linear) were significantly related to the in vitro BBB clearance values 
of a set of 11 structurally highly related adenosine A1 receptor agonists (Schaddelee et 
al. 2003). It was therefore of interest to investigate the potential of in silico prediction of 
the in vitro values for passive membrane transport for the whole set of opioids in this 
study. Thus, the relationships between Papp values and physicochemical properties were 
investigated by regression analysis. No significant correlations could be identified. This 
may be explained by the limited number of opioids included in the present analysis. 
Moreover, these opioids can be divided in two structurally different groups (figure 1). 
Taken together, in this stage, no conclusions can be drawn about the predictability of 
BBB transport of opioids on the basis of physicochemical properties.
It is concluded that the relative contribution of both Pgp mediated transport and 
passive permeability across the BBB should be considered in  the PK-PD relationships of 
opioids. For alfentanil, fentanyl, sufentanil and butorphanol, all having a high passive 
permeability value, membrane transport will be insensitive to Pgp. For nalbuphine, 
morphine and loperamide membrane transport is influenced by active Pgp transport, 
because of their low passive permeability membrane transport rates.
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Chapter 5
POPuLATION PHARMACOKINETIC MODELLING OF 
NON-LINEAR BRAIN DISTRIBuTION OF MORPHINE: 






Biophase equilibration must be considered to get more insight into the mechanisms 
underlying the pharmacokinetic-pharmacodynamic (PK-PD) correlations of opioids. 
The objective was to characterise in a quantitative manner the non-linear brain 
distribution kinetics of morphine. 
Experimental approach
Male rats received a 10-min infusion of 4 mg/kg of morphine, combined with a 
continuous infusion of the Pgp inhibitor GF120918 or vehicle, or 40 mg/kg. Unbound 
extracellular fluid (ECF) concentrations obtained by intracerebral microdialysis and 
total blood concentrations were analysed using a population modelling approach. 
Key results
Blood pharmacokinetics of morphine was best described with a three-compartment 
model and was not influenced by GF120918. Non-linear distribution kinetics in brain 
ECF was observed with increasing dose. A one compartment distribution model was 
developed, with separate expressions for passive diffusion, active saturable influx and 
active efflux by Pgp. The passive diffusion rate constant was 0.0014 min-1. The active 
efflux rate constant decreased from 0.0195 min-1 to 0.0113 min-1 in the presence of 
GF120918. The active influx was insensitive to GF120918 and had a maximum transport 
(Nmax/Vecf) of 0.66 ng/min.ml and is already saturated at low concentrations of morphine 
(C50 = 9.9 ng/ml). 
Conclusions and implications
Brain distribution of morphine is determined by 1) limited passive diffusion, 2) active 
efflux, reduced by 42% by Pgp inhibition and 3) low capacity active uptake. This 
implies blood concentration-dependency and sensitivity to drug-interactions. These 
factors should be taken into account in further investigations on PK-PD correlations of 
morphine.
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INTRODUCTION
The influence of biophase equilibration must be considered to get more insight into the 
mechanisms underlying the pharmacokinetic-pharmacodynamic (PK-PD) correlation 
of opioids. Biophase equilibration is mainly determined by blood brain-barrier (BBB) 
transport. The influence of BBB transport is dependent on (1) the morphology and 
functionality of the brain capillary endothelial cells representing the BBB, (2) the 
physiochemical properties of the drug and (3) the affinity of the drug for specific 
transporters present at the BBB. Transport across the BBB can be divided in passive and 
active transport processes. An important efflux transporter at the BBB is P-glycoprotein 
(Pgp), which is a member of the adenosine triphosphate-binding cassette super family 
and is encoded by the multidrug resistance gene (MDR1) (Thiebaut et al. 1987). This 
transporter has been shown to have an important influence on the brain distribution of 
a wide range of drugs (de Lange & Danhof 2002; Schinkel et al. 1995; 1996).
It is known from literature that opioids are substrate for Pgp (Henthorn et al. 1999; Letrent 
et al. 1998; 1999a; 1999b; Mahar Doan et al. 2002; Schinkel et al. 1995; 1996) (Henthorn et al. 
1999; Wandel et al. 2002). Recently, the relative contribution of Pgp mediated transport 
and passive permeability on the membrane transport of a wide range of opioids have 
been studied in an in vitro cell system comprising of MDCKII cells transfected with the 
human Pgp (chapter 4). It was shown that the influence of Pgp on membrane transport 
is highly dependent on the passive permeability of the opioids. Passive permeability 
is dependent on physicochemical properties like lipophilicity (van Bree et al. 1988); 
hydrophilic drugs are expected to have a low passive permeability whereas lipophilic 
drugs often have a high passive permeability. Alfentanil, fentanyl and sufentanil all 
have affinity for Pgp but the influence of Pgp mediated transport is minimal because of 
the high passive permeability rates of these opioids. In contrast, Pgp has as significant 
influence on the transport of morphine, loperamide and nalbuphine, because their 
passive permeability is relatively low. For morphine, transcortical microdialysis studies 
in Pgp-deficient mice (mdr1a -/- mice) and wild-type (mdr1a +/+) mice have shown that 
active transport mechanisms influence the brain distribution in vivo (Xie et al. 1999). In 
addition, brain perfusion studies have shown that the brain uptake is 1.24 times higher 
in mdr1a -/- mice compared to mdr1a +/+ mice (Dagenais et al. 2004). 
Furthermore, PK-PD studies in rats have revealed that after oral pre-treatment with the 
specific Pgp inhibitor GF120918, the anti-nociceptive effect of morphine was prolonged 
due to its prolonged half-life in the brain (Letrent et al. 1998; 1999a). Bouw and co-
workers have proposed a compartmental model to account for the delay of the anti-
nociceptive effect of morphine relative to corresponding plasma concentrations (Bouw 




The present investigations focus on the BBB transport of morphine in relation to the 
effect on the electroencephalogram (EEG) (Groenendaal et al., 2007 – chapter 6). For this 
purpose, the combined-EEG/microdialysis technique has been developed, which allows 
simultaneous investigation of both BBB transport and quantitative EEG monitoring in 
the same rat. The objective of this study was to characterise in a quantitative manner 
the relative contributions of passive and active transport mechanisms of morphine 
across the BBB upon intravenous administration of two distinct doses of morphine. 
METHODS
Study design
In order to investigate the influence of BBB transport on the PK-PD correlation of the 
EEG effect of morphine, the study was divided in three separate experiments, (1) EEG 
experiments, (2) combined EEG/MD experiments and (3) MD experiments. An overview 
of the experimental groups is shown in table 1. This paper focuses on the investigation 
of the transport mechanisms of morphine across the BBB (experiment 2 and 3) on the 
basis of population PK analysis of blood and extracellular fluid concentrations. The PK-
PD analysis of the EEG effect of morphine (experiment 1 and 2) will be discussed in a 
separate paper (Groenendaal et al., 2007 – chapter 6).
Chemicals
Morphine hydrochloride was purchased from Pharmachemie (Haarlem, The 
Netherlands) and GF120918 was kindly provided by GlaxoSmithKline (United 
Kingdom). Midazolam was obtained from BUFA (Uitgeest, The Netherlands). 
Vecuronium bromide (Norcuron®), heparin (20 U/ml) and physiological saline (0.9%) 
were both obtained from the hospital pharmacy of the Leiden University Medical 
Dose Treatment Method N Bodyweight (kg) Perfusate conc (ng/kg)
0 50 500
4 mg/kg Vehicle EEG 7 0.294 ± 0.023 n/a n/a n/a
EEG/MD 14 0.297 ± 0.014 N =10 N = 3 N = 3
MD 3 0.304 ± 0.023 N = 3
GF120918 EEG/MD 20 0.300 ± 0.030 N = 10 N = 5 N = 5
10 mg/kg Vehicle EEG 7 0.260 ± 0.015 n/a n/a n/a
40 mg/kg Vehicle EEG 5 0.273 ± 0.026 n/a n/a n/a
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Center (Leiden, The Netherlands). All chemicals were of analytical grade and solvents 
were of HPLC grade.
Microdialysis materials
Microdialysis probes, CMA/12 (4 mm, 400 μm inner diameter, 500 μm outer diameter) 
were supplied by Aurora Borealis Control BV (Schoonebeek, The Netherlands). 
The probe consisted of a polycarbonate-polyether co-polymeric membrane with a 
molecular cut-off of 20 kDa. The perfusion solution for microdialysis contained (in 
mM): NaCl 145, KCl 0.6, MgCl2 1.0, CaCl2 1.2 and ascorbic acid 0.2 in phosphate buffer, 
pH 7.4 (Moghaddam & Bunney 1989). The probes were connected to a BAS Beehive 
infusion pump (Bioanalytical systems Inc., Indiana, USA) with polyethylene tubing 
(O.D. 0.61 mm, I.D. 0.28 mm) supplied by Aurora Borealis Control BV (Schoonebeek, The 
Netherlands). Before use, the probes were activated according to the manufacturer’s 
protocol (CMA, Sweden).
Animals 
The protocol of these studies was approved by the Committee of Animal Experimentation 
of the Leiden University. Male Wistar rats weighing between 250-350 grams (Charles 
River, Maastricht, The Netherlands) were housed in groups for at least 7 days under 
standard environmental conditions (temperature 21 °C, humidity 60% and 12/12 hour 
dark/light cycle, with lights on at 7 AM). The animals had access to standard laboratory 
chow (RMH-TM, Hope Farms, Woerden, The Netherlands) and acidified water ad 
libitum. During the experiments, the animals were deprived of food and water.
Surgical procedures
The rats were divided into two different groups, the EEG/MD group (N=52) and 
the MD group (N=3). All rats were anesthetized with an intramuscular injection of 
0.1 mg/kg Domitor® (1 mg ml-1 medetomidine hydrochloride, Pfizer, Capelle a/d 
IJssel, The Netherlands) and a subcutaneous injection of 1 mg/kg Ketalar® (50 mg/ml 
Ketaminebase, Parke-Davis, Hoofddorp, The Netherlands). Ten days before the start 
of the experiments, four cortical electrodes were stereotactically implanted into the 
skull of the EEG rats as described before (Cox et al. 1997). Briefly, the electrodes were 
placed at the locations 11 mm anterior and 2,5 mm lateral (Fl), 3 mm anterior and 3,5 
mm lateral (Cl) and 3 mm posterior and 2,5 mm lateral (Ol) to lambda. A reference 
electrode was placed on lambda. In addition, a CMA/12 guide cannula with a dummy 
probe was placed in the striatum of the right brain hemisphere (anterior-posterior: 
+0.5 mm, lateral: +2.7 mm with bregma as reference and ventral: -3.5 mm ventral to 
the skull). The MD rats were only instrumented with a CMA/12 guide cannula with a 
dummy probe. The miniature connector and guide cannula were insulated and fixed 
to the skull with dental acrylic cement. For drug administration and the collection of 
blood samples, four indwelling cannulas were implanted to all groups of rats, one in 
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the right femoral artery for collection of serial blood samples and two in the left jugular 
vein (interna and externa) for morphine and midazolam administration. The fourth 
cannula was implanted into the right femoral vein to administer GF120918 or vehicle 
and vecuronium bromide. All cannulas were made from pyrogen free polyethylene 
tubing (Portex Limited, Hythe, Kent, United Kingdom). The arterial cannula consisted 
of 4 cm (I.D.=0.28, O.D.=0.61 mm) polyethylene tubing heat-sealed to 18 cm polyethylene 
tubing (I.D.=0.58, O.D.=0.96 mm). The venous cannula consisted of 3 cm (I.D.=0.28, 
O.D.=0.61 mm) polyethylene tubing heat-sealed to 10 cm polyethylene tubing (I.D.=0.58, 
O.D.=0.96 mm). The cannulas were subcutaneously tunnelled to the back of the neck 
of the rats. In order to prevent clotting the cannulas were filled with a 25% (w/v) 
polyvinylpyrrolidone (PVP, Brocacef, Maarssen, The Netherlands) solution in saline 
containing 50 IU/ml heparin (Pharmacy, Leiden University Medical Centre, Leiden, 
The Netherlands). During the surgical procedures, the body temperature of the rats 
was maintained constant at 38 °C using a CMA/140 temperature controller (Aurora 
Borealis, Schoonebeek, The Netherlands). After surgery, 4 mg ampicilline (A.U.V., 
Cuijk, The Netherlands) was administered to aid recovery. At 16 to 24 hours before 
the experiments, the dummy microdialysis probe was removed from the microdialysis 
guide and replaced by the brain probe (CMA/12, 4 mm membrane).
Microdialysis probe recovery
The microdialysis probe recovery was investigated both in vitro and in vivo. To check the 
flow rate through the microdialysis probes, the samples were collected in pre-weighed 
collection vials. At the end of the experiment, the vials were weighed to determine 
the volume collected within the sampling interval and thereby the flow rate.When the 
flow rate was too low (lower than 95% of 2μl/min) or too variable, the results were 
omitted from data analysis. The in vitro recovery was investigated to check the probe 
response time to changes in the bulk or perfusate in terms of rate and extent, as well as 
symmetry (gain=loss). Therefore, the probes were placed in blank perfusion fluid and 
perfused with blank perfusion fluid for 90 min to stabilize the system. Next, the probes 
were placed in perfusion fluid containing either 50 ng/ml or 500 ng/ml morphine and 
perfused with blank perfusion fluid for 90 min to determine the gain (equation 1).
Where Cout represents the morphine concentration in the dialysate outflow, and Cb 
represents the bath concentration in which the probes are placed. After a washout 
period (blank perfusion fluid in both bath and probe) of 90 min, the probes were placed 
in blank perfusion fluid and flushed with either 50 ng/ml or 500 ng/ml to determine 
the recovery using the retrodialysis method (Bouw & Hammarlund-Udenaes 1998). 
During the experiments, 15 minute fractions were collected at a flow rate of 2 μl/min. 
The in vitro recovery of morphine was calculated by measuring the loss of morphine 
(1)
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from the probe into the bath according to equation:
Where Cin is the morphine concentration flushed through the microdialysis probe 
and Cout is the morphine concentration in the dialysate outflow. The recovery was 
also determined in vivo to take into account the influence of periprobe processes 
(Bungay et al. 1990) and was used to calculate ECF concentrations from microdialysate 
concentrations. The experiment was performed according to a combined retro-DNNF 
method to determine in vivo recovery in order to obtain concentration- as well as 
time-dependent recovery values of morphine. The probes were perfused for 60 min 
with a blank perfusion solution to stabilise the microdialysis and to obtain blank 
samples. Subsequently, according to a retrodialysis approach (Bouw & Hammarlund-
Udenaes, 1998) the microdialysis probes were perfused with morphine concentrations 
of 0, 50 or 500 ng/ml (see table 1) for a period of 60 minutes before the intravenous 
administration of morphine, to determine whether the loss of morphine from the probe 
was concentration dependent or influenced by GF120918. The perfusion concentrations 
were maintained during the full experiment, according to the DNNF principle (Olson 
& Justice, Jr., 1993), in order to determine time-dependent values for in vivo recovery 
after iv administration of morphine. However, in contradiction to previous results for 
morphine in mice (Xie et al. 1999), in this case no conclusions could be drawn from the 
microdialysis data obtained for the DNNF rats after iv administration of morphine. 
Therefore these data were omitted from further analysis. The in vivo recovery was 
calculated from the retrodialysis period on the basis of the retrodialysis data of 
the 50 and 500 ng/ml perfusion concentrations (equation 2) and used to correct the 
microdialysis values obtained from the group of rats with the blank perfusion.
Experimental procedures
The EEG/MD rats were randomly divided in three groups and received a 10-min 
intravenous infusion of 4 or 40 mg/kg morphine combined with a continuous infusion 
of the Pgp inhibitor GF120918 or vehicle (figure 2). The MD rats all received a 10-min 
infusion of 4 mg/kg morphine and a continuous infusion of GF120918. Morphine 
hydrochloride was dissolved in saline. GF120918 infusion consisted of a 1-min bolus 
infusion of 6 mg/kg dissolved in DMSO followed by a continuous infusion of 25 ng/
min dissolved in DMSO/glucose/cyclodextrine 5/5/10% in saline. All rats also received 
a continuous infusion of midazolam to prevent opioid induced seizure activity at a rate 
of 5.5 mg/kg.h (Cox et al. 1997). Midazolam solutions were prepared in physiological 
saline containing an equimolar concentration of hydrochloric acid, based on the body 
weight of the rat. To reach steady state rapidly, midazolam was administered according 
to a Wagner infusion scheme, with an initial infusion rate of 3 times the steady state 




All experiments started between 8.30 and 9.30 AM to minimise the influences of 
circadian rhythms. At the start of the experiment (t=-120 min), EEG recording was 
started (when applicable), the microdialysis probes were equilibrated for 60 min and 
the GF120918 or vehicle infusion was started. After 30 min (t=-90 min), midazolam 
infusion was started followed by the retrodialysis phase of the experiment (t=-60 min). 
Thereafter, at t=0 morphine was administered in a zero-order infusion for 10 minutes 
using a BAS Beehive infusion pump (Bioanalytical systems Inc., Indiana, USA). During 
the experiment, a total number of between 25 and 30 dialysate fractions (10 to 60 μl each) 
at a flow rate of 2 μl/min and 15 arterial blood samples (50 to 200 μl) were collected at 
pre-defined time intervals for determination of morphine concentrations. Additionally, 
6 blood samples (50 μl) were collected for determination of GF120918 and midazolam 
concentrations. The total volume of blood collected did not exceed 2 ml (including blood 
gas samples, see below). During the experiments, body temperature was stabilised 
between 37.5 and 38.5 °C using a CMA/140 temperature controller (Aurora Borealis, 
Schoonebeek, The Netherlands). Bipolar EEG leads on the left hemisphere (Cl-Ol) 
were continuously monitored and analysed off-line with fast-Fourier transformation. 
Changes in the amplitudes in the d-frequency band of the EEG (0.5-4.5 Hz) were used 
as a pharmacodynamic endpoint. Details of the EEG effect measurements will be 
presented in a separate paper. 
Monitoring of blood gas status and artificial ventilation
During and after the infusion of morphine, arterial blood samples were collected to 
monitor arterial pH, pO2 and pCO2 levels using a Corning 248 Blood Gas Analyzer 
(Bayer, Meidrecht, The Netherlands) and to identify respiratory depression. During 
and after administration of 40 mg/kg morphine, severe respiratory depression and 
muscle rigidity occurred. These rats were artificially ventilated with preheated air (32 
°C) using an Amsterdam Infant Ventilator, model MK3 (Hoekloos, Amsterdam, The 
Netherlands) through a custom made ventilation mask as described by Cox and co-
workers (Cox et al. 1997). The ventilation settings were: ventilation frequency 62 beats/
min, I-E ratio 1:2 and air supply flow rate 0.7-1.0 l/min. 5 minutes after start of the 
morphine infusion, the rats received an intravenous bolus dose of 0.15 mg vecuronium 
bromide dissolved in saline and artificial ventilation was started. Vecuronium bromide 
was used to counteract muscle rigidity to enable artificial ventilation. Vecuronium 
doses of 0.10 mg were administered repeatedly when muscle rigidity re-appeared until 
respiratory activity re-occurred. Blood gas status was carefully monitored during and 
after artificial ventilation.
Drug analysis
Morphine blood samples – Samples were analysed by high performance liquid 
chromatography with electrochemical detection (HPLC-ECD) as described previously 
(Groenendaal et al. 2005 – chapter 3). Briefly, after addition of internal standard 
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(nalorphine 500 ng/ml, 50 μl) the blood samples were alkalinised with carbonate buffer 
(0.15 mM, pH 11, 500 μl) and extracted with 5 ml ethyl acetate. The organic layer was 
transferred into clean glass tubes and evaporated to dryness under reduced pressure at 
37 °C. The HPLC system consisted of a LC-10AD HPLC pump (Shimadzu, Kyoto, Japan), 
a Waters 717 plus autosampler (Waters, Milford, MA, USA), a pulse damper (Antec 
Leyden, Zoeterwoude, The Netherlands) and a digital electrochemical amperometric 
detector (DECADE, software version 3.02) from Antec Leyden. The electrochemical 
detector consisted of a VT-03 electrochemical flow cell combined with a 25 μm spacer 
and an Ag/AgCl reference electrode operating in the DC mode at a temperature of 
30 °C, set at a voltage of +0.75V. Chromatography was performed on C18 Ultrasphere® 
5 μm column (4.6 mm I.D. x 150 mm) (Alltech, Breda, The Netherlands) equipped with 
a refill guard column. The mobile phase was a mixture of 0.1 M phosphate buffer 
(pH 4) and methanol (75:25, v/v) and contained a total concentration of 20 mg/l EDTA 
and 2.0 mM octane-sulfonic acid. The flow rate was set at 1 ml/min. Data acquisition and 
processing was performed using the Empower integration software (Waters, Milford, 
MA, USA). The intra- and inter-assay variation was less than 10% and the lower limit of 
quantification was 25 ng/ml for a 50 μl blood sample.
Morphine dialysate samples – Samples were analysed by high performance liquid 
chromatography with electrochemical detection (HPLC-ECD) as described previously 
(Groenendaal et al., 2005 – chapter 3). The samples were analysed without sample pre-
treatment. Internal standard nalorphine (500 ng/ml) was added to the samples in a 2:5 
ratio, which means 2 μl of internal standard solution for every 5 μl of sample. Since the 
volume of the microdialysate samples varied throughout the experiment, this method 
was required to keep the concentration of internal standard constant in all samples. The 
HPLC system was the same as described for the blood samples. The electrochemical 
detector consisted of a VT-03 electrochemical flow cell combined with a 25 μm spacer 
and an Ag/AgCl reference electrode operating in the DC mode at a temperature of 
30 °C, set at a voltage of +0.85V. Chromatography was performed on C18 Ultrasphere® 
5 μm column (2.0 mm I.D. x 150 mm) (Alltech, Breda, The Netherlands) equipped with 
a refill guard column. The mobile phase was a mixture of 0.1 M phosphate buffer (pH 
2.5) and methanol (75:25, v/v) and contained a total concentration of 20 mg/l EDTA and 
10 mM octane-sulfonic acid. The flow rate was set at 0.15 ml/min. Data acquisition and 
processing was performed using the Empower integration software (Waters, Milford, 
MA, USA). The lower limit of quantification was 0.5 ng/ml for a 40 μl dialysate sample. 
The intra-assay variation was less than 0.1% and inter-assay variation was less than 
10%.
GF120918 blood samples – Samples were analysed by high performance liquid 
chromatography with fluorescence detection. After addition of internal standard 
(chloropromazine, 500 ng/ml, 50 μl) the samples were alkalinised with sodium 
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hydroxide (0.1 M, 500 μl) and extracted with ethyl acetate. After centrifugation (10 min, 
4000 rpm), the organic layer was transferred into clean glass tubes and evaporated to 
dryness under reduced pressure at 37 °C. The HPLC system consisted of a LC-10AD 
HPLC pump (Shimadzu, Kyoto, Japan), a Waters 717 plus auto sampler (Waters, Milford, 
MA, USA), and a fluorescence detector (Perkin Elmer) set at lex = 260 nm and lem = 
460 nm. Chromatography was performed on a stainless-steel Microsphere® C18 3 μm 
cartridge column (10 mm x 4.6 mm I.D.) (Chrompack Nederland BV, Bergen op Zoom, 
The Netherlands). The mobile phase was a mixture of 0.4 M acetate buffer (pH 4.6) 
and acetonitrile (50:50, v/v). The flow rate was set at 1 ml/min. Data acquisition and 
processing was performed using the Empower integration software (Waters, Milford, 
MA, USA). The intra- and inter-assay variation was less than 20% and the lower limit of 
quantification was 100 ng/ml for a 50 μl blood sample.
Midazolam blood samples – Samples were analysed as described previously by 
Mandema and co-workers (Mandema et al. 1991). The method consisted of a liquid-
liquid extraction with NaOH and dichloromethane/petroleumether (45/55, v/v). After 
extraction, samples were injected onto an HPLC coupled to an ultraviolet detector. The 
intra- and inter-assay variation was less than 6% and the lower limit of quantification 
was 50 ng/ml for a 50 μl blood sample.
Pharmacokinetic data analysis
The pharmacokinetic data of both blood and brain ECF were analysed using non-
linear mixed effect modelling as implemented in the NONMEM software version V, 
level 1.1 (Beal & Sheiner 1999). Parameter estimation was undertaken using the first-
order conditional estimation method (FOCE interaction). All fitting procedures were 
performed on an IBM-compatible computer (Pentium IV, 1500 MHz) running under 
Windows XP with the Fortran Compiler Compaq Visual Fortran version 6.1. Structural 
model selection for both the blood and the ECF PK model was based on the likelihood 
ratio test, diagnostic plots (observed concentrations vs. individual and population 
predicted concentrations, weighted residuals vs. predicted time and concentrations), 
parameter correlations and precision in parameter estimates. The likelihood ratio test is 
based on a comparison of the minimum value of the objective function (MVOF) of two 
models. The significance level was set at 0.01, which corresponds to a decrease of MVOF 
of 6.6 points when an extra parameter is included in the structural model under the 
assumption that the difference in MVOF between two nested models is c2 distributed. 
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where Pi is the individual value of the model parameter P, Ptyp is the typical value 
(population value) of parameter P in the population, and hi is realisation from a 
normally distributed inter-animal random variable with mean zero and variance w2. 
Inter-individual variability was investigated for each parameter and was fixed to zero 
when no significant decrease in the MVOF was obtained. Correlations between the 
inter-individual variability of the various parameters were graphically explored.
The residual error, which accounts for unexplained errors (e.g. measurement and 
experimental errors) in the blood drug concentrations, was best described with a 
proportional error model according to equation:
with
where Cobs,ij is the j-th observation of the i-th individual, Cpred,ij is the predicted 
concentration and eij is from a normally distributed residual random variable with 
mean zero and variance s2.
The accuracy of the pharmacokinetic models was investigated by an internal validation 
method, the visual predictive check (Cox et al. 1999; Duffull & Aarons 2000; Yano et 
al. 2001). With this method, 1000 curves were simulated from the final PK parameter 
estimates. The median, lower (2.5%) and upper (97.5%) limit of the interquantile range 
of the simulated concentrations were calculated and compared with the position of the 
observations.
Pharmacokinetic analysis of blood profiles
For the development of the pharmacokinetic structural models for blood, both two- and 
three-compartment models were tested. On the basis of model selection criteria a three-
compartment model was chosen. Pharmacokinetic analysis was performed with the 
PREDPP subroutines ADVAN 11 TRANS 4 implemented in NONMEM with estimation 
of the pharmacokinetic parameters clearance (Cl), inter-compartmental clearances (Q2 
and Q3) and the volumes of distribution (V1, V2 and V3). 
To refine the pharmacokinetic model, the relationship between bodyweight and the 
different parameters was explored graphically. The following equation was used to 
model the parameter as a function of bodyweight (BW):
where Pi is the individual value of a model parameter and q1 and q2 are the intercept and 
slope factor of the relationship between the individual parameter and bodyweight.








In which GF120918 is a factor, set to 1 if GF120918 is co-infused and set to 0 if vehicle is 
co-infused.
Pharmacokinetic analysis of morphine brain distribution
Simulations were performed to evaluate the influence of different transport mechanisms 
on the transport of morphine across the BBB. The simulations were performed using 
Berkeley Madonna (version 8.0.1, Macey & Oyster) and were based on the approach by 
Hammarlund and co-workers (1997). The population parameter values of the blood PK 
model were used in the simulations. The non-linear transport model contains specific 
expressions for 1) passive diffusion, 2) an active saturable uptake mechanism and 3) an 
active efflux by Pgp (figure 1).
The transport model is based on indications from literature on the active uptake of 
morphine (Xie et al., 1999), simulations of different transport processes (Hammarlund-
Udenaes et al. 1997) and the models proposed by Upton and co-workers (Upton et 
al. 2000; Xie et al. 1999). The model consists of one brain ECF compartment which is 
poorly perfused and diffusion limited. The BBB is located between the blood and ECF 
compartment. 
The mass exchange between the blood and ECF compartment consists of three terms, 
a passive diffusion flux Qdiff.(Cblood-Cecf), an active saturable influx and an active Pgp 
mediated efflux which can be described following equation:
in which the right side of the equation represents the net mass exchange between the 
blood and ECF compartment. Aecf is the amount of morphine in the ECF compartment, 
(9)
Figure 1: A schematic overview of the non-linear transport model to describe the brain ECF data. The morphine 
blood pharmacokinetics are described with a three-compartment model and used as input function for morphine 
in	the	brain.	The	brain	model	consists	of	one	brain	compartment	and	mass	exchange	between	blood	and	brain	is	
described	with	separate	expressions	for	passive	diffusion,	active	saturable	influx	and	active	efflux	by	Pgp,	which	
could	 be	 influenced	 by	GF120918.	 Abbreviations:	 kdiff is the diffusion rate constant between blood and brain 
compartment; Nmax	 is	 the	maximum	active	 influx;	C50	 is	 the	morphine	blood	concentration	at	which	50%	of	 the	
maximum	active	influx	is	reached	and	keff	is	the	active	efflux	rate	constant,	which	is	influenced	by	GF120918.
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Qdiff is the diffusion clearance, Cblood is the concentration in the central blood compartment, 
Cecf is the concentration in the ECF compartment, Nmax is the maximal active influx, C50 
is the morphine concentration in the blood compartment at which 50% of the maximal 
active influx is reached and (Qeff.Cecf) is the active efflux by Pgp which is influenced by 
GF120918. 
Accordingly, the concentration in the ECF compartment can be described as:
Parameter aggregation yields:
Where kdiff is the diffusion rate constant and keff is the active efflux rate constant.
Pharmacokinetic analysis of brain ECF profiles
For the development of the pharmacokinetic structural models for brain ECF, the 
PREDPP subroutine ADVAN6 was used, which is a general nonlinear model that uses 
the numerical solution of the differential equations. The influence of co-infusion of 
GF120918 on the PK parameter was investigated following equation 8.
RESULTS
Pharmacokinetics in blood
Figure 2 shows the observed, population predicted and 2.5% and 97.5% quantiles for 
morphine concentrations in blood, after administration of a 10-min infusion of 4, 10 and 
40 mg/kg in the presence of vehicle or GF120918. Based on the MVOF and diagnostics, the 
pharmacokinetics of morphine in blood was best described with a three-compartment 
model and was not influenced by co-infusion of GF120918. A tendency towards dose-
dependent elimination was observed (figure 2). The parameters were estimated 
accurately with acceptable coefficient of variance (table 2). Covariate analysis showed 
linear relationships between bodyweight and Cl and between bodyweight and V2. The 
accuracy of the models was investigated using the predictive check. The selected PK 
models could well predict the time course of morphine after intravenous infusion as is 





Parameter Estimate Cv% LLCI – uLCI
Structural model
Cl (ml/min)
Intercept 20 5.6 18.5 – 23.1
Slopefactor 5.35 25.2 5.66 – 11.3
V1 (ml) 68.1 16.7 45.8 – 90.4
Q2 (ml/min) 15.5 11.3 12.1 – 18.9
V2 (ml)
Intercept 739 7.6 629 – 849
Slopefactor 8.5 17.1 2.70 – 7.99
Q3 (ml/min) 17.8 18.4 11.4 – 24.2
V3 (ml) 133 15.9 91.6 – 174
Interanimal variability
ω2 Cl 0.129 17.2 0.085 – 0.173
ω2 V2 0.099 24.7 0.051 – 0.147
Residual variability
Proportional error 0.074 10.2 0.059 – 0.089
Figure 2:	Pharmacokinetics	of	morphine	in	blood.	Observed	(grey	dots),	population	predicted	(solid	line)	and	2.5%	
and	97.5%	quantiles	(dotted	lines)	are	depicted	for	each	dose	group.	The	grey	bar	indicates	the	infusion	time.
Table 2: Population pharmacokinetic parameter estimates of morphine in blood obtained with a three compartment 
model.
Abbreviations: Cl = clearance; Q2/Q3 = inter-compartmental clearances; V1 = volume of  distribution in central 
compartment, V2/V3 = volumes of distribution in peripheral compartment; slopefactor = linear relationship between 
bodyweight and Cl or V2; CV% = coefficient of variation; LLCI = lower limit of confidence interval; ULCI = upper 
limit of confidence interval.
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GF120918 blood concentrations
Three blood samples were collected for determination of the GF120918 concentrations 
in blood. The first sample was collected at the end of the bolus infusion and the mean 
(± SEM) concentration in blood was 11650 ± 2560 ng/ml. The second and third blood 
samples were collected randomly from start of the morphine infusion until the end of 
the experiment. The mean (± SEM) GF120918 concentration in blood was 214 ± 16 ng/ml, 
which was sufficient to block Pgp (GSK, personal communication).
Midazolam blood concentrations
Three blood samples were collected for determination of the midazolam concentrations 
in blood. The first sample was collected prior to morphine administration and the mean 
(± SEM) concentration in blood was 879 ± 75 ng/ml. The second and third blood samples 
were collected randomly from the start of the morphine infusion until the end of the 
experiment. The mean (± SEM) midazolam concentration in blood was 937 ± 56 ng/ml, 
which was sufficient to suppress potential opioid-induced seizure activity (Cox et al. 
1997).
Recovery of the microdialysis probes
The in vitro recovery experiments showed that gain is equal to loss, indicating that no 
adhesion to probe materials occurs with an instantaneous reflection of bulk morphine 
concentrations. The individual recovery values were calculated on the basis of six 
microdialysis fractions. The average recovery values in vitro were 25 ± 5.0 and 24 ± 5.6 % 
for retrodialysis solutions of 50 and 500 ng/ml, respectively.
The average recovery values in vivo, as determined with prior to systemic administration 
of morphine, were 16 ± 9.9 and 20 ± 3.5 % for retrodialysis solutions of 65 and 622 ng/
ml. No difference was found between the vehicle and GF120918 pre-treated group, 
indicating that co-infusion of GF120918 does not influence the in vivo recovery. Since 
the experimental design does not allow estimation of individual recovery values, for 
the 4 mg/kg and the 4 mg/kg + GF120918 group the average recovery value of 16.1% is 
used and for the 40 mg/kg group a value of 20.3 % was used.
Pharmacokinetics in brain ECF
Morphine brain distribution kinetics was investigated using two distinctly different 
doses for an extensive period of 4-6 hours. With this approach data were collected over 
a broad concentration range, which allowed detailed pharmacokinetic analysis. The 
individual observed morphine concentrations in brain ECF are shown in figure 3.
The brain ECF concentrations increased rapidly after start of the morphine infusion, 
the maximum concentration of morphine was observed within 40 minutes after start 
of the infusion for the 4 mg/kg groups and within 20 min for the 40 mg/kg group. For 
the 4 mg/kg groups, after 20 min a relatively stable plateau in morphine brain ECF 
concentrations was reached. However, for the 40 mg/kg a clear decline in brain ECF 
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concentration was observed. When morphine concentrations were normalised to a dose 
of 4 mg/kg, the non-linearity in distribution kinetics in brain ECF was evident (figure 
4). Moreover, at higher doses a reduction of the dose-normalized AUC is observed. The 
dose-normalised AUC was calculated over the largest common interval (0 – 165 min) 
using the log-linear trapezoidal rule and had mean values of 6810 ± 1890, 8460 ± 2790 
and 3990 ± 2180 ng.h/ml for the 4 mg/kg, mg/kg + GF120918 and the 40 mg/kg group, 
respectively.
For the 4 mg/kg dose group, the net elimination from the brain was much slower 
compared to the 40 mg/kg dose group. This process could not be described with a 
linear brain model, and the profiles suggested that transport of morphine is influenced 
both by an active influx transport process and the active efflux transport, mediated by 
Pgp. The active influx was supposed to be saturated already at low concentrations of 
morphine (4 mg/kg). 
Figure 4: Observed morphine brain ECF concentrations after normalisation for dose (normalisation dose 4 mg/
kg). The grey bar indicates the infusion time. The dose is depicted at the top of each panel.
Figure 3: Observed morphine brain ECF concentrations for each dose group. The grey bar indicates the infusion 
time.
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This behaviour of the proposed brain distribution model was evaluated using 
simulations in Berkeley Madonna. Figure 5 shows the simulated time courses of the 
brain ECF concentrations upon administration of morphine with doses ranging from 4 
to 40 mg/kg in the absence and presence of GF120918. Results show that, consistent with 
the observations in the experiments, relatively stable ‘plateau’ brain ECF concentrations 
or morphine are observed at low doses, while with increasing doses a clear decline is 
observed.
Next, the non-linear transport model was fitted to the data and resulted in a good 
description of the brain ECF profiles. Morphine concentrations could be adequately 
described with this model as shown in figure 6 and table 3. Specifically, when the 
active efflux of morphine in the presence of GF120918 was set to zero, this resulted in a 
significant worsening of the fit. The best fit was obtained when different values of the 
efflux rate constant keff were estimated for the presence or absence of GF120918. In the 
presence of GF120918, the value of the efflux rate constant keff decreased from 0.0195 to 
0.0113 min-1. This suggests that around 50% of the active efflux process is mediated by 
transporters other than Pgp.
In the population analysis, precise estimates could be obtained for all parameters. The 
coefficients of variation were all below 50% except for the C50 which was estimated at 
71.5%. Inter-animal variability (w2) was estimated for kdiff and keff and was 0.238 and 
0.080, respectively. In addition, a correlation was found between the post-hoc individual 
estimates of kdiff and keff and therefore a covariance block was included in the final model. 
Inter-animal variability could not be estimated accurately for the other parameters 
and was therefore fixed to zero. The individually observed morphine brain ECF 
concentrations do not deviate substantially from individual predicted concentrations 
as is shown by the goodness-of-fit plots (figure 7). The weighted residuals, which is 
the difference between observed and predicted morphine ECF concentrations, were 
Figure 5:	Simulations	of	the	proposed	non-linear	transport	model,	consisting	of	separate	expressions	for	passive	
diffusion,	active	saturable	influx	and	active	efflux	by	Pgp,	which	could	be	influenced	by	GF120918.	The	grey	line	
represents the pharmacokinetics in plasma and the black lines the pharmacokinetics in brain ECF.
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randomly distributed around zero in time, indicating that the structural model is 
plausible. In general the model can predict the brain ECF concentration adequately as is 
shown in figures 6 and 7. The model development was mainly driven by knowledge of 
different transport processes, such as efflux by Pgp (Xie et al., 1999, Letrent et al., 1999).
Parameter Estimate Cv% LLCI – uLCI
Structural model
kdiff  (min-1) 0.001 12.6 0.0010 – 0.0017
keff (min-1)
-GF120918 0.0195 12.2 0.0149 – 0.0241
+GF120918 0.0113 25.4 0.0057 – 0.0169
Nmax* (ng/min) 0.658 26.1 0.321 – 0.995
C50 (ng/min) 9.92 71.5 -3.97 – 23.8
Interanimal variability
ω2 kdiff 0.238 56.3 -0.025 – 0.501
ω2 keff 0.08 36.8 0.022 – 0.137
ω2 keff ~ ω2 keff 0.059 85 -0.039 – 0.158
Residual variability
Proportional error 0.094 21.4 0.055 – 0.134
Abbreviations: kdiff = diffusion rate constant; keff = active efflux rate constant; Nmax* = maximum active influx; C50 = 
morphine blood concentration at which 50% of the maximal active influx is reached; CV% = coefficient of variation; 
LLCI = lower limit of confidence interval; ULCI = upper limit of confidence interval.
Figure 6: Pharmacokinetics of morphine in brain ECF. Observed (grey dots), population predicted (solid line) and 
2.5%	and	97.5%	quantiles	(dotted	lines)	are	depicted	for	each	dose	group.	The	grey	bar	indicates	the	infusion	
time. 
Table 3: Population pharmacokinetic parameter estimates of the non-linear transport model of morphine in brain 
ECF
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DISCUSSION
The influence of biophase equilibration must be considered to get more insight into the 
mechanisms underlying the pharmacokinetic-pharmacodynamic (PK-PD) correlation 
of opioids. Biophase equilibration is mainly determined by blood brain-barrier (BBB) 
transport. For morphine clear indications exist that BBB transport influences the 
biophase equilibration (Bouw et al. 2000). As part of the present investigations that focus 
on the BBB transport of morphine in relation to the PK-PD correlation for the effect on 
the electroencephalogram (EEG) (Groenendaal et al., 2007 – chapter 6), the objective 
of the present study was to characterise, in a quantitative manner, the influence of 
passive and active transport mechanisms of morphine across the BBB. To this end, a 
large concentration-range of morphine in blood and brain ECF following intravenous 
administration 4 mg/kg, in the presence and absence of GF120918, and 40 mg/kg have 
been analysed on the basis of a three compartment pharmacokinetic model and a one 
compartment brain distribution model, respectively. It was deduced that BBB transport 
of morphine consists of passive diffusion, in parallel with active saturable influx and 
active efflux mechanisms.
Pharmacokinetics in blood
The pharmacokinetics of morphine in blood was best described by a three-compartment 
model, based on blood concentration data up to 360 min after the start of the morphine 
infusion. In previous studies plasma pharmacokinetics were described with a two-
compartment model, for data up to 180 min (Bouw et al. 2000; Tunblad et al. 2004). This 
longer sampling period allows a more detailed analysis of the terminal phase of the 
Figure 7:	Goodness-of-fit	plots	of	morphine	concentrations	 in	brain	ECF	for	 the	non-linear	 transport	model.	 In	
the left panel a scatterplot is depicted of the observed morphine concentrations versus the individual model 
predictions. The line represents the line of unity. In the right panel a scatterplot is depicted of weighted residuals 
versus time (right panel). The circles represent the data of the 4 mg/kg group, the triangles represent the 4 mg/kg 
+ GF120918 group and the squares represent the 40 mg/kg group.
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morphine pharmacokinetics, especially following the administration of a higher dose 
(40 mg/kg). A tendency towards dose-dependent elimination was observed (figure 2). 
However, there are no indications from literature for a dose-dependent elimination of 
morphine, nor could it be identified on the basis of the current data.
It is known that morphine is metabolised into glucuronides. The main metabolite in 
rats is morphine-3-glucuronide (M3G). In humans, morphine is also metabolised into 
M6G. However, upon intravenous administration of morphine in rats, M6G has not 
been detected in plasma (Coughtrie et al., 1989, van Grugten et al., 1997, Salem and Hope, 
1997). Research has shown that M3G only has minor antinociceptive effects (Ekblom et 
al. 1993; Gardmark et al. 1993), it has not been analysed in this study. Also, because M3G 
is not a Pgp substrate (Letrent et al. 1999a; Xie et al. 1999), the potential influence of M3G 
on P-glycoprotein interaction could be excluded. On that basis it seems highly unlikely 
that the glucuronide metabolites are of significant influence on the BBB transport in 
our experiments.
Distribution into brain ECF
The proposed novel brain distribution model is rather complex; in contrast to previously 
proposed models it contains a passive diffusion component and two active transport 
mechanisms, contributing to the influx and the efflux, respectively. The transport 
model is based on indications from literature on the active uptake of morphine (Xie et 
al., 1999), simulations of different transport processes across the BBB (Hammarlund-
Udenaes et al. 1997) and the models proposed by Upton and co-workers (2000). 
To describe transport from blood to brain over a large concentration-range, a model was 
developed by a stepwise approach. Linear brain distribution models with and without 
active efflux could not describe the data. Next, a model was developed that consisted 
of a perfusion (cerebral blood flow-limited) compartment and a deeper membrane-
limited compartment (the brain ECF). However, this perfusion component could not be 
identified nor did inclusion of this term yield a significant improvement in the goodness-
of-fit. For this reason, the perfusion term was removed from the model. This indicated 
that cerebral blood flow is not a rate-limiting step in the transport of morphine across 
the BBB. This was expected on the basis of its physico-chemical properties (logP of ~0.7, 
and pKa of 7.9) and literature data on in vivo uptake clearance. A clearance value of 0.010 
ml/min.g brain was found in mice (Dagenais et al 2001), and values ranging from 0.011 
to 0.014 ml/min.g brain in rat (Bouw et al., 2000 ; Tunblad et al., 2004). and an in situ PS 
value of 0.008 ml/min.g brain in rat (Wu et al., 1997). These values are much lower than 
cerebral blood flow values of around 1-2 ml/min.g brain in mice and rats. 
The non-linearity in the brain ECF concentration data indicated the presence of active 
efflux that was sensitive to inhibition by GF120918 as well as the presence of active 
saturable influx. Since, the uptake into the brain is composed of passive diffusion and 
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active influx, the uptake clearance (Clin) is not a single value and can therefore not 
be directly compared with literature data. However, based on the literature values 
of Clin ranging between 0.011-0.014 ml/min.g brain obtained with a rather similar 
experimental setting (Bouw et al. 2000; Tunblad et al. 2004), it can be concluded that this 
value is much smaller than rat CBF. At high doses, like many other opioids, morphine 
induces respiratory depression as a side-effect, which results in a decrease in pO2, 
an increase in pCO2 and a decrease in pH. To keep these changes to a minimum, in 
our experiments artificial ventilation was applied at the 40 mg/kg dose of morphine. 
Passive diffusion of morphine (with pKa of 7.9) into the brain pH dependent; at higher 
pH values, because of relatively more neutral morphine molecules available. This 
has been demonstrated experimentally by Bouw and co-workers (2000). The artificial 
ventilation in our experiments prevented a decrease in pH and therefore probably has 
resulted in a higher value for the passive diffusion uptake clearance in our study.
The influence of an active saturable influx transporter has never been proposed in 
population pharmacokinetic analyses. In an earlier study using microdialysis in mice, 
the presence of an active influx process was already indicated by brain/blood ratios 
that were much higher at low blood concentrations, both in MDR1a (+/+) and (-/-) mice 
(Xie et al. 1999). These observations also indicated that the active influx is not sensitive 
to changes in Pgp efflux. Our study is the first to characterize such an active influx 
in quantitative terms. Other studies only had access to concentrations after a single 
morphine dose of 1 mg/kg with low resolution PK microdialysis data of 30 min intervals 
(Letrent et al. 1998; 1999a) or concentrations that resulted from a dose range of 10 and 40 
mg kg-1 that probably already had saturated the active influx component (Bouw et al. 
2000). However, Letrent and co-workers (1999) found morphine brain ECF/blood ratios 
of ~0.5 which were about 2-fold higher compared to the brain ECF/plasma ratio of ~0.25 
found by Bouw and co-workers (2000). This also supports the existence of active influx 
at lower blood concentrations. It remains to be elucidated, however, if such active influx 
is also present in and relevant for the human situation.
Several in vitro and in vivo studies have shown that morphine is a substrate for Pgp 
(Dagenais et al. 2004; Letrent et al. 1998; 1999a; 1999b; Schinkel et al. 1995; Wandel et al. 
2002; Xie et al. 1999). In this study, a clear influence of active brain efflux could also 
be identified, as a two-fold difference in keff existed in the presence and absence of 
GF120918. Interestingly, the active efflux component could not be blocked completely 
with GF120918. The mean GF120918 blood concentration was 214 ng/ml, which was 
sufficient to completely block Pgp in vivo (personal communication with GSK) and 
therefore it appears that morphine efflux from the brain is also mediated by transporters 
other than Pgp. Tunblad and co-workers showed that morphine is also substrate for the 
probenecid-sensitive transporters at the BBB. Co-administration of probenecid resulted 
in a decrease in efflux clearance of morphine from the brain (Tunblad et al., 2004).
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Apart from the Pgp inhibitor GF120918, two other drugs were co-administered to 
morphine in this study. First, midazolam was continuously administered to prevent 
opioid-induced seizure activity and second, vecuronium bromide was used for 
muscle relaxation to enable artificial ventilation. An important question is whether 
these drugs could influence Pgp functionality. For midazolam, an inhibitory effect 
on Pgp functionality in vitro, has been shown, only at high concentrations (100 μM) 
(Mahar Doan et al. 2002; Tolle-Sander et al. 2003). The steady-state concentrations in our 
experiments were around 3 μM and present in all conditions tested and therefore the 
influence of midazolam on Pgp could be neglected. For vecuronium bromide we could 
not find any indications on a drug interaction with morphine.
In conclusion, the BBB transport of morphine could be accurately described with a model 
based on (slow) passive diffusion, combined with both active efflux and active saturable 
influx. This active efflux is partly explained by the interaction of morphine with Pgp. 
These observations indicate a blood concentration-dependency and sensitivity to drug-
interactions. The complex brain distribution kinetics of morphine has an important 
impact for investigations on the PK-PD correlation of morphine.
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Chapter 6
PHARMACOKINETIC-PHARMACODYNAMIC 
MODELLING OF THE ELECTROENCEPHALOGRAM 
EFFECTS OF MORPHINE:






The aim was to investigate the influence of biophase distribution including P-
glycoprotein (Pgp) functionality on the pharmacokinetic-pharmacodynamic correlation 
of morphine.
Experimental approach
Male rats received a 10-min infusion of morphine as 4 mg/kg, combined with a 
continuous infusion of the Pgp inhibitor GF120918 or vehicle, 10 or 40 mg/kg. EEG 
signals were recorded continuously and blood samples were collected. 
Key results
Profound hysteresis was observed between morphine blood concentrations and 
EEG effect. Only the offset of the EEG effect was influenced by GF120918. Biophase 
distribution was best described with an extended-catenary biophase distribution model, 
with a sequential transfer and effect compartment. The rate constant for transport 
through the transfer compartment (k1e) was 0.038 min-1, being unaffected by GF120918. 
In contrast, the rate constant for the loss from the effect compartment (keo) decreased 
60% by GF120918, from 0.043 to 0.015 min-1. The EEG effect was directly related to the 
concentrations in the effect compartment using the sigmoidal Emax model. The values 
of the pharmacodynamic parameters E0, Emax, EC50 and Hill factor were 45.0 μV, 44.5 μV, 
451 ng/ml and 2.3, respectively.
Conclusions and implications
The effects of GF120918 on the distribution kinetics of morphine in the effect 
compartment were consistent with recent observations on the distribution in brain 
extracellular fluid (ECF) as estimated by intracerebral microdialysis. However, the 
time-course of morphine concentrations at the site of action in the brain, as deduced 
from the biophase model, is distinctly different from the brain ECF concentrations.
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INTRODUCTION
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models for the central 
action of opioids contain expressions for a) blood pharmacokinetics, b) biophase 
distribution, which is mainly determined by blood-brain barrier (BBB) transport, c) 
receptor interaction kinetics and d) signal transduction (Danhof et al. 2005). Especially 
for morphine, biophase distribution is an important determinant of the onset and 
duration of the effect because of its hydrophilic nature and the interaction with 
the efflux transporter P-glycoprotein (Pgp). Research on the influence of biophase 
distribution on morphine PK-PD relationships has so far primarily focussed on rather 
empirical biophase distribution model. Bouw and co-workers have proposed a single 
biophase compartment model to account for the delay of the anti-nociceptive effect of 
morphine relative to corresponding plasma concentrations (Bouw et al. 2000). It was 
found that BBB transport accounts for 84% of the observed hysteresis. For morphine, a 
limited number of studies have focused on the role of active transport mechanisms at 
the BBB. Specifically, it has been shown that after oral pre-treatment with the specific 
Pgp inhibitor GF120918, the anti-nociceptive effect of morphine was prolonged due to 
its prolonged half-life in the brain, presumably resulting from inhibition of Pgp as an 
active efflux mechanism (Letrent et al. 1998; 1999). Moreover, the role of transporters 
other than Pgp efflux at the BBB on brain distribution of morphine has been indicated 
by interaction studies with probenecid (Tunblad et al., 2004).
In recent investigations, the brain distribution of morphine has been characterised in 
greater detail with intracerebral microdialysis (Groenendaal et al., 2007 - chapter 5). 
Brain distribution was non-linear and was successfully described by a complex brain 
distribution model with specific expression for 1) passive diffusion, 2) active saturable 
influx and 3) active efflux which could in part be inhibited by GF120918. Against this 
background, it is of considerable interest to characterise in a mechanistic manner the 
biophase distribution kinetics of morphine in a PK-PD investigation.
Detailed characterisation of the biophase distribution kinetics requires the availability 
of high density pharmacodynamic data. In this respect, quantitative analysis of drug 
effects on the electroencephalogram (EEG) yields attractive biomarkers, which are 
continuous, sensitive and reproducible (Dingemanse et al. 1988). Meanwhile, quantitative 
EEG parameters have been widely used as a pharmacodynamic endpoint in pre-clinical 
and clinical investigations on the PK-PD correlations of a variety of CNS active drugs. 
It has also been shown that the synthetic opioid alfentanil, which is frequently used in 
anesthesia produces a progressive slowing of the EEG with a pre-dominant increase in 
the delta frequency band (0.5-4.5 Hz) of the EEG power spectrum in both animals (Cox 
et al. 1997; Mandema & Wada 1995; Wauquier et al. 1988; Young & Khazan 1984) and 
humans (Scott et al. 1985; Wauquier et al. 1984; Young & Khazan 1984). Meanwhile the 
increase in the delta frequency band of the EEG has been widely used as a biomarker in 
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numerous studies on the PK-PD correlations of synthetic opioids. In preclinical studies 
it has been demonstrated that the increase in the delta frequency band of the EEG reflect 
μ-opioid receptor activation (Cox et al. 1997; 1998; 1999). Moreover, in clinical studies, 
this biomarker has been validated as a surrogate marker for depth of anaesthesia (Egan 
et al. 1996; Lemmens et al. 1995; Scott et al. 1991; Scott et al. 1985).
The aim of the present study was to investigate the influence of biophase distribution 
and Pgp interaction at the BBB on the PK-PD relationships of morphine and to compare 
the time course of the predicted effect-site concentrations with the time course of 
the brain extracellular fluid (ECF) concentrations as determined by intracerebral 
microdialysis. 
METHODS 
The pharmacokinetics in blood and pharmacodynamics were investigated in two sets 
of experiments, the classic EEG experiments and the EEG/MD experiments. The details 
of the EEG/MD experiments have been described previously (Groenendaal et al. 2007 
- chapter 5).
Surgical procedures
Details on the anaesthesia and surgical procedures have been described previously 
(Groenendaal et al. 2007 - chapter 5). For the EEG experiments, seven cortical electrodes 
were stereotaxically implanted into the skull of rats ten days before the start of the 
experiments as described before (Cox et al. 1996). Briefly, the electrodes were placed 
at the locations 11 mm anterior and 2,5 mm lateral (Fl and Fr), 3 mm anterior and 3,5 
mm lateral (Cl and Cr) and 3 mm posterior and 2,5 mm lateral (Ol and Or) to lambda. A 
reference electrode was placed on lambda. Stainless-steel crews were used as electrodes 
and connected to a miniature connector. For the EEG/MD experiments, the rats were 
chronically instrumented with four EEG electrodes at the Fl, Cl, Ol and reference position 
and with a CMA/12 guide cannula with a dummy probe placed in the striatum of the 
right brain hemisphere (anterior-posterior: +0.5 mm, lateral: +2.7 mm with bregma as 
reference and ventral: -3.5 mm ventral to the skull).
Experimental procedures
All experimental procedures were identical for both the EEG groups and the EEG/
MD groups, as described previously (Groenendaal et al. 2007 - chapter 5). The EEG 
signal was continuously monitored via bipolar EEG leads on the left hemisphere (Cl-
Ol) using a Nihon-Kohden AB-621G Bioelectric Amplifier (Hoekloos BV, Amsterdam, 
The Netherlands) and concurrently digitized at a rate of 256 Hz using a CED 1401plus 
interface (CED, Cambridge, United Kingdom). The digitized signal was transferred into 
a Pentium III computer and stored on hard disk for off-line analysis. For each 5-sec epoch, 
quantitative EEG parameters were obtained off-line by Fast Fourier Transformation 
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with a user-defined script within the software package Spike2 for Windows, version 
3.18 (CED, Cambridge, United Kingdom). Changes in the amplitudes in the δ-frequency 
band of the EEG (0.5-4.5 Hz) averaged over 1-minute time intervals were used as a 
pharmacodynamic endpoint. Further reduction of the EEG data was performed by 
averaging the signals over predetermined time intervals using a user-defined script 
within the software package Matlab®, version 6.1 (The Mathworks Inc., Gouda, The 
Netherlands). The size of the intervals was dependent on the different periods of the 
experiment. The intervals were 3 min for baseline, 3 min between start of infusion 
(time = 0) and 75 min, 5 min between 75 and 200 min after start of infusion and 10 min 
between 200 and 360 min after start of the infusion. These intervals were chosen on the 
basis on visual inspection of the 1-min datafile.
Blood samples were analysed for morphine, GF120918 and midazolam as described 
previously (Groenendaal et al. 2005 - chapter 3).
Data analysis
The details on the general modelling procedures have been described previously 
(Groenendaal et al. 2007 - chapter 5). The EEG effects of morphine were analysed using 
non-linear mixed effect modelling as implemented in the NONMEM software version 
V, level 1.1 (Beal & Sheiner 1999). Population analysis was undertaken using the first-
order conditional estimation method (FOCE interaction). Individual pharmacokinetic 
parameter estimates were used as input for the pharmacodynamic models. Individual 
blood concentrations were calculated at the times of the EEG measurements.
The selection of the biophase distribution model
A profound delay in the EEG effect (hysteresis) of morphine was observed. The 
hysteresis was characterized on the basis of two biophase distribution models: A) the 
one-compartment biophase distribution model, also known as the effect-compartment 
model and B) the extended-catenary biophase distribution model (figure 1). 
A) One-compartment biophase distribution model 
Hysteresis is often characterised on the basis of the one-compartment biophase 
distribution model. With this model the assumption is made that the rate of onset and 
offset of the drug effect is governed by the rate of drug distribution to the hypothetical 
“effect-site” (Sheiner et al. 1979). This effect-compartment is then linked to the blood 
concentrations with the rate constant k1e and the rate constant for drug loss keo. The rate 
of change of the drug concentration in the effect compartment can then be expressed 
by equation:




concentration. Under the assumption that in equilibrium the effect-site concentration 
equals the blood concentration, this equation can be simplified to:
This model describes a symmetrical biophase. In contrast, when k1e is not equal to keo, 
the biophase is considered to be a-symmetrical. Both models were investigated.
 
B) Extended-catenary biophase distribution model
The extended-catenary biophase distribution model consists of two sequential 
compartments, a transfer (et) and an effect (e) compartment which was based on the 
“tank-in-series” models described by Upton and co-workers and provides a simple 
method for accounting for dispersion of drug in transit through the brain (Upton et al. 
2000). The rate of change of the concentrations in the effect compartments can then be 
described as follows:
where Cet and Ce describe the concentrations in the transfer and effect-compartment, 
respectively. The concentrations in the effect-compartment were then linked to the 
pharmacological effect. Both the symmetrical (k1e=keo) and the asymmetrical (k1e≠keo) 





biophase distribution model (panel B) to describe the biophase kinetics of morphine. The blood pharmacokinetics 
were described with a three-compartment model and used as input function for morphine in the brain. The one-
compartment distribution model consists of one effect compartment (e), whereas the biophase distribution model 
consists of two sequential compartments, the transfer (et) and the effect (e) compartment. The concentrations in 
the	effect	compartment	were	related	to	the	EEG	effect	on	the	basis	of	the	sigmoidal	Emax	model.	Abbreviations:	
k1e represents the rate constant for transport through the transfer compartment; keo represents the rate constant 
for	 loss	from	the	effect	compartment	and	is	 influenced	by	GF120918;	Emax	represent	the	intrinsic	activity	and	
EC50 represents the potency.
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PK-PD analysis of the EEG effect
For the development of the structural PK-PD model for the EEG effect of morphine, the 
PREDPP subroutine ADVAN6 was used, which is a general nonlinear model that uses 
a numerical solution of the differential equations.
After hysteresis minimization, the individual concentration-effect relationships were 
fitted to the sigmoidal Emax model:
Where E0 is the no-drug response, Emax is the intrinsic activity, EC50 is the potency and 
nH is the slope factor. 
In the experiments described here, two experimental approaches were used, the EEG 
method and the EEG/MD method. Since the removal of three EEG electrodes and the 
subsequent implantation of a microdialysis probe could possibly result in a change in 
baseline EEG, a covariate was included in the analysis to validate the EEG/MD method. 
The following equation was used:
where Pi is the individual value of model parameter and q1 and q2 are the parameter 
values obtained with METHOD=1 for EEG/MD and METHOD=0 for EEG. 
The influence of co-infusion of GF120918 on the biophase distribution rate constants 
was tested with the following equation:
Where Pi is the individual value of model parameter and q3 and q4 are the parameter 
estimate and Pgp inhibition value and GF120918 is a factor, set to 1 if GF120918 is co-
infused and set to 0 is vehicle is co-infused.
Inter-animal variability on E0 and Emax was described with a proportional variability 
model according to equation:
with  
where Pi is the individual value of the model parameter P, Ptyp is the typical value 
(population value) of parameter P in the population, and hi is inter-animal random 
variable. The assumption was made that all other parameters were log normal 








The inter-animal variability on all other parameters was described with an exponential 
error model according to equation:
with  
Inter-animal variability was investigated for each parameter and was fixed to zero 
when the MVOF did not improve. Correlations between the inter-animal variability of 
the various parameters were graphically explored. In addition, correlations between 
the PD parameters and dose and between the PD parameters and the co-infusion of 
GF120918 were also investigated graphically.
The residual error, which accounts for unexplained errors (such as measurement and 
experimental errors) in the EEG measurements, was best described with a proportional 
error model according to equation:
where Cobs,ij is the j-th observation of the i-th individual, Cpred,ij is the predicted 
concentration and eij is a realisation from the normally distributed residual random 
variable with mean zero and variance s2:
RESULTS
Pharmacodynamics and hysteresis
After the start of the morphine infusion, a gradual increase in the EEG effect, 
expressed as the absolute amplitude in the 0.5-4.5 Hz frequency range, was observed. 
The maximal effect was 60 μV and was observed around 20 minutes after the end of 
the morphine infusion. The duration of the effect (from the start of the infusion until 
the return to baseline values) was around 180 minutes following the infusion of 4 and 
10 mg/kg morphine whereas after a dose of 4 mg/kg combined with GF120918 or 40 
mg/kg morphine the duration of the effect was around 360 minutes. In figure 2, the 
pharmacokinetics and the pharmacodynamics of a typical rat of each experimental 
group are shown. It was found that the derived blood concentration-EEG effect 
relationships showed profound hysteresis for all experimental groups (figure 3), which 
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The selection of the biophase distribution model
In order to describe the observed hysteresis, two biophase distribution models were 
proposed: 1) the one compartment distribution model and 2) the extended-catenary 
biophase distribution model. First, the biophase distribution kinetics was fitted 
according to the one-compartment biophase distribution model. Both the symmetrical 
and a-symmetrical effect compartment model was tested. With the symmetrical 
(k1e=keo) biophase distribution no results were obtained (minimisation terminated) 
whereas with the asymmetrical (k1e≠keo) effect compartment model no precise estimates 
could be obtained and bias was observed between the observed and predicted 
values Therefore, the extended-catenary biophase distribution model was proposed, 
consisting of two sequential compartments; a transfer and an effect compartment. Both 
Figure 2: Pharmacokinetics and pharmacodynamics of a typical rat after administration of the opioids. Observed 
blood concentrations (grey dots), individual predicted blood concentrations (black line) and observed EEG effect 
(grey open dots) are depicted for each dose group. The grey bar indicates the infusion time.
Figure 3: PK-PD relationship after administration of morphine. Observed (grey dots) and population predictions 




the symmetrical and asymmetrical model was used. The asymmetrical model resulted 
in the lowest objective function, 24671 (k1e≠keo) versus 24936 (k1e=keo) and precise 
estimates of the parameters of the biophase distribution kinetics were obtained (table 1). 
The value of the rate constant for transport through the transfer compartment (k1e) was 
0.038 min-1 and was unaffected by the co-administration of GF120918. The values for 
transport rate constants for the loss from the effect compartment (keo) in the presence 
and absence of GF120918 were 0.0015 min-1 and 0.043 min-1, respectively. The population 
predictions of blood and biophase concentration-time profiles are shown in figure 4. 
Parameter Estimate Cv% LLCI – uLCI
Structural model
k1e  (min-1) 0.038 8.4 0.0315 – 0.0441
keo (min-1)
-GF120918 0.0426 10 0.0342 – 0.0510
+GF120918# 0.0152
Pgp inhibition factor -0.644 -7.3 -0.736 – -0.552
Interindividual variability
ω2 keo 0.237 20.2 0.143 – 0.331
Table 1: Population pharmacokinetic parameter estimates of the biophase distribution of morphine obtained with 
the	extended-catenary	biophase	distribution	model
# keo(+GF120918) = keo(-GF120918)*(1+Pgp inhibition factor)
Abbreviations: k1e = rate constant for transport to the effect-site; keo = rate constant for the loss from the effect-site; 
CV% = coefficient of variation; LLCI = lower limit of confidence interval; ULCI = upper limit of confidence interval 
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The best fit was obtained when the influence of GF120918 was described with a Pgp 
inhibition factor that influences the keo. This Pgp inhibition factor was estimated at a 
value of –0.64 indicating that in the presence of GF120918, the keo is decreased with 64% 
from 0.043 to 0.015 min-1. The inter-animal variability (w2) on keo was estimated with an 
exponential error model and was equal to 0.237. The inter-animal variability could not 
be estimated for the other parameters and were therefore fixed to zero.
Pharmacokinetic-pharmacodynamic analysis of the EEG effect
The individual predicted biophase concentrations were related to the EEG effect 
on the basis of the sigmoidal Emax pharmacodynamic model. Since the EEG and 
EEG/MD experiments were performed in parallel, covariate analysis was included 
to investigate the influence of the microdialysis probe on the pharmacodynamic 
parameters. Since no differences were observed in E0 and Emax values between the 
EEG and the EEG/MD group, a single parameter value was estimated. Morphine 
PK-PD relationships were accurately described as shown in figure 5 and table 2. 
Co-infusion of GF120918 did not influence the pharmacodynamic parameters. The 
values of the pharmacodynamic parameters E0, Emax, EC50 and nH were 45.0 μV, 44.5 
μV, 451 ng/ml and 2.3, respectively. Inter-animal variability (w2) was estimated with a 
proportional error model for E0 and Emax and was equal to 0.034 and 0.121, respectively. 
Inter-animal variability could not be estimated for the other parameters and were 
therefore fixed to zero. Graphical analysis showed that no significant correlations 
Parameter Estimate Cv% LLCI – uLCI
Structural model
E0 (µV) 44.6 2.3 42.6 – 46.6
Emax	(µV) 44.5 8 37.5 – 51.5
EC50 (ng ml-1) 451 17.3 298 - 604
N 2.32 10.4 1.85 – 2.79
Interindividual variability
ω2 kE0 0.034 17.8 0.022 – 0.045
ω2 kEmax 0.121 24.1 0.064 – 0.178
Residual variability
Proportional error 0.027 7.6 0.023 – 0.031
Table 2: Population pharmacodynamic parameter estimates of morphine EEG effect obtained with the sigmoidal 
Emax	model	after	hysteresis	minimisation	with	the	extended-catenary	biophase	distribution	model.
Abbreviations: E0 is the no-drug response; Emax is the intrinsic activity; EC50 is the potency; nH is the slope factor; 
CV% = coefficient of variation; LLCI = lower limit of confidence interval; ULCI = upper limit of confidence interval 
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were observed between the estimates of the PD parameters and dose and between PD 
parameter estimates and co-infusion of GF120918.
DISCUSSION
Biophase distribution can be defined as the distribution processes between the blood 
and the effect-site. The aim of the present study was to investigate the influence of 
biophase distribution and Pgp interaction at the BBB on the PK-PD relationships of 
morphine and to compare the time course of the predicted effect-site concentrations 
with the time course of the brain ECF concentrations as determined by intracerebral 
microdialysis.
So far the PK-PD investigations of morphine have focussed on the anti-nociceptive 
effects (Bouw et al. 2000; Letrent et al.1998). In these studies, the hysteresis has been 
described with the standard symmetrical effect compartment model consisting of a 
single effect compartment, where k1e is equal to keo. In these models, a wide difference 
in keo values (hysteresis) was observed; the keo values were 0.228 min-1 and 0.022 min-1, 
for the doses of 1 mg/kg and 10/40 mg/kg, respectively. This difference may be 
explained by the different dose used (1 mg/kg versus 10/40 mg/kg), the difference 
in infusion speed (bolus versus 10 min infusion) and the differences in experimental 
set-up to measure the anti-nociceptive effect (hot-lamp tail-flick latency assay versus 
electrical stimulation vocalisation method). With anti-nociceptive effect measurements 
only a limited number of data points can be obtained, which may limit a detailed PK-
PD analysis. 
Morphine induces both analgesia and sedation. Changes in EEG are often used as a 
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measurements have the advantage of being continuous, sensitive, objective and 
reproducible, EEG has been used in this study to investigate the influence of biophase 
distribution on the PK-PD relationship of morphine. Between rats, only very small 
differences were observed in baseline (E0) values, indicating the robustness of the EEG 
model. The method, either EEG or EEG/MD, had no influence on the E0 and Emax. 
A profound counter clockwise hysteresis was observed for the concentration-effect 
relationships of each group, which may result from the formation of metabolites 
that influence the effect of morphine. In rats, only the metabolite M3G is formed in 
significant amounts. Since the affinity of M3G for the μ-opioid receptor is much lower 
compared to morphine (Bartlett & Smith 1995; de Jong et al. 2005; Loser et al. 1996), it 
was concluded that the influence of M3G on the observed hysteresis could be neglected. 
Therefore, M3G was not quantitated in the present study. The hysteresis of the EEG 
effects of morphine was characterized on the basis of two biophase distribution 
models: A) the one-compartment biophase distribution model, also known as the 
effect-compartment model and B) the extended-catenary biophase distribution model. 
The biophase distribution kinetics could neither be described with the symmetrical 
nor the asymmetrical one-compartment biophase distribution model, indicating that 
the biophase distribution process of the EEG effect included multiple distribution 
processes. Therefore the extended-catenary biophase distribution model was developed. 
This model consists of two sequential biophase-compartments; the transfer and the 
effect compartment. The extended-catenary biophase distribution model is based on a 
“tank-in-series” model as proposed by Upton and co-workers (Upton et al. 2000). This 
model provides a simple method for accounting for dispersion of drug in the transit 
through the brain (Upton et al. 1999). The concentrations in the effect compartment 
were related to the EEG effects, defined by the rate constant for transport through the 
transfer compartment (k1e) and for loss from the effect compartment (keo). These rate 
constants are distinctly different since only the keo could be influenced by co-infusion 
of the specific and potent Pgp inhibitor GF120918.
The biophase distribution observed for morphine is more complex compared to other 
opioids. For alfentanil, the biophase distribution was too fast to be identified, while for 
fentanyl and sufentanil, the hysteresis could be described with simple keo values of 0.32 
min-1 and 0.17 min-1, for fentanyl and sufentanil, respectively (Cox et al., 1998). These 
observations confirm that application of morphine as an anaesthetic is more difficult 
compared to fentanyl-like opioids. 
The pharmacodynamic parameters of the EEG effects of morphine could be accurately 
described with the sigmoidal Emax model. All EEG experiments were performed in the 
presence of a steady state infusion of midazolam to prevent opioid induced seizure 
activity. Since a constant midazolam concentration was present in all treatment groups, 
the comparison of the biophase distribution and EEG effect is still valid. In addition, 
midazolam is a weak Pgp inhibitor, but is not transported by Pgp (Mahar Doan et al. 
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2002) and therefore the influence of midazolam could be neglected. 
The next step was to correlate the biophase distribution kinetics with the previously 
investigated brain ECF distribution pharmacokinetics (Groenendaal et al., 2007 – 
chapter 5). To describe the brain ECF distribution kinetics a non-linear transport model 
was proposed consisting of one brain compartment with distinction between passive 
diffusion, active linear efflux which is partly mediated by Pgp and active saturable 
influx by a yet unknown transport mechanism. In contrast, the extended-catenary 
biophase distribution model consists of two sequential compartments. There were no 
indications for non-linearity in the biophase distribution kinetics of morphine. The 
difference between the models indicates that transport into the brain ECF is distinctly 
different from transport to the effect-site. Transport into the brain ECF is dependent on 
both passive diffusion and active saturable influx, whereas for biophase distribution 
the transport to the effect-site is a linear process. The effects of GF120918 on the 
distribution kinetics of morphine in the effect compartments were consistent with 
recent observations on the distribution in brain ECF (Groenendaal et al., 2007 – chapter 
5). When comparing the concentration-time profiles in brain ECF and biophase, it 
could be noted that they were distinctly different (figure 6). The concentration in brain 
ECF peaked early, whereas the maximum biophase concentration showed a profound 
delay. In addition, at the low dose of morphine a “plateau” was observed in brain ECF 
whereas in the biophase concentrations a clear decline over time was observed. These 
observations indicate that the brain ECF cannot be used to explain the hysteresis. This 
is in contrast with the observation by Bouw and co-workers where 85% of the observed 
hysteresis for the anti-nociceptive effect could be explained by distribution into the 
brain ECF (2000). In addition, Bouw and co-workers did not identify the active uptake of 
Figure 6:	 Comparison	 of	 the	 population	 predicted	 biophase	 concentration-time	 profiles	 (black	 lines)	 and	 the	
population	predicted	brain	ECF	fluid	concentration-time	profiles	(grey	lines)	as	obtained	previously	(see	companion	
paper). It is shown that the time-course of the biophase concentrations differs substantially from the time-course of 
the brain ECF concentrations indicating that biophase equilibration is slower than transport into the brain ECF.
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morphine in the brain ECF. This indicates that the site of action for the anti-nociceptive 
effects is distinctly different from that for the EEG effect. 
A discrepancy between the predicted effect-site concentration and the measured 
CNS time course has also been observed for the EEG effects of amobarbital, where 
the amobarbital effect-site concentrations did not reflect the measured cerebrospinal 
fluid concentrations (Mandema et al. 1991). In addition, Chenel and co-workers showed 
that the extensive time delay between EEG effect and plasma concentrations of 
norfloxacin, best described with an effect-compartment model, could not be explained 
by slow distribution to the biophase (Chenel et al. 2004). For norfloxacin the brain ECF 
concentrations peaked very early, whereas the EEG effect was delayed, which was also 
seen for morphine. For norfloxacin the brain ECF profiles were parallel to the plasma 
profiles whereas for morphine a non-linearity was observed at the low dose (4 mg/kg). 
Chenel and co-workers showed that the keo did not decrease when the ECF data were 
included in the PK-PD analysis, whereas for morphine the brain ECF and EEG effects 
could not be analysed simultaneously.
In conclusion, the biophase distribution kinetics of morphine was adequately described 
with the extended-catenary biophase distribution model. Comparison with the 
previously developed non-linear distribution model for morphine distribution into 
the brain showed that the time-course of morphine at the site of action in the brain is 
distinctly different from the brain ECF concentrations as estimated by intracerebral 
microdialysis.
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The objective of this investigation was to characterize the role of complex biophase 
distribution kinetics in the pharmacokinetic-pharmacodynamic correlation of a wide 
range of opioids. Following intravenous infusion of morphine, alfentanil, fentanyl, 
sufentanil, butorphanol and nalbuphine the time course of the EEG effect was 
determined in conjunction with blood concentrations. Different biophase distribution 
models were tested for their ability to describe hysteresis between blood concentration 
and effect. For morphine, hysteresis was best described by an extended catenary 
biophase distribution model with different values for k1e and keo of 0.038 ± 0.003 and 
0.043 ± 0.003 min-1, respectively. For the other opioids hysteresis was best described by 
a one-compartment biophase distribution model with identical values for k1e and keo. 
Between the different opioids, the values of k1e ranged from 0.04 and 0.47 min-1. The 
correlation between concentration and EEG effect was successfully described by the 
sigmoidal Emax pharmacodynamic model. Between opioids significant differences in 
potency (EC50 range: 1.2 - 451 ng/ml) and intrinsic activity (α range: 18 –109 μV) were 
observed.
In addition, membrane transport characteristics of the opioids were investigated in vitro, 
using MDCK:MDR1 cells and in silico with QSAR analysis. A statistically significant 
correlation was observed between the values of the in vivo k1e and the apparent passive 
permeability as determined in vitro in MDCK:MDR1 monolayers.
It is concluded that unlike other opioids, only morphine displays complex biophase 
distribution kinetics, which can be explained by its relatively low passive permeability 
and the interaction with active transporters at the blood-brain barrier.
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INTRODUCTION 
Biophase distribution kinetics can be an important determinant of the pharmacokinetic-
pharmacodynamic (PK-PD) correlations of CNS active drugs, and is often described by 
a one-compartment biophase distribution model, also known as the effect-compartment 
model. With the effect compartment model the assumption is made that the rate of 
onset and offset of the drug effect is governed by the rate of drug distribution to the 
hypothetical “effect-site” (Sheiner et al. 1979). This effect-compartment is then linked 
to the blood concentrations with the rate constant k1e and the rate constant for drug 
loss keo. Typically, the biophase distribution is considered to be symmetrical under 
the assumption that in equilibrium the effect-site concentration equals the blood 
concentration, in other words, where k1e is equal to keo. However, also more complex 
biophase distribution models have been proposed. For example, for the neuroactive 
steroid alphaxolone a concentration dependent keo was observed (Visser et al. 2002). 
It was shown that the keo was correlated to the Cmax in plasma. In addition, Mandema 
and co-workers have reported two equilibration rate constants for the dual effects of 
heptabarbital and have shown that the equilibration kinetics of amobarbital were best 
described with a bi-exponential transducer function instead of a simple first-order 
mono-exponential equilibration model (Mandema & Danhof 1990; Mandema et al. 
1991b).
For opioids, modelling of complex biophase distribution kinetics is of interest, given 
the interaction with active transporters and the wide range in lipophilicity. In previous 
investigations, morphine and loperamide have been identified as substrates for P-
glycoprotein (Pgp) in both in vitro and in vivo models (Letrent et al. 1999b; Mahar Doan et 
al. 2002; Schinkel et al. 1995; 1996;Wandel et al. 2002). Furthermore, PK-PD studies in rats 
have revealed that after oral pre-treatment with the specific Pgp inhibitor GF120918, 
the anti-nociceptive effect of morphine was prolonged due to its prolonged half-life 
in the brain (Letrent et al. 1998; 1999a). Alfentanil and sufentanil were not identified 
as Pgp substrates within the abovementioned in vitro studies, whereas inconsistencies 
have been reported for fentanyl (Henthorn et al. 1999; Wandel et al. 2002). In addition, for 
fentanyl, in situ brain perfusion studies indicated Pgp mediated efflux (Dagenais, Graff, 
& Pollack 2004). Nalbuphine, a semi-synthetic opioid analgesic, was also found to be a 
Pgp substrate in a MDCKII-MDR1 cell-system (Mahar Doan et al. 2002), whereas to our 
knowledge so far no studies have been performed on butorphanol.
In order to study the differences in biophase distribution kinetics between opioids, an in 
vivo model is required that is able to study changes in pharmacological effects in great 
detail. Previous investigations have shown that quantitative analysis of the increase in 
the delta frequency band of the electroencephalogram (EEG) is a suitable biomarker for 
the PK-PD correlation of opioids (Cox et al. 1998; Groenendaal et al. 2007 – chapter 6). 
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PK-PD analysis with the one-compartment biophase distribution model showed that 
only small differences were observed between alfentanil, fentanyl and sufentanil, no 
hysteresis (keo) was observed for alfentanil, whereas for fentanyl and sufentanil the keo 
values were 0.32 min-1 and 0.17 min-1, respectively. In this analysis, all opioids behaved 
as full agonists with an intrinsic activity of around 100 μV, but differed in potency (EC50 
values of 1.43 – 289 ng/ml). For morphine profound hysteresis was observed between 
the blood pharmacokinetics and EEG effects. Co-infusion of the Pgp inhibitor GF120918 
prolonged the offset of the EEG effect but had no influence on the onset of the hysteresis. 
The biophase distribution kinetics were best described with the extended-catenary 
biophase distribution model, consisting of two sequential effect compartments (i.e. a 
transfer and an effect compartment) and two rate constants for transport through the 
transfer compartment (k1e) and for loss from the effect compartment (keo) (Groenendaal 
et al. 2007 – chapter 6). In this study, morphine behaved as a low efficacy agonist with 
an intrinsic activity of 44.5 μV.
The objective of the study presented here was to study the biophase distribution 
kinetics in the PK-PD correlation of a wide range of opioids. The opioids selected were 
alfentanil, fentanyl, sufentanil, morphine, butorphanol and nalbuphine (figure 1). 
Nalbuphine and butorphanol were added because they behave as partial agonists in 
vivo (Emmerson et al. 1996). The biophase distribution kinetics was investigated with 
both the one-compartment biophase distribution model, and the extended-catenary 
biophase distribution model as previously proposed for morphine (Groenendaal et 
al., 2007 – chapter 6). In vitro and in silico studies were also included to investigate the 
membrane transport characteristics of all the opioids with respect to P-glycoprotein 
interaction, apparent membrane permeability and physico-chemical properties. The 
predicted effect-site concentrations were related to the EEG effect on basis of the 
sigmoidal Emax pharmacodynamic model. 
Figure 1: Chemical structures of the opioids. The individual names of the compounds are depicted below the 
chemical structures.
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MATERIALS AND METHODS
Animals and surgical procedures
The protocol of these studies was approved by the Committee of Animal Experimentation 
of the Leiden University. Male Wistar rats weighing between 250-350 grams were housed 
in groups for at least 7 days under standard environmental conditions (temperature 
21 °C, humidity 60% and 12/12 hour dark/light cycle, with lights on at 7 a.m.). The 
animals had access to standard laboratory chow (RMH-TM, Hope Farms, Woerden, The 
Netherlands) and acidified water ad libitum.
Nine days before the start of the experiments, seven cortical electrodes were implanted 
into the skull as described before (Cox et al. 1997). Briefly, the electrodes were placed 
at the locations 11 mm anterior and 2,5 mm lateral (Fl and Fr), 3 mm anterior and 3,5 
mm lateral (Cl and Cr) and 3 mm posterior and 2,5 mm lateral (Ol and Or) to lambda. 
A reference electrode was placed on lambda. Stainless-steel screws were used as 
electrodes and connected to a miniature connector, which was insulated and fixed to 
the skull with dental acrylic cement. 
Two days before the start of the experiments, three/four indwelling cannulas were 
implanted, one in the right femoral artery for collection of serial blood samples 
and two in the left jugular vein (interna and externa) for opioid and midazolam 
administration. The fourth cannula was implanted into the right femoral vein to 
administer vecuronium bromide which was only required for the experiments with 
alfentanil, fentanyl, sufentanil and morphine. All cannulas were made from pyrogen 
free polyethylene tubing (Portex Limited, Hythe, Kent, United Kingdom). The arterial 
cannula consisted of 4 cm (I.D.=0.28, O.D.=0.61 mm) polyethylene tubing heat-sealed to 
18 cm polyethylene tubing (I.D.=0.58, O.D.=0.96 mm). The venous cannula consisted of 
3 cm (I.D.=0.28, O.D.=0.61 mm) polyethylene tubing heat-sealed to 10 cm polyethylene 
tubing (I.D.=0.58, O.D.=0.96 mm). The cannulas were subcutaneously tunnelled to the 
back of the neck of the rats. In order to prevent clotting the cannulas were filled with a 
25% (w/v) polyvinylpyrrolidone (PVP, Brocacef, Maarssen, The Netherlands) solution 
in saline containing 50 IU/ml heparin (Pharmacy, Leiden University Medical Centre, 
Leiden, The Netherlands).
All rats were anesthetized with an intramuscular injection of 0.1 mg/kg Domitor® (1 
mg/ml medetomidine hydrochloride, Pfizer, Capelle a/d IJssel, The Netherlands) and 
subcutaneous injection of 1 mg/kg Ketalar® (50 mg/ml Ketaminebase, Parke-Davis, 
Hoofddorp, The Netherlands). After the first surgery, 4 mg ampicilline (A.U.V., Cuijk, 
The Netherlands) was administered to aid recovery.
Drugs and dosages
Alfentanil hydrochloride, fentanyl citrate and sufentanil citrate were kindly donated by 
Johnson& Johnson Pharmaceutical Research and Development, a Division of Janssen 
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Pharmaceutica N.V (Beerse, Belgium). Morphine hydrochloride was purchased from 
Pharmachemie (Haarlem, The Netherlands), nalbuphine hydrochloride and nalorphine 
hydrochloride were purchased from Sigma Aldrich (Zwijndrecht, The Netherlands) 
and butorphanol tartrate was purchased from Sigma Aldrich (St. Louis, MI, USA). 
Midazolam was obtained from BUFA (Uitgeest, The Netherlands). Vecuronium bromide 
(Norcuron®) was obtained from the hospital pharmacy of the Leiden University Medical 
Center (Leiden, The Netherlands).
Solutions of the opioids were prepared in physiological saline (0.9%) on the day of the 
experiment. 500-1500 μl of the infusion solution was administered to each rat. The doses 
and concentrations are expressed as free base and the concentrations of the infusion 
solutions were based on the body weight of each rat. Midazolam was administered 
to prevent opioid induced seizures at a rate of 5.5 mg/kg/h (Cox et al. 1997). To reach 
steady state rapidly, midazolam was administered according to a Wagner infusion 
scheme, with an initial infusion rate of 3 times the steady state infusion rate for 16 min 
(Wagner 1974). Vecuronium bromide solutions were prepared at a concentration of 2 
mg/ml in physiological saline, independent of body weight.
Pharmacokinetic/pharmacodynamic experiments
The original data and details of the experiments with alfentanil, fentanyl, sufentanil 
and morphine have been published previously (Cox et al.1998; Groenendaal et al. 2007 
– chapter 6). The experimental protocols for nalbuphine and butorphanol were similar 
as described for alfentanil, fentanyl and sufentanil. Animals were randomly assigned 
to the treatment groups. Detailed information regarding the complete experimental 
design are shown in table 1. 
All experiments were started between 8.30 and 9.30 a.m. to minimize influences of 
circadian rhythms. During the experiments, the animals were deprived of food and 
water. Bipolar EEG leads on the left hemisphere (Cl-Ol) were continuously monitored 
using a Nihon-Kohden AB-621G Bioelectric Amplifier (Hoekloos BV, Amsterdam, 
The Netherlands) and concurrently digitized at a rate of 256 Hz using a CED 1401plus 
interface (CED, Cambridge, United Kingdom). The digitized signal was transferred 
into a Pentium III computer and stored on hard disk for off-line analysis. For each 
5-sec epoch, quantitative EEG parameters were obtained off-line by Fast Fourier 
Transformation with a user-defined script within the software package Spike2 for 
Windows, version 3.18 (CED, Cambridge, United Kingdom). Changes in the amplitudes 
in the δ-frequency band of the EEG (0.5-4.5 Hz) averaged over 1-minute time intervals 
were used as a pharmacodynamic endpoint. Further reduction of the EEG data was 
performed by averaging the signals over predetermined time intervals using a user-
defined script within the software package Matlab®, version 6.1 (The Mathworks Inc., 
Gouda, The Netherlands). 
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The EEG baseline was recorded for 15 min. Thereafter, midazolam infusion was started. 
30 minutes after the start of the midazolam infusion, the opioids were administered in 
a zero-order infusion using a BAS Beehive infusion pump (Bioanalytical systems Inc., 
Indiana, USA). The EEG signals were recorded up to a maximum of 360 minutes after 
start of the opioid infusions. For determination of opioid and midazolam concentrations, 
serial arterial blood samples were collected at predetermined time intervals and 
immediately hemolysed with 0.5 ml of millipore water and stored at –20 °C.
During and after the infusion of the opioids, respiratory depression occurred. Arterial 
blood samples were collected to monitor arterial pH, pO2 and pCO2 levels using a 
Corning 248 Blood Gas Analyzer (Bayer, Mijdrecht, The Netherlands). During and 
after administration of 40 mg/kg morphine, alfentanil, fentanyl and sufentanil, severe 
respiratory depression and muscle rigidity occurred. These rats were artificially 
ventilated with preheated air (32 °C) using an Amsterdam Infant Ventilator, model MK3 
(Hoekloos, Amsterdam, The Netherlands) through a custom made ventilation mask 
as described by Cox and co-workers (1997). The ventilation settings were: ventilation 
frequency 62 beats/min, I-E ratio 1:2 and air supply flow rate 0.7-1.0 l/min. 5 minutes after 
start of the infusion, the rats received an intravenous bolus dose of 0.15 mg vecuronium 
bromide and artificial ventilation was started. Vecuronium doses of 0.10 mg were 
administered repeatedly when muscle rigidity re-appeared until respiratory activity 
resumed. Blood gas status was carefully monitored during the whole experiment.
During the experiments, body temperature was stabilized between 37.5 and 38.5 °C using 
a CMA/140 temperature controller (Aurora Borealis, Schoonebeek, The Netherlands).
Compound N Dose (mg/kg) Infusion time (min) Body weight (kg)
Morphineb 24 4 10 0.297 ± 0.003
7 10 10 0.260 ± 0.006
18 40 10 0.298 ± 0.006
Alfentanila 7 3.14 40 0.278 ± 0.005
Fentanyla 8 0.15 20 0.290 ± 0.012
Sufentanila 7 0.03 40 0.297 ± 0.006
Butorphanol 7 2.5 10 0.284 ± 0.006
6 5 10 0.260 ± 0.002
6 10 10 0.254 ± 0.004
Nalbuphine 6 5 10 0.275 ± 0.009
9 10 10 0.273 ± 0.006
5 15 10 0.283 ± 0.006c
Saline 6 n/a 10 0.290 ± 0.007
Table 1:	Experimental	design	of	the	studies	investigating	the	PK-PD	relationships	of	the	EEG	effects	of	opioids.
aExperiments described previously by Cox et al. 1997
bExperiments described previously by Groenendaal et al. 2006




The analysis methods for the opioids in blood samples have been described previously 
(Cox et al. 1997; 1998; Groenendaal et al. 2005 – chapter 3). The blood concentrations 
of alfentanil were determined by gas chromatography with nitrogen-phosphorus 
detection, after a liquid-liquid extraction of the hemolyzed blood samples with sodium 
triphosphate and pentane. The intra- and interassay variability was generally less than 
5% and the lower limit of quantification was 1 ng/ml for a 0.1 ml sample. The blood 
concentrations of fentanyl and sufentanil were determined by radio-immunoassay, 
after liquid-liquid extraction of the samples with sodium hydroxide and n-heptane/
isoamylalcohol (98.5/1.5, v/v). The intra- and inter-assay variability were less than 40% 
and the lower limits of quantification were 0.040 ng/ml for a 1 ml sample obtained at 
the end of the experiment for both fentanyl and sufentanil.
Morphine, nalbuphine and butorphanol blood samples were analyzed by an HPLC 
method coupled to an electrochemical detector, after a liquid-liquid extraction of the 
hemolyzed blood samples with phosphoric acid and/or sodium carbonate and ethyl 
acetate. The intra- and inter-assay variation was less than 15% for morphine, nalbuphine 
and butorphanol. The lower limits of quantification for a 50 μl blood sample were 25, 25 
and 50 ng/ml for morphine, nalbuphine and butorphanol, respectively (Groenendaal 
et al. 2005 – chapter 3).
The blood concentrations of midazolam were determined as described previously by 
Mandema and co-workers (Mandema et al. 1991a). The method consisted of a liquid-
liquid extraction with NaOH and dichloromethane/petroleumether (45/55, v/v). After 
extraction, samples were injected onto an HPLC coupled to an ultraviolet detector. The 
intra- and inter-assay variation was less than 6% and the lower limit of quantification 
was 50 ng/ml for a 50 μl blood sample. 
Pharmacokinetic-pharmacodynamic data analysis
The pharmacokinetic and pharmacodynamic data of the opioids were analysed using 
non-linear mixed effect modelling as implemented in the NONMEM software version 
V, level 1.1 (Beal & Sheiner 1999). Population analysis was undertaken using the first-
order conditional estimation method (FOCE interaction) for pharmacokinetic analysis. 
All fitting procedures were performed on an IBM-compatible computer (Pentium IV, 
1500 MHz) running under Windows XP with the Fortran Compiler Compaq Visual 
Fortran version 6.1. 
Pharmacokinetic analysis
For the development of the pharmacokinetic structural models for the opioids, both two- 
and three-compartment models were tested. Model selection was based on the likelihood 
ratio test, diagnostic plots (observed concentrations vs. individual and population 
predicted concentrations, weighted residuals vs. predicted time and concentrations), 
parameter correlations and precision in parameter estimates. The likelihood criteria 
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test is based on a comparison of the minimum value of the objective function (MVOF) 
of two models. The significance level was set at 0.01 which corresponds to a decrease 
of MVOF of 6.6 points when an extra parameter is included in the structural model 
under the assumption that the difference in MVOF between the two nested models is 
c2 distributed. On the basis of model selection criteria a three-compartment model was 
chosen for alfentanil, morphine and nalbuphine, whereas a two-compartment model 
was the best choice for fentanyl, sufentanil and butorphanol. Pharmacokinetic analysis 
was performed with the PREDPP subroutines ADVAN 11 TRANS 4 (three-compartment 
model) and ADVAN 3 TRANS 4 (two-compartment model) implemented in NONMEM. 
For a three compartment model the pharmacokinetic parameters clearance (Cl), inter-
compartemental clearances (Q2 and Q3) and the volumes of distribution (V1, V2 and 
V3) are estimated whereas Q3 and V3 are excluded when using a two-compartment 
model.
The interanimal variability in the pharmacokinetic parameters was assumed to be log 
normally distributed:
with
where Pi is the individual value of the model parameter P, Ptyp is the typical value 
(population value) of parameter P in the population, and hi is the realization from a 
normally distributed inter-animal random variable with mean zero and variance w2. 
Inter-animal variability was investigated for each parameter and was fixed to zero 
when the MVOF did not improve. Correlations between the inter-animal variability of 
the various parameters were graphically explored.
The residual error, which accounts for unexplained errors (e.g. measurement and 
experimental errors), in the blood drug concentrations was best described with a 
proportional error model according to equation:
with
Where Cobs,ij is the j-th observation of the i-th individual, Cpred,ij is the predicted 
concentration and eij is the normally distributed residual random variable with mean 
zero and variance s2. 
To refine the pharmacokinetic models, the relationship between bodyweight and the 
different parameters was explored graphically. The following equation was used to 







where Pi is the individual value of model parameter P and qi and qj are the intercept and 
slope of the relationship between the parameter and bodyweight.
The accuracy of the pharmacokinetic was investigated by an internal validation 
method, the predictive check (Cox et al. 1999; Yano et al. 2001). With this method, 1000 
curves were simulated from the final PK parameter estimates. The median, lower (2.5%) 
and upper (97.5%) limit of the interquantile range of the simulated concentrations were 
calculated and compared with the positions of the observations.
Individual pharmacokinetic parameter estimates were used as input for the 
pharmacodynamic models. Individual blood concentrations were calculated at the 
times of the EEG measurements. 
Biophase distribution models
In this study, the changes in the delta frequency band of the EEG are used as a measure 
of drug response. A delay in effect (hysteresis) was observed for all opioids except 
alfentanil. The hysteresis was characterized on the basis of two biophase distribution 
models: A) the one-compartment biophase distribution model, also known as the effect-
compartment model and B) the extended-catenary biophase distribution model. 
A) One-compartment biophase distribution model 
With the one-compartment distribution model, the effect-compartment is linked to the 
blood concentrations with the rate constant k1e and the rate constant for drug loss keo. 
The rate of change of the drug concentration in the effect compartment can then be 
expressed by equation:
where Cb represents the blood concentration and Ce represents the effect-site 
concentration. Under the assumption that in equilibrium the effect-site concentration 
equals the blood concentration, this equation can be simplified to:
This model describes a symmetrical biophase. In contrast, when k1e is not equal to 
keo, the biophase is considered to be asymmetrical. For all opioids both models were 
investigated. 
B) Extended-catenary biophase distribution model
With the extended-catenary biophase distribution model, an extra effect-compartment 
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concentrations in the effect compartments can then be described as follows:
where Cet and Ce1 describe the concentrations in the transfer and effect-compartment, 
respectively. The concentrations in the second effect-compartment will then be linked 
to the pharmacological effect. Both the symmetrical (k1e=keo) and the asymmetrical 
(k1e≠keo) biophase models were investigated.
A schematic diagram of the PK-PD models used in the analysis is shown in figure 2.
(4)
(4)
Figure 2: A schematic overview of the PK-PD models used in the analysis. Panel A shows the one-compartment 
biophase distribution, also known as the effect-compartment model, consisting of one effect (e) compartment. Panel 
B	shows	the	extended	catenary	biophase	distribution	model	which	consists	of	two	sequential	effect	compartments,	
the transfer (et) and the effect (e) compartment. The concentrations in the effect compartment were related to the 




After hysteresis minimization, the individual concentration-effect relationships were 
fitted simultaneously to the Hill equation:
where E0 is the no-drug response, α is the intrinsic activity, EC50 is the potency and nH 
is the slope factor. The stochastic part of the model, used to describe the inter-animal 
variability in the pharmacodynamic parameters consisted of a proportional error 
model for E0 and α (equation 11) and an exponential error model for EC50 (equation 1).
with  
Similar to the pharmacokinetics, the residual error in the pharmacodynamics could be 
best described with a proportional error model according to equation 6. The accuracy of 
the pharmacodynamic models was investigated by an internal validation method, the 
predictive check as explained for the pharmacokinetics. 
In vitro transport characteristics
The interaction with Pgp and the apparent membrane permeability (Papp) were 
determined in vitro using monolayers of MDCK:MDR1 cells. The cells were cultered 
in DMEM – glutamax media, formulated with D-glucose (4.5 g/l), L-alanyl-glutamine 
and phenol red and supplemented with penicillin (10000 U/ml)-streptomycin (10000 
μg/ml) and 10% (v/v) fetal calf serum at 37 °C and 5% CO2. Cells were trypsined every 
4 days. For the studies, cells were seeded onto BD Falcon™ HTS 24-Multiwell Inserts at 
a seeding density of 50000 cells/well and grown for 3 days in DMEM full media.
Before each experiment, transepithelial electrical resistance was measured with an 
EVOMTM voltohmmeter (World Precision Instruments, Stevenage, United Kingdom). 
The experiments were performed in transport buffer (DMEM containing 25 mM HEPES 
without phenol red and sodium pyruvate). Cells were pre-incubated with transport 
buffer containing GF120918 (2 μM) or vehicle (0.5% DMSO) for 15 min at 37°C. After 
removal of pre-incubation solutions, the test solutions were added and the cells were 
incubated for 90 min at 37°C under continuous shaking. Donor test solutions contained 
DMSO or GF120918, lucifer yellow (10 μM) and opioid (3 μM) or amprenavir (3 μM). 
Receiver test solutions were identical to the pre-incubation solutions. All experiments 
were performed automatically using the robotic TECANTM genesis workstation 
(TECAN, Reading, United Kingdom). Reference drugs for paracellular transport (lucifer 
yellow) and Pgp-efflux (amprenavir) were included in each experiment to test the 
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collected to determine lucifer yellow, amprenavir and test compound concentrations. 
Transport was measured in two directions: apical-to-basolateral (a→b) and basolateral-
to-apical (b→a) and in duplicate. 
Alfentanil, fentanyl, sufentanil and butorphanol were analysed by dual high-
performance liquid chromatography with tandem mass spectrometry (LC/MS/
MS). The system consisted of an API-365 (Applied Biosystems, Warrington, United 
Kingdom) LC/MS/MS employing positive ion turbospray ionisation with a CTC 
HTS PAL autosampler (CTC Analytics, Hitchin, United Kingdom). Chromatography 
was conducted on a 50 mm x 2.1 mm HyPURITY column (ThermoHypersil, Runcorn, 
United Kingdom) at a flow rate of 0.8 ml/min  and a split ratio of 1:2. The mobile phase 
consisted of two solvents: (A) 10 mM ammonium acetate pH 4 and (B) 100% acetonitrile. 
The gradient profile was at 0 min 80% A and 20% B, at 1 min 0% A and 100% B and at 1.1 
min 80% A and 20% B. Total run time was 1.5 min. Data acquisition was performed with 
PE Sciex version 1.1 (Applied biosystems, Warrington, United Kingdom) and data were 
reported at the ratio of test compound peak area over internal standard peak area. 
Nalbuphine and morphine samples were analysed by high performance liquid 
chromatography with electrochemical detection (HPLC-ECD) as described above for 
the samples from the PK-PD studies.
Lucifer yellow samples were analysed by a Polarstar® fluorescence microplate reader 
with λex=430 nm and λem=538 nm (BMG-Labtech, Aylesbury, United Kingdom).
The efflux ratio was calculated by dividing the amount transported from basolateral to 
apical (b→a) by the amount transported from apical to basolateral (a→b). Involvement of 
Pgp mediated efflux was identified if the efflux ratio was >1.5 (Mahar Doan et al. 2002). 
To confirm that efflux was due to Pgp-mediated transport, the efflux ratio was also 
determined in the presence of the Pgp inhibitor GF120918. In the presence of GF120918, 
the efflux ratio should decrease to 1. The apparent permeability of the compounds was 
calculated using the equation:
where Papp represents the apparent permeability in nm/sec, VD and VR are the donor 
and receiver chamber volumes (cm3), A is the area of the permeability barrier (cm2), t is 
the time of the measurements (s), CR(t) is the drug concentration in the receiver chamber 
and is described by equation 11.
where describes the average system concentration, VD and VR are the donor 





concentrations at time t (Tran et al. 2004; 2005).
In all studies, amprenavir efflux ratios, apparent permeability of lucifer yellow and mass 
balance were used as controls.  The mass balance was calculated using the equation:
where %MB is the mass balance, Art is the drug amount in receiver chamber at time (t), 
Adt is the drug amount in donor chamber at time (t) and Ad0 is the drug amount in the 
donor chamber at t=0. This calculation of Papp takes into account the loss of drug from 
the donor compartment, which results in a better estimation of the Papp.
Experiments were only included when efflux ratio of amprenavir > 16 and when 
apparent permeability of lucifer yellow < 50 nm/sec and mass balance > 70 %.
Quantitative structure activity relationships – physico-chemical relationships
Log octanol/water partition coefficients (cLogP) was calculated using Daylight 
Software v4.71/82 (Daylight Chemical Information Systems Inc., Irvine, CA). Polar 
surface areas (PSA) were calculated according to Ertl and co-workers (2000). A predictor 
of BBB transport characteristics was also determined based on the Abraham equation 
(Abraham et al. 1994):
where LogBB is the logarithm of the blood-brain concentration ratio and R2, πH2, αH2, βH2 
and Vx are defined as the excess molar refractivity, dipolarity/polarisability, hydrogen 
bond acidity, hydrogen bond basicity and the solute McGowan volume, respectively, as 
described by Platts and co-workers (Platts et al. 1999).
Statistical analysis
The in vitro data were analysed using an unpaired Student’s t-test (two-tailed) or one-
way analysis of variance (ANOVA) (Graphpad Instat®) version 3.00). A value of p<0.05 
was considered a significant difference. All data are expressed as mean ± SEM, unless 
indicated otherwise. Each experiment was performed at least three times. Linear 
regression analysis of in vivo k1e with the in vitro Papp and the physicochemical properties 
(cLogP, PSA, LogBB) were performed in S-plus 6.0 professional, release 1 (Insightful 
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RESULTS
Pharmacokinetics
Figure 3 shows the observed, population predicted and 2.5% and 97.5% quantiles for 
3.14 mg/kg alfentanil in 40 min, 0.15 mg/kg fentanyl in 20 min, 0.030 mg/kg sufentanil 
in 40 min, 4/10/40 mg/kg morphine in 10 min, butorphanol 2.5/5/10 mg/kg in 10 min 
and nalbuphine 5/10 mg/kg in 10 min. The pharmacokinetics of fentanyl, sufentanil 
and butorphanol were best described with a two-compartment model, whereas a 
three-compartment pharmacokinetic model was used for alfentanil, morphine and 
nalbuphine. All parameters were estimated accurately as shown in table 2. Covariate 
analysis showed a linear relationship between bodyweight and CL for fentanyl, a linear 
relationship between bodyweight and V2 for butorphanol and linear relationships 
between bodyweight and CL and bodyweight and V2 for morphine. No individual 
differences in posthoc values were found between the different dosages of morphine, 
butorphanol and nalbuphine. Between the opioids, differences were observed between 
the pharmacokinetic parameter values, especially for the volume of the peripheral 
compartments (V2+V3), ranging from 175 to 1845 ml for alfentanil and nalbuphine, 
respectively.
Compound Cl (ml/min) v1 (ml) q2 (ml/min) v2 (ml) q3 (ml/min) v3 (ml)
Morphine 20.8 ± 1.2 68 ± 11 15.5 ± 1.8 739 ± 56 17.8 ± 3.3 133 ± 21
-0.13 (--) (--) -0.1 (--) (--)
Alfentanil 10.0 ± 0.8 19 ± 5 22.9 ± 2.6 111 ± 10 1.97 ± 0.3 64 ± 14
-0.03 (--) (--) -0.01 (--) -0.06
Fentanyl 11.5 ± 1.2 98 ± 9 11.4 ± 2.8 586 ± 94 -- --
-0.02 (--) (--) -0.03 (--) (--)
Sufentanil 20.6 ± 2.7 113 ± 42 31.2 ± 3.6 1370 ± 204 -- --
-0.07 (--) (--) -0.06 (--) (--)
Butorphanol 22.9 ± 2.3 81 ± 23 58.8 ± 5.9 1030 ± 89 -- --
-0.14 (--) (--) -0.09 (--) (--)
Nalbuphine 39.0 ± 3.0 130 ± 29 37.8 ± 4.7 1580 ± 294 44.2 ± 12.4 265 ± 74
-0.04 (--) (--) -0.34 (--) -0.27
Table 2: Population blood pharmacokinetic parameter estimates and standard error of estimate (mean ± SE) for 
Cl, V1, Q2, V2, Q3 and V3. The variances (w2) describing the inter-individual variability are shown in parentheses.
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The accuracy of the models was investigated using the predictive check. The selected 
PK models could well predict the time course of the opioids after intravenous infusion 
as shown in figure 3.
Pharmacodynamics and hysteresis
After start of the opioid infusion, a gradual increase in EEG effect was observed, 
expressed as absolute amplitude in the 0.5-4.5 Hz frequency range. Large differences 
in onset of the effect and maximum effect were observed between the opioids (figures 
4 and 5). For example, for alfentanil the maximum effect was observed at the end of the 
infusion, whereas for morphine, the maximal effect was observed around 20 minutes 
after the end of the infusion. The maximum effect (α) of alfentanil and sufentanil were 
around 100 μV, whereas for fentanyl, morphine, butorphanol and nalbuphine and 
butorphanol the maximum effect was 78, 45, 57 and 18 μV, respectively. Duration of 
the effect (from the start of the infusion until the return to baseline values) was around 
180 minutes for alfentanil, 4 and 10 mg/kg morphine, all doses of butorphanol and 
nalbuphine, whereas for fentanyl, sufentanil and 40 mg/kg morphine, the duration 
of the effect was around 360 min. The baseline values for alfentanil, fentanyl and 
Figure 3:	Blood	pharmacokinetics	of	the	opioids.	Observed	(grey	dots),	population	predicted	(solid	line)	and	2.5%	
and	97.5%	quantiles	(dotted	lines)	are	depicted	for	each	individual	opioid	per	dose.	The	name	of	the	compound	
and	 the	dose	are	depicted	at	 the	 top	of	each	panel.	Time	 in	minutes	 is	depicted	on	 the	x-axis	and	 the	blood	
concentration	is	depicted	on	the	y-axis	on	a	logarithmic	scale.	The	grey	bar	indicates	the	infusion	time.
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sufentanil were significantly higher than the baseline values for morphine, butorphanol 
and nalbuphine. This is probably caused by differences in surgical and experimental 
conditions, since the data for alfentanil, fentanyl and sufentanil have been collected and 
published previously (Cox et al. 1998). Validation experiments with fentanyl indicated 
that a difference in baseline does not affect the actual effect-time profile and maximal 
effect (data not shown). 
The individual pharmacokinetic parameters were used to calculate the blood 
concentrations at the time points of the individual EEG measurements. The derived 
concentration-effect relationships showed hysteresis for all opioids, except alfentanil. 
For each opioid and each dose the concentration-effect relationships are shown in 
figure 5.
Figure 4: Blood pharmacokinetics and EEG effect (pharmacodynamics) of a typical rat after administration of 
the opioids. Observed concentrations (grey dots), individual predicted concentrations (black line) and observed 
effect are depicted for each individual opioid per dose. The grey bar indicates the infusion time. Time in minutes is 
depicted	on	the	x-axis,	the	blood	concentration	is	depicted	on	the	left	y-axis	on	a	logarithmic	scale	and	the	effect	
as	EEG	amplitude	 in	 the	d-frequency	range	 is	depicted	on	the	right	y-axis	on	a	 linear	scale.	The	name	of	 the	




Both the one-compartment distribution model and the extended-catenary biophase 
distribution model were investigated for all opioids except alfentanil, including 
the symmetrical and a-symmetrical biophase distribution kinetics. A summary of 
the goodness-of-fit of the four biophase distribution models is shown in table 3. For 
morphine the extended-catenary biophase distribution model best described the 
biophase distribution kinetics as has been shown previously (Groenendaal et al., 
2007 – chapter 6). In contrast, for fentanyl, sufentanil, nalbuphine and butorphanol, 
the symmetrical one-compartment biophase distribution model best described the 
transport to the effect-site. A-symmetrical biophase distribution kinetics could not be 
identified for the opioids except for morphine. Analysis with the extended-catenary 
biophase distribution model resulted in an increase in minimum value of objective 
function or did not result in successful minimization. The k1e values for transport to 
the effect-site (is equal to keo except for morphine) ranged from 0.47 min-1 (t1/2,k1e = 1.45 
min) for fentanyl to 0.04 min-1 (t1/2,k1e = 17.3 min) for morphine (table 5). Based on the k1e 
values the following range in distribution kinetics could be identified: alfentanil (value 
close to infinity) > fentanyl (0.47 min–1) > butorphanol (0.21 min-1) > nalbuphine (0.20 
min-1) > sufentanil (0.17 min-1) > morphine (0.04 min-1).
Figure 5: The PK-PD relationship after administration of the opioids. Observed (grey dots) and individual 
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PK-PD analysis
After hysteresis minimization, the effect site (biophase) concentration-effect 
relationships were analysed with the Hill equation (equation 3), resulting in estimates 
for baseline (E0), intrinsic activity (α), potency (EC50) and slope (nH). The effect-site 
concentration-effect relationship of each opioid is shown in figure 6. The highest 
intrinsic activity was found for alfentanil (109 μV) and the lowest for butorphanol (18 
μV). Based on the intrinsic activity, the following range of agonism could be identified: 
alfentanil (109 μV) > sufentanil (99 μV) > fentanyl (78 μV) > nalbuphine (57 μV) > 
morphine (45 μV) > butorphanol (18 μV). The estimated pharmacodynamic parameters 
are shown in table 4.
In vitro transport characteristics and QSAR modeling
The in vitro transport characteristics of the opioids were investigated in MDCK:
MDR1 cells expressing the human Pgp. Substrate assessment studies were performed 
to identify Pgp substrates and to calculate the Papp value, a measure of the passive 
membrane transport. 
No statistically significant differences were found in the Pgp substrate efflux ratios for 
alfentanil, fentanyl, sufentanil and butorphanol in the presence or absence of GF120918. 
For morphine and nalbuphine the concentrations in the receiver compartment were 
below the limit of quantification of the assay when using the donor concentration of 
3 μM. However, at a donor concentration of 100 μM morphine was identified as a Pgp 
substrate. For nalbuphine literature values were used (Mahar Doan, Humphreys et al. 
2002). At a donor concentration of 10 μM, nalbuphine was identified as a Pgp substrate. 
The experimental settings used by Mahar Doan and co-workers were similar to the 
Compound One-compartment biophase Extended-catenarybiophase
distribution model distribution model
k1e=keo k1e≠keo k1e=keo k1e≠keo
Morphine m.t. 25234 24936 24671
Fentanyl 2497 2497 2504 m.t.
Sufentanil 2297 2298 2324 m.t.
Butorphanol 2542 2542 2620 m.t.
Nalbuphine 2796 2796 2793 2793
Table 3:	 Summary	 of	 goodness-of-fit	 based	 on	 the	 minimum	 value	 of	 objective	 function,	 of	 four	 biophase	
distribution	models	containing	expressions	for	transport	to	the	effect-site	and	loss	from	the	effect	site.	This	models	
include the symmetrical (k1e=keo)  and a-symmetrical (k1e≠keo)	extended-catenary	biophase	distribution	model	and	
the symmetrical (k1e=keo) and a-symmetrical (k1e≠keo) one-compartment distribution model.
Abbreviations: m.t.= minimization terminated
Note: alfentanil is not included in this analysis since no hysteresis was observed.
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Compound k1e (min-1) keo (min-1) E0 (µv) α (µV) EC50 (ng/ml) nH
Morphine 0.038 ± 0.003 0.043 ± 0.003 45 ± 1 45 ± 4 451 ± 78 2.3 ± 0.2
-0.24 -0.03 -0.12 (--) (--)
Alfentanil -- -- 56 ± 2 109 ± 13 303 ± 56 1.6 ± 0.2
-0.01 -0.11 -0.16 (--)
Fentanyl 0.47 ± 0.10 0.47 ± 0.10 53 ± 4 78 ± 9 8.9 ± 0.8 3.2 ± 0.3
-0.06 -0.11 -0.04 (--)
Sufentanil 0.17 ± 0.05 0.17 ± 0.05 72 ± 4 99 ± 8 1.2 ± 0.2 2.1 ± 0.4
-0.02 -0.02 -0.21 (--)
Butorphanol 0.21 ± 0.03 0.21 ± 0.03 32 ± 2 18 ± 4 195 ± 34 4.1 ± 0.8
-0.05 -0.73 -0.36 (--)
Nalbuphine 0.20 ± 0.04 0.20 ± 0.04 37 ± 2 57 ± 4 205 ± 24 3.4 ± 0.6
-0.03 -0.07 -0.15 (--)
Note: For morphine the extended catenary biophase distribution model was used to describe the biophase 
distribution, for fentanyl, sufentanil, butorphanol and nalbuphine the one-compartment distribution model was 
used, whereas no hysteresis was observed for alfentanil.
Figure 6: PK-PD relationships of the opioids after hysteresis minimisation. Observed (grey dots), population 
predicted	(solid	line)	and	2.5%	and	97.5%	quantiles	(dotted	lines)	are	depicted	for	each	individual	opioid	per	dose.	
The name of the compound is depicted at the top of each panel. The predicted lines were obtained using the 
effect-compartment model with the Hill equation. 
Table 4: Population pharmacodynamic estimates and standard error of estimate (mean ± SE) for, intrinsic activity 
(α),	potency	(EC50), Hill slope (nH) and baseline (E0). The variances (w2) describing the inter-individual variability 
are shown in parentheses. 
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ones used in the present investigation and therefore the use of literature values was 
justified.
The Papp values of the opioids were calculated on the basis of the amount transported 
across the monolayer over time (nm/s), in both directions, in the presence of GF120918. 
Papp values > 500 nm/s were found for alfentanil, fentanyl, sufentanil and butorphanol, 
whereas the Papp values of nalbuphine and loperamide were 156 and 206 nm/s, 
respectively. For morphine, the Papp value was 16 nm/s, indicating that almost no 
morphine is transported across the monolayer within the experimental period of 90 
min.
The efflux ratios in the absence and presence of GF120918, the Papp values and the 
calculated cLogP, logBB and PSA are listed in table 5.
In vitro/in silico/in vivo correlations
Regression analysis was performed to investigate the possible correlations between 
the in vivo k1e and the in vitro Papp and the in vivo k1e with the physico-chemical 
properties of the selected opioids. The results are shown in figure 7. For all opioids 
except morphine, the k1e was equal to the keo. For morphine the k1e was estimated 
separately. A significant correlation was found between the in vitro Papp and the in vivo 
k1e, which could be described on the basis of: k1e = 0.13*logPapp – 0.09. For physicochemical 
properties, no significant correlations could be identified.
Compound Efflux ratio Papp (nm/sec) cLogP LogBB PSA (Ǻ)
Buffer GF120918
Morphine 4.1 n.d. 16 0.6 -0.28 52.9
Alfentanil 0.83 ± 0.05 1.05 ± 0.11 698 ± 39 2.1 0.277 85.5
Fentanyl 0.72 ± 0.07 0.81 ± 0.07 728 ± 105 3.6 0.886 23.6
Sufentanil 1.09 ± 0.39 0.76 ± 0.07 590 ± 42 3.6 0.932 32.8
Butorphanol 0.61 ± 0.10 0.74 ± 0.14 779 ± 48 3.7 0.253 43.7
Nalbuphine 2.17 1.01 156 ± 0.1 1.4 -0.247 73.2
Abbreviations: cLogP – calculated LogP value, which is indicative for lipophilicity, LogBB - BBB transport on basis 
of Abraham equation, PSA - polar surface area (Ǻ) and n.d. – not determined.
Table 5: Results of the in vitro transport studies in MDCK:MDR1 cells and physico-chemical properties. In vitro 
studies:	averaged	(mean	±	SEM,	n=3)	estimate	of	efflux	ratio	(transport	b	→a	/	transport	a	→	b)	and	apparent	





The objectives of the study presented here were to study the biophase distribution 
kinetics in the PK-PD correlation of a wide range of opioids. Previously, the biophase 
distribution kinetics of morphine have been investigated in the rat EEG model, which 
were best described with the extended-catenary biophase distribution model. This 
model consists of two sequential effect compartments (i.e. a shallow and a deep effect 
compartment) and two rate constants for transport through the transfer compartment 
(k1e) and for loss from the effect compartment (keo) (Groenendaal et al., 2007 – chapter 
6). Morphine behaved as a low efficacy agonist with an intrinsic activity of 44.5 μV. It 
was of interest to extent the investigations on the biophase distribution kinetics for a 
wide range of opioids. In the current study, two biophase distribution models were 
investigated, with respect to intrinsic activity and onset of the EEG effect: 1) the one-
compartment biophase distribution model (the effect-compartment model) and 2) the 
extended-catenary biophase distribution model. The predicted biophase concentrations 
were related to the EEG effect on the basis of the sigmoidal Emax pharmacodynamic 
model. In addition, in vitro and in silico studies were also included to investigate the 
membrane transport characteristics of opioids with respect to P-glycoprotein interaction, 
apparent membrane permeability and physico-chemical properties. 
Pharmacokinetics
The pharmacokinetics of all opioids could be successfully described using population 
PK analysis. For fentanyl, sufentanil and butorphanol, a two-compartment model 
Figure 7: Correlation between the k1e and the Papp and the k1e and the physicochemical properties of the opioids. 
The	compounds	are	depicted	with	the	first	letter	of	the	opioid	name.
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best described the data whereas for alfentanil, morphine and nalbuphine a three-
compartment model was most suitable. Previously, Cox and co-workers used a two-
compartment model to describe the pharmacokinetics of alfentanil (1997; 1998). However, 
in the present analysis a population approach was used for the analysis whereas Cox 
and co-workers analyzed the data per individual. With a population approach both 
intra- and inter-individual variability are taken into account, thereby increasing the 
power of the models. All pharmacokinetic parameters could be accurately estimated as 
shown in table 2. Internal validation with the predictive check confirmed the accuracy 
of the pharmacokinetic models. Differences were found in the pharmacokinetic 
characteristics of the opioids, especially in the volume of distribution of the peripheral 
compartments. For alfentanil a total peripheral volume of 175 ml was found in contrast 
to nalbuphine where a total peripheral volume of 1845 ml was observed, indicating the 
butorphanol is widely distributed into tissues compared to alfentanil. The clearance 
values ranged from 10 ml/min for alfentanil to 39 ml/min for nalbuphine. 
Biophase distribution models
Both the one-compartment distribution model and the extended-catenary biophase 
distribution model were investigated for all opioids, including the symmetrical and a-
symmetrical biophase distribution kinetics. The concentration-effect profiles (figure 5) 
revealed that for all opioids except alfentanil, a delay in effect was observed. Therefore, 
for alfentanil no distribution models were tested. The biophase distribution kinetics of 
morphine were best described with the extended-catenary biophase distribution model 
as shown previously (Groenendaal et al., 2007 – chapter 6), with different values for k1e 
and keo (asymmetrical biophase). When the data from the rats co-infused with GF120918 
were removed from the analysis, the asymmetrical biophase distribution could still 
be identified. The values for k1e and keo were 0.038 min-1 and 0.043 min-1, respectively. 
Simplification to the asymmetrical model resulted in a significant increase in objective 
function and a significant worsening of the fit.
The symmetrical one-compartment biophase distribution model, where k1e=keo, yielded 
the most accurate parameter estimates for the biophase distribution kinetics of fentanyl, 
sufentanil and butorphanol. The use of the a-symmetrical one-compartment biophase 
model did not result in an improvement of the accuracy of the parameters, while no 
parameter estimates could be obtained when using the extended-catenary biophase 
distribution model. These findings were expected since the delay in the EEG effect 
was relatively short, as is confirmed by the k1e values of 0.47 min-1, 0.17 min-1 and 0.21 
min-1 for fentanyl, sufentanil and butorphanol, respectively. For nalbuphine, a small 
increase of 2 points in objective function was observed when the biophase distribution 
was simplified from the extended-biophase distribution model to the one-compartment 
distribution model. The accuracy of the parameter estimates did not improve and 
therefore, it was concluded that the simplest model, the one-compartment model was 
most appropriate to describe the biophase distribution kinetics of nalbuphine. In 
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addition, asymmetrical distribution could not be identified for nalbuphine and the 
estimated k1e (and keo) value was 0.20 min-1.
PK-PD analysis
The differences in intrinsic activity were shown by the PK-PD analysis with the 
empirical Hill equation.  Alfentanil, fentanyl and sufentanil behaved as high efficacy 
agonists and all displayed the same intrinsic activity of around 100 μV, although 
the intrinsic activity of fentanyl was slightly lower (78 μV). Morphine, butorphanol 
and nalbuphine had an intrinsic activity of 45, 18 and 57 μV, respectively, and could 
therefore be classified as low efficacy agonists. Only small differences were observed 
in parameter estimates when compared to the paper by Cox and co-workers (1998) 
indicating that estimation of the inter-animal variability in the population approach 
and the difference in the pharmacokinetic model for alfentanil does not significantly 
influence the outcome of the PK-PD modelling. Furthermore, it should be mentioned 
that the estimation of the pharmacodynamic parameters of butorphanol was difficult, 
because the changes in EEG amplitude were only marginal compared to the baseline 
EEG taking into consideration the noise in the EEG signal. This is reflected in the inter-
animal variability for the intrinsic activity of butorphanol. For all the opioids this value 
is around 0.1 whereas for butorphanol this value is 0.73 suggesting that the model has 
difficulties estimating the intrinsic activity. The EEG effects of butorphanol have the 
lowest intrinsic activity and the estimate for the Hill factor of 4.1 suggests an on-off 
response.
In vitro transport characteristics and QSAR modelling
In vitro studies were performed to investigate the contribution of Pgp and Papp in 
transport to the effect site. Morphine and nalbuphine were identified as Pgp substrates 
whereas for the other opioids, alfentanil, fentanyl, sufentanil and butorphanol, no 
Pgp-mediated transport was identified. The results were in accordance with literature 
(Wandel et al.  2002). Furthermore, it was shown that the Papp in the presence of GF120918 
of alfentanil, fentanyl, sufentanil and butorphanol (> 500 nm/sec) was much higher 
compared to nalbuphine (156 nm/sec) and in particular for morphine with a calculated 
Papp of only 16 nm/sec. The Papp values of <50, 50-250, >250 nm/sec were considered 
as low, moderate and high, respectively. These results indicate that transport to the 
biophase will not be rate-limiting for alfentanil, fentanyl, sufentanil and butorphanol, 
due to their very high passive permeabilities, while it should be taken into account for 
nalbuphine and especially morphine. 
For the opioids, to investigate the predictability of the in vivo results based on in vitro and 
in silico data, a regression analysis was performed to specifically test the correlations 
between the in vivo k1e and the in vitro Papp and that between the in vivo k1e and the 
physico-chemical properties as determined in silico. The physicochemical properties 
that were investigated are cLogP, logBB and PSA. cLogP is a measure for lipophilicity 
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of the compound, logBB is a prediction of the transport characteristics across the BBB, 
whereas PSA represent the area (size) of the compound. A significant correlation was 
found between the k1e and the passive permeability which could be described on the 
basis of: k1e = 0.13*logPapp – 0.09 (R2 = 0.83, P=0.03). No significant correlations could 
be identified between the k1e and the physico-chemical properties, although some 
trends were observed. Probably, the number of opioids was too limited and moreover 
these opioids could be divided into two structurally different groups (figure 1). It is 
therefore expected that the correlations will improve upon inclusion of more opioids. 
However, based on currently available data, it is concluded that in the in vitro Papp is a 
better predictor for the in vivo k1e than were the physico-chemical properties. However, 
it should be taken into consideration that processes other the BBB transport, such as 
distribution within the brain, can also have an impact on the biophase distribution 
kinetics (Liu et al. 2005).
It is concluded that within the wide range of opioids used in this study, only morphine 
displays complex biophase distribution kinetics, which can be explained by its relatively 
low passive permeability and the interaction with active transporters at the blood-brain 
barrier.
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The objective of the current study was to identify the operational model of agonism 
for the EEG effects of opioids. Unbound biophase concentration-EEG effect relation-
ships of the opioids alfentanil, fentanyl, sufentanil, morphine, butorphanol and nalbu-
phine were simultaneously analysed with a) the Hill equation and b) the operational 
model of agonism.  
Individual concentration-effect relationships were analysed with the Hill equation 
and showed that large differences in potency (EC50 range 0.22 – 1215 nM) and intrinsic 
efficacy (α range 0.11 – 1). 
Subsequent analysis with the operational model of agonism was performed with the 
values of the system maximum Em (123 μV) and n (1.44) constrained to the values 
of alfentanil which displayed the highest intrinsic activity. The values of the in vivo 
affinity parameter pKA ranged from 5.64 (morphine) to 9.15 (sufentanil) and of the 
efficacy parameter log τ from 0.421 for alfentanil to -0.342 for nalbuphine. When the 
estimated in vivo pKA values were correlated with the in vitro pKi values, indications 
for two distinct subpopulations were obtained. In addition, a poor correlation was 
observed between the in vitro Na/GTP-shift and the in vivo log τ indicating that the in 
vitro efficacy measures cannot predict the in vivo EEG effect. These observations might 
be explained by 1) the involvement of active transport processes in distribution from 
blood to biophase, 2) the existence of μ-opioid receptor subtypes and 3) the interaction 
with other types of opioid receptors.
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INTRODUCTION
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models contain 
specific expressions for processes on the causal path between drug administration 
and effect. This includes expressions to describe a) the pharmacokinetics in blood or 
plasma, b) the biophase distribution kinetics, which for CNS-active drugs includes 
blood-brain barrier transport (BBB) transport, c) target binding and activation and 
d) transduction (Danhof et al. 2007). Recent investigations on the PK-PD correlations 
of opioids (alfentanil, fentanyl, sufentanil, morphine, butorphanol and nalbuphine) 
have focused on the role of biophase distribution kinetics as a determinant of the time 
course of the EEG effect as a biomarker for μ-opioid receptor activation. A number 
of structurally different biophase distribution models have been proposed and these 
models have been successfully applied to derive the biophase concentration-EEG effect 
relationships of this wide range of opioids (Groenendaal et al., 2007 – chapter 6, chapter 
7). It has been shown that particularly for morphine the functionality of transporters at 
the BBB is a major determinant of the time-course of the EEG effect as a biomarker of 
μ-opioid receptor activation (Groenendaal et al., 2007 – chapter 6).
The biophase concentration effect relationships of opioids have so far primarily been 
described on the basis of the sigmoidal Emax pharmacodynamic model (Hill equation). 
Moreover, an analysis of the relationship between the in vivo pharmacodynamic 
parameters and the in vitro receptor binding characteristics has not been accomplished. 
In this respect it is important that although the Hill equation is useful for descriptive 
purpose, it provides only limited insight in the factors that determine the shape and the 
location of the concentration-effect relationships (van der Graaf et al. 1997). Specifically, 
the potency (EC50) and intrinsic activity (Emax) are functions of both compound (i.e. target 
affinity, intrinsic efficacy) and system (i.e. receptor density and signal transduction) 
characteristics. To fully understand the in vivo concentration-effect relationships, more 
mechanistic modelling approaches are needed to describe target binding and activation 
processes, including a clear distinction between drug-specific and biological system-
specific properties (Danhof et al. 2005; 2007).
In the recent years, important progress has been made with the incorporation of 
receptor theory in PK-PD modelling for the prediction of in vivo concentration-effect 
relationships (van der Graaf & Danhof 1997b). Meanwhile, receptor theory has been 
successfully applied in the PK-PD analysis of adenosine A1 receptor agonists (van 
der Graaf et al. 1997; 1999) benzodiazepines (Tuk et al. 1999; 2003; Visser et al. 2001), 
neuroactive steroids (Visser et al. 2002) and 5-HT1A receptor agonists (Zuideveld et al. 
2004). For the adenosine A1 receptor agonists a good correlation was observed between 
the in vivo pKA and the in vitro pKi and also between the in vivo efficacy parameter τ 
and the in vitro GTP shift thus enabling the prediction of in vivo concentration-effect 
relationships. In addition, excellent in vitro-in vivo correlations have also been observed 
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for benzodiazepines and neuroactive steroids (Visser et al. 2002). In contrast, for the 5-
HT1A receptor agonists, despite a good correlation between in vivo efficacy parameter τ 
and the in vitro GTP shift, a rather poor correlation was found between the in vivo pKA 
and the in vitro pKi. This could in part be explained by complexities at the level of blood-
brain distribution (Zuideveld et al. 2004). 
So far, limited progress has been made with the incorporation of receptor theory in 
mechanism-based PK-PD models of opioids. For the opioids alfentanil, fentanyl and 
sufentanil, it has been shown by simulation that the concentration-effect relationships 
could be explained by the operational model of agonism under the assumption 
of a considerable receptor reserve (Cox et al. 1998). Moreover, after pre-treatment 
with the irreversible μ-opioid receptor antagonist β-funaltrexamine, a shift in the 
concentration-effect relationship of alfentanil was observed, which is consistent with 
the 40-60% reduction in the number of specific μ-opioid binding sites as shown in an 
in vitro receptor bioassay (Garrido et al. 2000). However, despite these efforts, a formal 
incorporation of receptor theory in a mechanism-based PK-PD model of opioids has not 
been accomplished. Complexities at the level of biophase distribution are presumably 
kinetics were an important factor in this respect. 
The objective of the current study was to simultaneously analyse the biophase 
concentration-effect relationships of six opioids (alfentanil, fentanyl, sufentanil, 
butorphanol and nalbuphine), as obtained in a previous investigation (chapter 7), 
with the operational model of agonism. The relationships between the values of the 
drug-specific parameters receptor affinity (KA) and intrinsic efficacy (τ), as determined 
with the operational model of agonism, and the estimates of the receptor affinity and 
intrinsic efficacy, as determined in an in vitro binding assay, are also analysed.
MATERIALS AND METHODS
In vivo PK-PD experiments
The details of the PK-PD experiments have been described previously (chapter 7). 
Briefly, these studies were conducted in male Wistar rats (Charles River, Maastricht, 
The Netherlands) weighing between 250 and 300 grams. Nine days prior to the 
experiments, seven cortical electrodes were implanted for continuous EEG monitoring. 
In addition, three/four indwelling cannulas were implanted, one in the right femoral 
artery for collection of serial blood samples and two in the left jugular vein (interna and 
externa) for opioid and midazolam administration. The fourth cannula was implanted 
into the right femoral vein to administer vecuronium bromide which was only required 
for the experiments with alfentanil, fentanyl, sufentanil and morphine. At the day 
of the experiments, after recording of the EEG baseline, the opioids or saline were 
administered in a zero-order infusion. The EEG signals were recorded up to a maximum 
of 360 minutes after start of the opioid infusions. An overview of the experimental 
groups is shown in table 1. During and after the infusion of the opioids, arterial blood 
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samples were collected to monitor arterial pH, pO2 and pCO2 levels. During and after 
administration of 40 mg/kg morphine, alfentanil, fentanyl and sufentanil, artificial 
ventilated was required to maintain arterial blood gas values within physiological 
limits. For determination of drug concentrations, serial arterial blood samples were 
collected at predetermined time intervals and immediately haemolysed with 0.5 ml of 
millipore water and stored at –20 °C pending analysis with gas chromatography (Cox 
et al. 1997), radio-immunoassay (Cox et al. 1998) or HPLC coupled to electrochemical 
detection (Groenendaal et al. 2005 – chapter 3). Changes in the amplitudes in the δ-
frequency band of the EEG (0.5-4.5 Hz) averaged over 1-minute time intervals were used 
as a pharmacodynamic endpoint. Further reduction of the EEG data was performed by 
averaging the signals over predetermined time intervals.
Protein binding
Protein binding of morphine, nalbuphine and butorphanol was determined ex 
vivo, whereas for alfentanil, fentanyl and sufentanil literature values were used 
(Meuldermans et al.1982). For determination of the degree of plasma protein binding, 
blood samples were collected and incubated with morphine, nalbuphine or butorphanol 
for 1 hour at 37 °C. The concentrations were 100, 1000 and 5000 ng/ml for nalbuphine 
and butorphanol and 250, 2500 and 25000 ng/ml for morphine. Blood was centrifuged 
and from the remaining plasma, the free fraction was isolated using ultra filtration 
(Centrifee, Millipore Corporation, Belford, MA).
Compound N Dose (mg/kg) Infusion time 
(min)
Body weight (kg)
Alfentanila 7 3.14 40 0.278 ± 0.005
Fentanyla 8 0.15 20 0.290 ± 0.012
Sufentanila 7 0.03 40 0.297 ± 0.006
Morphineb 24 4 10 0.297 ± 0.003
7 10 10 0.260 ± 0.006
18 40 10 0.298 ± 0.006
Butorphanolb 7 2.5 10 0.284 ± 0.006
6 5 10 0.260 ± 0.002
6 10 10 0.254 ± 0.004
Nalbuphineb 6 5 10 0.275 ± 0.009
9 10 10 0.273 ± 0.006
Salineb 6 n/a 10 0.290 ± 0.007
Table 1:	Experimental	design	of	the	studies	investigating	the	PK-PD	relationships	of	the	EEG	effects	of	opioids	
in rats.
aExperiments described previously by Cox et al. 1997
bExperiments described previously by Groenendaal et al. 2007c
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In vitro receptor binding assays
Brain homogenates were prepared according to the method of (Lohse et al.1984). Briefly, 
Wistar rat brains (minus cerebellum and corpus striatum) were collected in 0.32 M 
sucrose solution and homogenized at 25 °C. The suspension was centrifuged for 10 
minutes at 1000 rpm and the supernatant was collected. Next, the supernatant was 
centrifuged for 30 min at 31000 rpm at 4 °C and the remaining pellet was resuspended 
and centrifuged (15 minutes, 31000 rpm) twice in 50 mM Tris-HCl solution. The 
remaining pellet was resuspended in 20 ml Tris-HCl and aliquotted. The protein 
concentration in the stock-homogenate was 15 mg/ml, as determined with the Pierce 
Micro BCA assay (Pierce, Rockford, IL). Before the experiments, the brain homogenate 
was diluted to 1.5 mg/ml.
First, the μ-opioid receptor binding characteristics of the radioligand 3H-naloxone 
(Amersham, specific activity 63 Ci/mmol), Kd and Bmax, were determined in a saturation 
experiment. Brain aliquots of 100 μl were incubated with various concentrations (0.5 – 
12 nM) of 3H-naloxone at 25 °C. After 30 minutes, the incubation was stopped by adding 
1 ml 50 mM Tris-HCl buffer of 4 °C and the samples were filtered through a presoaked 
glass fiber filter (Whatman GF/B) and eluted six times using 3 ml 50 mM Tris-HCl buffer 
of 4 °C. The filters were submerged in 3.5 ml Packard Ultima Gold scintillation fluid and 
radioactivity was measured for 5 minutes by a Hewlett Packard Tri-Carb 1500 liquid 
scintillation counter. Non-specific binding was determined by calculating the binding 
of 3H-naloxone in the presence of 10-4 M fentanyl. Free radioligand concentrations were 
calculated by subtracting the non-specific binding from the total concentrations. In the 
displacement studies, the concentration of 3H-naloxone was equivalent to the Kd value 
as determined in the saturation experiments in the presence of buffer.
Secondly, the μ-opioid receptor binding was determined by displacement of 3H-
naloxone. Brain homogenate aliquots of 100 μl were incubated with 2.5 nM 3H-naloxone 
at various concentrations of the opioids (10-10 – 10-5 M). The experimental conditions 
were similar as described above with the exception of the number of elutions, which 
was three times in the displacement studies. 
To investigate the agonistic character of the opioids, the receptor affinity of the opioids 
and 3H-naloxone was determined in the presence of buffer, 100 mM NaCl or 1 mM GTP. 
Previously, it has been shown that the shift in Ki observed after incubation with a high 
concentration of sodium (100 mM) is a reflection of the agonist efficacy of the ligand 
(Pert & Snyder 1974). The sodium shift is expressed as the ratio between the Ki in the 
presence and absence of 100 mM NaCl. Another measure of efficacy is the GTP shift, 
which is ratio between the Ki in the presence and absence of 1 mM GTP (see (Kenakin 
1996)). In each experiment, the binding characteristics were determined in buffer, 100 
mM NaCl and 1 mM GTP to minimise inter-assay variability. All experiments were 
repeated three times and within an experiment duplicates were obtained.
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Data analysis
Both the blood pharmacokinetics and the EEG effects of the opioids were analysed 
using non-linear mixed effect modelling as implemented in the NONMEM software 
version V, level 1.1 (Beal & Sheiner 1999). Population analysis was undertaken using the 
first-order conditional estimation method (FOCE interaction). All fitting procedures 
were performed on an IBM-compatible computer (Pentium IV, 1500 MHz) running 
under Windows XP with the Fortran Compiler Compaq Visual Fortran version 6.1.
Blood pharmacokinetics and biophase distribution analysis
The population analyses of the blood pharmacokinetics and the biophase distribution 
kinetics of the various opioids have been described previously (chapter 7). Briefly, the 
pharmacokinetics of alfentanil, morphine and nalbuphine were best described with 
a three-compartment model whereas a two-compartment model best described the 
pharmacokinetics of fentanyl, sufentanil and butorphanol. The biophase distribution 
kinetics of morphine was best described with the extended-catenary biophase 
distribution model, while for the other opioids the one-compartment distribution was 
preferred. 
PK-PD analysis
The derived biophase concentrations were converted from ng/ml to nM and corrected 
for protein binding. The concentration effect relationships were then simultaneously 
analysed with the sigmoid Emax model (Hill equation) using the following equation:
where Emax is the maximum effect of the drug with highest intrinsic activity (alfentanil), 
while α is the fraction of the Emax that can be reached by the opioid other the alfentanil; 
for alfentanil α =1, EC50,u is the potency expressed as the unbound concentration, Ce,u is 
the unbound biophase concentration and nH is the Hill factor, describing the steepness 
of the concentration-effect relationships.
Inter-animal variability on Emax or nH (when applicable) was described with a additive 
error model according to equation:
with  
where Pi is the individual value of the model parameter P, Ptyp is the typical value 
(population value) of parameter P in the population, and hi is inter-animal random 
variable. 








Inter-animal variability was investigated for each parameter and was fixed to zero 
when the MVOF did not improve. Correlations between the inter-animal variability of 
the various parameters were graphically explored. In addition, correlations between 
the PD parameters and dose and between the PD parameters and the co-infusion of 
GF120918 were also investigated graphically.
The residual error, which accounts for unexplained errors (such as measurement and 
experimental errors) in the EEG measurements, was best described with an additive 
error model according to equation:
where Cobs,ij is the j-th observation of the i-th individual, Cpred,ij is the predicted 
concentration and eij is a realisation from the normally distributed residual random 
variable with mean zero and variance s2:
Next, the in vivo concentration-effect relationships were analysed according to the 
operational model of agonism (Black & Leff 1983):
where Em is the maximum effect achievable in the system, KA is the agonist dissociation 
equilibrium constant, n is the slope index for the occupancy-effect relationship and τ is 
the efficacy parameter. This efficacy parameter is expressed according to equation:
where R0 is the total number of available receptors in the biological system and KE is 
the concentration of the drug-receptor complex required to produce the half-maximal 
effect for that drug. 
Inter-animal variability on the parameters was described according to equations 2 and 
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equation:
where Cobs,ij is the j-th observation of the i-th individual, Cpred,ij is the predicted 
concentration and eij is a realisation from the normally distributed residual random 
variable with mean zero and variance s2:
In vitro receptor binding
The receptor binding characteristics of the radioligand 3H-naloxone and the opioids 
were analysed using the non-linear regression curve-fitting program GraphPad Prism, 
version IV (Graphpad Software Inc, San Diego, CA).The receptor binding characteristics 
of 3H-naloxone were determined by fitting the data, as obtained from the saturation 
experiments, to the following equation:
where B is the number of receptors occupied, Bmax is the total number of specific binding 
sites, Kd is the ligand concentration at which 50% of the receptors is occupied and Cf is 
the free ligand (3H-naloxone) concentration.
The IC50 values for the six opioids were determined by fitting the data, as obtained with 
the displacement experiments, to the following equation:
in which B0 is the specific binding for the radioligand in the absence of the displacer 
(opioid) and Cd is the concentration of the displacer added and IC50 is the opioid 
concentration that displaces 50% of the radioligand 3H-naloxone. The Ki values were 
calculated from the IC50 values according to the Cheng-Prusoff equation:
where L* is the concentration of 3H-naloxone and Kd* is the equilibration dissociation 









In vivo concentration-effect relationships
After administration of the opioids, a gradual increase in the delta frequency (0.5-4.5 
Hz) band of the EEG was observed (figure 1). 
Previously, the pharmacokinetics in blood and the biophase distribution kinetics have 
been investigated (chapter 7). The pharmacokinetics in blood of alfentanil, morphine 
and nalbuphine were best described with a three compartment model, whereas for 
fentanyl, sufentanil and butorphanol, a two-compartment model best described the 
pharmacokinetics in blood. The fraction unbound (mean ± SD) was 0.77 ± 0.01, 0.25 
± 0.06 and 0.097 ± 0.021 for morphine, nalbuphine and butorphanol, respectively. No 
differences were found between the different concentrations tested (data not shown). 
For alfentanil, fentanyl and sufentanil literature values of the fraction were used. These 
values were 0.164, 0.166 and 0.069 for alfentanil, fentanyl and sufentanil, respectively 
(Meuldermans et al. 1982). For all opioids except alfentanil and morphine, biophase 
distribution was best described with a one-compartment distribution model for all 
opioids except morphine. For morphine, the extended-catenary biophase distribution 
model was developed which consists of two sequential distribution compartments. 
The results of the simultaneous analysis of the unbound biophase concentration-effect 
relationships of all six opioids are shown in figure 2. Analysis with the Hill equation 
was performed on all individual concentration-effect data to provide estimates 
Figure 1:	EEG	amplitude	–time	profile	of	a	typical	rat	after	intravenous	administration	of	alfentanil	3.14	mg/kg	in	
40 min, fentanyl 0.15 mg/kg in 20 min, sufentanil 0.03 mg/kg in 40 min, morphine 4 (black circles), 10 (light gray 
triangles) and 40 (gray squares) mg/kg in 10 min, butorphanol 2.5 (black circles), 5 (light gray triangles) and 10 
(gray squares) mg/kg in 10 min, nalbuphine 5 (black circles) and10 (light gray triangles) mg/kg in 10 min and 
saline.
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(mean ± SEM and w2 for inter-animal variation) of the PD parameters including 
maximum achievable effect (Emax), the fraction of the Emax that can be reached by the 
opioid (α), the potency expressed as the unbound concentration (EC50,u) and the Hill 
factor (nH). The derived parameters are shown in table 2.  
Compound Emax (µv) F EC50u (nM) nH
Alfentanil 123±13 1 FIXED 136±29 1.44±0.16
-878 -0.2 (--)
Sufentanil 0.81±0.10 0.21±0.03 2.06±0.26
(--) -0.21 (--)
Fentanyl 0.62±0.11 4.48±0.40 2.74±0.22
-0.06 -0.06 (--)
Morphine 0.36±0.05 1223±42 2.51±0.14
-0.09 (--) (--)
Nalbuphine 0.16±0.03 141±4 3.34±0.43
-0.13 -0.13 (--)
Butorphanol 0.10±0.03 54±10 3.97±0.59
-0.74 -0.33 (--)
Figure 2: Unbound biophase concentration-effect relationships for the effect on the delta-frequency (0.5-4.5 Hz) 
band of the EEG after intravenous infusion of the opioids alfentanil, fentanyl, sufentanil, morphine, butorphanol 







Between the opioids, large differences in intrinsic activity and potency were observed 
with values of α ranging from 1 (alfentanil) to 0.10 (butorphanol) and of EC50,u, ranging 
from 0.21 nM (sufentanil) to 1223 nM (morphine). 
Mechanism-based analysis: estimation of in vivo affinity and intrinsic efficacy at the 
µ-opioid receptor
Individual unbound biophase concentration-effect relationships for all agonists, as 
obtained by the analysis with the Hill equation, were simultaneously analysed on the 
basis of the operational model of agonism according to the comparative method with 
n = 1.44 and Emax = 123 ± 13 μV. The in vivo pKA of sufentanil was fixed to the in vitro 
pKi value in the presence of 100 mM NaCl or in the presence of 1 mM GTP.  Only 
small differences were observed between the analyses, but the parameter estimation 
was more precise when the in vitro pKi of sufentanil in the presence of 100 mM NaCl 
was constrained.  The estimates of in vivo affinity (pKA) and efficacy (log τ) are shown 
in table 3. The pKA ranged from 5.64 (morphine) to 9.15 (sufentanil) and of the log τ from 
0.421 (alfentanil) to -0.342 (nalbuphine).
In vitro receptor binding assays
The results of the binding assays are shown in table 4. In buffer, the receptor affinity 
for the μ-opioid receptor ranged from 0.09 nM for sufentanil to 5.84 nM for alfentanil. 
In the presence of either 100 mM NaCl or 1 mM GTP, the receptor affinity of the opioids 
decreased substantially. As a measure of intrinsic efficacy, both the Na-shift and the 
GTP-shift were calculated. In the presence of Na, alfentanil showed the highest efficacy, 
whereas in the presence of GTP, fentanyl had the highest agonist character. The sodium-
shift ranged from 22 (alfentanil) to 3.8 (morphine) and the GTP-shift ranged from 11. 
(fentanyl) to 2.4 (butorphanol).
Compound pKA Log t
Alfentanil 6.42 ± 0.23 0.421 ± 0.215
Sufentanil 9.15	* 0.393 ± 0.060
Fentanyl 7.81 ± 0.14 0.296 ± 0.177
Morphine 5.64 ± 0.06 -0.064 ± 0.058
Nalbuphine 6.73 ± 0.09 -0.342 ± 0.073
Butorphanol 7.25 ± 0.22 -0.326 ± 0.165
Table 3: Estimates of pKA, log t and EC50,u as derived from simultaneous analysis with the operational model of 
agonism. Results are presented as mean ± SE
* pKA of sufentanil has been fixed to the pKi value in the presence of 100 mM NaCl as obtained in in vitro receptor 
bindings assay
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In vitro – in vivo correlations
When the estimated in vivo pKA values were correlated with the in vitro pKi values, 
evidence for two distinct subpopulations was obtained.  Figure 3 shows the correlation 
between the apparent in vivo pKA estimates with the pKi values found in vitro in the 
presence of either 1 mM GTP (left panel) or 100 mM NaCl (right panel). When taking all 
data together, no statistically significant correlation between the in vivo pKA and the in 
vitro pKi values was obtained. On contrast, for the subset containing alfentanil, fentanyl 
and sufentanil highly significant correlations were obtained. These correlations could 
be best described by pKA = 1.3096*pKi – 2.7991 (R2 = 0.9584, P = 0.131) and by pKA = 
1.1911*pKi – 1.681 (R2 = 0.9873, P = 0.072) for 1 mM GTP and 100 mM NaCl, respectively. 
In addition, for the second set containing morphine, butorphanol and nalbuphine the 
correlation for 1 mM GTP could be best described by pKA = 1.1231*pKi – 2.7064 (R2 = 
0.8932, P = 0.211), whereas for 100 mM NaCl the correlation was best described by pKA 
= 1.6264*pKi – 6.8076 (R2 = 0.9925, P = 0.055). For alfentanil, fentanyl and sufentanil the 
correlation between the in vivo pKA and the in vitro pKi in the presence of 100 mM NaCl 
was closest to the line of unity. In general, for morphine, butorphanol and nalbuphine 
a rightward shift was observed compared to the line of unity.
Compound Ki (nM) Ki +Na (nM) Ki +GTP (nM) Na-shift GTP-shift
Alfentanil 5.84 ± 1.69 129.27 ± 32.59 59.88 ± 12.30 22 10
Sufentanil 0.09 ± 0.01 0.70 ± 0.22 0.43 ± 0.22 7.7 4.8
Fentanyl 1.28 ± 0.46 15.13 ± 5.57 14.36 ± 4.54 12 11
Morphine 5.55 ± 1.38 21.22 ± 6.89 25.14 ± 10.33 3.8 4.5
Nalbuphine 0.67 ± 0.20 5.33 ± 0.74 7.44 ± 1.04 7.9 11
Butorphanol 0.45 ± 0.12 2.12 ± 0.78 1.07 ± 0.44 4.7 2.4
Table 4: In vitro receptor binding characteristics as obtained in the displacement studies. Results are presented 
as mean ± SEM
Figure 3: Relationship between the apparent in vivo pKa estimates for the EEG effect of opioids and the in vitro 
pKi values for the opioids in the presence of 1mM GTP (left panel) or 100 mM NaCl (right panel). The dashed line 




Figure 4 depicts the relationship between in vivo measure for efficacy log τ and the in 
vitro efficacy parameter GTP-shift (left panel) and Na-shift (right panel). No statistically 
significant relationship between the in vivo efficacy parameter log τ and the in vitro 
efficacy measures was observed (P > 0.1). When describing the correlations between the 
two parameters with the equation pKA = a*pKi + b, the correlation between log τ and 
Na-shift was R2 = 0.4096 (P = 0.171), while the correlation was R2 = 0.1332 between log τ 
and GTP-shift (P = 0.478).
DISCUSSION 
The objective of the current study was to develop a mechanism-based pharmacodynamic 
model for the characterisation of the biophase concentration-EEG effect relationships of 
opioids. To this end, the unbound biophase concentration-effect relationships of a series 
of opioids which consisted of alfentanil, fentanyl, sufentanil, morphine, butorphanol 
and nalbuphine were simultaneously analysed with both the empirical sigmoid Emax 
model and the mechanistic operational model of agonism. The values of the parameters 
obtained with the operational model of agonism, characterizing the in vivo affinity 
(pKA) and intrinsic efficacy (log τ) were compared with the estimates of the receptor 
affinity and intrinsic efficacy as determined in in vitro binding assays. 
An important feature of this investigation was that the in vivo biophase concentration-
EEG effect relationships have been determined using previously developed biophase 
distribution models (chapter 7). For morphine it has been demonstrated that the 
biophase distribution kinetics is best described with an extended-catenary biophase 
distribution model consisting of a transfer and an effect compartment model. In contrast, 
the biophase distribution kinetics of fentanyl, sufentanil, butorphanol and nalbuphine 
were best described with the effect-compartment model, whereas for alfentanil a direct 
relationship was observed between blood concentrations and EEG-effect.
In the current investigations, EEG monitoring was used as a pharmacodynamic endpoint. 
Figure 4: Relationship between the in vivo	 logt	estimates	 for	 the	EEG	effect	of	opioids	and	 the	 in vitro GTP-
shift (left panel) and Na-shift (right panel). The solid line was obtained by linear regression. The compounds are 
depicted	with	the	first	letter	of	the	opioid	name.
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Quantitative analysis of drug effects on the electroencephalogram (EEG) yields an 
attractive biomarker, which is continuous, sensitive and reproducible (Dingemanse et 
al. 1988). It has been shown that the synthetic opioid alfentanil, which is frequently used 
in anesthesia produces a progressive slowing of the EEG with a pre-dominant increase 
in the delta frequency band (0.5-4.5 Hz) of the EEG power spectrum in both animals 
(Cox et al. 1997; Mandema & Wada 1995; Wauquier et al. 1988; Young & Khazan 1984) and 
humans (Scott et al. 1985; Wauquier et al. 1984; Young & Khazan 1984). Meanwhile the 
increase in the delta frequency band of the EEG has been widely used as a biomarker in 
numerous studies on the PK-PD correlations of synthetic opioids. In preclinical studies 
evidence has been obtained that the increase in the delta frequency band of the EEG 
reflect μ-opioid receptor activation (Cox et al. 1997; 1998; 1999). However, it remains to be 
elucidated whether changes in the delta frequency band are solely caused by μ-opioid 
receptor activation.
Simultaneous PK-PD analysis with the Hill equation showed that alfentanil had the 
highest intrinsic activity (123 ± 13 μV). This analysis was performed in order to enable 
a ranking in intrinsic activity for the set of opioids. This fraction (α) ranged from 0.81 
to 0.10 for sufentanil and butorphanol, respectively which corresponds to an Emax 
value of 100 μV for sufentanil and 12 μV for butorphanol. Previously, the biophase 
concentration-effect relationships have been investigated with the Hill equation for 
each opioid separately (chapter 7). The parameters derived from the simultaneous 
analysis are not distinctly different compared to the separate analysis except for the 
Emax of nalbuphine. In the separate analysis an Emax of 56 μV was found, whereas in the 
simultaneous analysis an Emax fraction of 0.16 was obtained, which corresponds to an 
Emax of 20 μV. A possible explanation for this difference is that with the simultaneous 
analysis one residual error is estimated whereas with the separate analysis a residual 
error is estimated for each compound. 
A limitation of the Hill equation is that, although very useful for descriptive purposes, 
it is only of limited value to understand factors which determine the shape and location 
of the concentration-effect relationship. Specifically, the pharmacodynamic parameters 
of the Hill equation are mixed parameters which depend on both the properties of the 
drug and the biological system (van der Graaf et al. 1997; 1997a). To fully understand 
the in vivo concentration-effect relationship, more mechanistic modeling approaches 
are needed to describe target binding and activation processes, including a clear 
distinction between drug-specific and biological system specific properties (Danhof et 
al. 2005; 2007). Recently, the operational model of agonism has been successfully applied 
for explaining and predicting the effects of differential expression of agonism in vivo 
(Black & Leff 1983; van der Graaf et al. 1997; Zuideveld et al. 2004). 
Previously, simulation on the basis of the operational model of agonism indicated that 
the μ-opioid receptor functions with high efficiency. As a result, the synthetic opioids 
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alfentanil, fentanyl and sufentanil were all found to behave as full agonists, which 
complicated identification of the operational model of agonism (van der Graaf et al. 1997; 
1997b). The simultaneous analysis of the six opioids with the Hill equation has shown 
that these compounds display a wide range in intrinsic efficacy and were therefore 
particularly useful for identification of the operational model of agonism.
For the analysis of the operational model of agonism, the comparative method (Black & 
Leff 1983; Leff et al. 1990; van der Graaf et al. 1997) was applied where Emax (123 μV) and 
n (1.44) were constraint to alfentanil which displays the highest intrinsic activity in vivo 
as proposed by Leff and co-workers. In addition, the pKA of sufentanil was fixed to the 
in vitro pKi (9.15), since this opioid displays the highest affinity. The constraint of the in 
vivo pKA to the in vitro pKi has been applied previously (Black & Leff 1983; Jonker et al. 
2005; van der Graaf et al. 1997; Zuideveld et al. 2004). When analyzing the concentration-
effect relationships of the opioids two subsets were seen in the efficacy parameter log 
τ which ranged from 0.3 to 0.4 for alfentanil, fentanyl and sufentanil and from -0.3 to 
-0.06 for morphine, nalbuphine and butorphanol. 
The in vitro Ki values of alfentanil, fentanyl and sufentanil were slightly lower 
compared to the results reported previously, whereas the values for the sodium shift 
were largely similar (Cox et al. 1998). The observed difference in binding affinity may 
be explained by differences in the method of membrane preparation and the source of 
the membranes. When using both the Na-shift and the GTP-shift as measures of the in 
vitro intrinsic efficacy, the opioids alfentanil, fentanyl, and nalbuphine displayed the 
highest efficacy. The GTP-shift ranged from 11 for fentanyl to 2.4 for butorphanol and 
the Na-shift ranged from 22 for alfentanil to 3.8 for morphine. Interestingly, nalbuphine 
showed a relatively high efficacy in both assays, whereas the effect in vivo is relatively 
small (Emax fraction 0.16 compared to alfentanil).
When taking all compounds together, the correlations between the in vivo pKA and 
the in vitro pKi determined in the presence of 1 mM GTP or 100 mM NaCl were not 
statistically significant (P>0.05). However, there were clear indications for two (sub-) 
populations of opioids. The estimated in vivo pKA for alfentanil, fentanyl and sufentanil 
were similar to the values obtained in vitro, whereas for morphine, butorphanol and 
nalbuphine, the pKA was higher. A possible explanation for this observation is the 
influence of complex biophase distribution processes with emphasis on interaction with 
transporters. Although analysis with the biophase distribution models has resulted 
in accurate biophase concentration- effect relationships, it could still be possible that 
interaction with active transporters influences the biophase concentration-time profiles 
and thereby the estimation of the pharmacodynamic parameters. The influence of 
active transport mechanisms as a confounder of the analysis of the in vitro-in vivo 
corrlations of pKA values has also been identified for 5-HT1A receptor agonists in 
particular with regard to flesinoxan (Zuideveld et al. 2004). No significant correlations 
between in vitro pKi and in vivo pKA were observed for a set of 5-HT1A receptor agonists 
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including flesinoxan. However, when flesinoxan was excluded from the analysis the 
correlation became statistically significant. Zuideveld and co-workers concluded that 
the in vivo pKA determined on the basis of blood concentrations was not representative 
for the flesinoxan concentrations at the site of the 5-HT1A receptor due to interaction 
with transporters at the BBB which had previously been shown by Van der Sandt and 
co-workers (2001). 
Another possible explanation for the existence of two sub-populations is the interaction 
with different μ-opioid receptor subtypes. After pre-treatment with β-FNA, the Hill 
factor of alfentanil is increased to 2.75 (Garrido et al. 2000). It has been speculated that 
antagonist-induced curve-steepening could be indicative for receptor heterogeneity 
(van der Graaf et al. 1996) and that the EEG effect of alfentanil is mediated via multiple 
receptor types which differ in their sensitivity to β-FNA (Garrido et al. 2000). Recently, 
alternative spliced μ-opioid receptor isoforms have been identified, which might be 
involved with different aspects of the pharmacology of alfentanil (Pasternak, 2005; 
Zernig et al. 1994). In addition, for the opioids morphine, butorphanol and nalbuphine it 
is known that they have affinity for both the μ- and κ-opioid receptor, whereas fentanyl 
is a specific μ-opioid receptor agonist  (Chen et al. 1993). In literature, little is known 
about the receptor affinity of alfentanil and sufentanil, but they have been specifically 
designed to bind exclusively to the μ-opioid receptor (Chen et al. 1988). Furthermore, 
it is known that heterodimerisation of opioid receptors can potentiate the effects of 
opioids (Gomes et al. 2000).
Finally, the correlation between the in vitro measures for efficacy, the GTP-shift and 
the Na-shift, and the in vivo log τ were poor. This indicates that the EEG effects of 
opioids are not determined by interaction with a single receptor system. For example, 
nalbuphine shows a relatively high efficacy in vitro (Na-shift = 7.94) whereas the in vivo 
efficacy is the lowest of the six opioids tested (log τ = -0.342). As mentioned above, 
nalbuphine has affinity for both μ- and κ-opioid receptors suggesting that interaction 
with both receptors determines the in vivo EEG effect. 
In conclusion, analysis with the operational model of agonism has provided insight 
into the complex process of receptor interaction in the EEG effect of opioids. Since many 
opioids have affinity for both the μ- and the κ-opioid receptor, the predictive value of 
the in vitro Ki at the μ-opioid receptor is of limited value.
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1. SCOPE OF THESIS AND GENERAL BACKGROUND
The objective of the research described in this thesis was to develop a mechanism-based 
pharmacokinetic-pharmacodynamic (PK-PD) model for the electro-encephalogram 
(EEG) effects of opioids. The central effects of opioids are determined by four main 
processes: (1) blood/plasma pharmacokinetics, (2) biophase distribution, which is 
largely determined by blood-brain barrier (BBB) transport, (3) kinetics of target binding 
and activation and (4) transduction (figure 1). 
Under the assumption that within a single species the transduction mechanisms are 
similar for all opioids, the focus of this thesis was on the role of biophase distribution 
kinetics and the kinetics of target binding and activation on the pharmacokinetic-
pharmacodynamic (PK-PD) relationships of opioids in the rat.
The opioids selected were alfentanil, fentanyl, sufentanil, morphine, butorphanol and 
nalbuphine because they differ widely in their brain distribution kinetics and efficacy.
Biophase distribution is considered to be a major determinant of the effects of opioids 
because they have to cross the blood-brain barrier (BBB) to enter the brain and to 
exert their central effect. Transport across the BBB can be a critical factor in the PK-PD 
relationships of opioids, since it determines the rate and extent of biophase distribution. 
For BBB transport, apart from restricted paracellular diffusion by the presence of tight 
junctions between the endothelial cells of the BBB, active transport mechanisms may 
play an important role, especially the efflux transport mediated by P-glycoprotein 
(Pgp).
In order to develop a mechanism-based PK-PD model, the influence of receptor binding 
and activation should also be considered. A distinction between affinity and intrinsic 
efficacy at the μ-opioid receptor can be made using concepts of receptor theory (i.e. the 
operational model of agonism).
In this chapter, the results of the investigations described in this thesis are reviewed 
and discussed. Furthermore, considerations and perspectives are presented.
Figure 1: Determinants of in vivo drug effects
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2. MECHANISMS OF BIOPHASE DISTRIBUTION IN VITRO
The membrane transport characteristics of opioids were investigated in vitro with 
the focus on the relative contribution of passive permeability and P-glycoprotein 
(Pgp)-mediated efflux. Such information was also present in literature for some of 
the opioids (Schinkel et al. 1995; 1996; Wandel et al. 2002). However, in the context of 
the development of mechanistic PK-PD models for opioids, it is important to have 
comparative data for Pgp interaction on the selected opioids, obtained in a single test 
system an using an identical experimental design. To this end, for all selected opioids, 
studies were conducted in an in vitro cell system using monolayers of either the MDCK:
MDR1 cells, which were transfected with the MDR1 gene encoding for human Pgp, 
or LLC-PK1:MDR1a cells, which were transfected with the MDR1a gene encoding for 
rodent Pgp. Moreover, unlike in previous studies, here the Pgp mediated transport 
relative to the passive membrane transport component was explicitely addressed. In 
these investigations, the passive permeability, as reflected by the Papp, of the different 
opioids was determined in the presence of a relatively high concentration of the potent 
and specific Pgp-blocker GF120918 (Hyafil et al. 1993).
2.1 Interaction with P-glycoprotein
The interaction of the opioids with Pgp was determined indirectly by investigating the 
inhibition of Pgp-mediated efflux of 3H-digoxin and directly by a substrate assessment 
study. In the latter study, the transport of opioids was determined in the presence and 
absence GF120918.
The 3H-digoxin inhibition studies showed that alfentanil, fentanyl, sufentanil, 
morphine and loperamide were able to reduce the efflux transport of 3H-digoxin. 
The fact that loperamide is a strong Pgp substrate and therefore does not cross the 
BBB is a quantifiable extent (Schinkel et al. 1996; Wandel et al. 2002) explains why this 
anti-diarrhoeal agent with an opioid-like structure and receptor pharmacology does 
not exert any opioid-like effect in vivo (DeHaven-Hudkins et al. 1999; Niemegeers et al. 
1979). 
In the substrate assessment studies only morphine and loperamide were identified as 
Pgp substrates. For alfentanil, fentanyl and sufentanil no Pgp mediated transport could 
be detected, which is in accordance with literature (Wandel et al. 2002). For nalbuphine, 
literature values were included (Mahar Doan et al. 2002) to calculate a Pgp substrate 
efflux ratio, since in the present study no quantifiable transport could be obtained at the 
concentration tested. A transport ratio of 2 was found, which indicates that nalbuphine 
is a substrate for Pgp, while no inhibition of Pgp mediated transport of 3H-digoxin by 
nalbuphine was found. This apparent contradiction might be explained by the existence 
of several Pgp binding sites (Martin et al. 2000).
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2.2 Apparent permeability and QSAR
From the Pgp substrate assessment data after pre-incubation with GF120918, the 
apparent passive permeability (Papp) could be calculated. It was shown that the Papp of 
alfentanil, fentanyl, sufentanil and butorphanol was high (>500 nm/sec) whereas for 
loperamide and nalbuphine the Papp was below 200 nm/sec. For morphine the lowest 
value of Papp (16 nm/sec) was observed. A schematic overview of the results of the in 
vitro transport studies is shown in table 1. It shows that the relative contributions of 
Pgp transport and passive permeability to the overall membrane transport were widely 
different between the opioids. Specifically, as a result of the high passive permeability, 
the relative contribution of Pgp-mediated transport to the overall transport of alfentanil, 
fentanyl and sufentanil are minimal. In contrast, for morphine, with a very low passive 
permeability, Pgp has a significant influence on the membrane transport of morphine, 
because the passive permeability is very low. This implicated the need for further in 
vivo BBB transport measurements in order to characterise the biophase distribution 
kinetics in the PK-PD relationships of morphine.
An interesting question is to what extent the passive permeability of opioids could 
be predicted on the basis of their physicochemical properties. To this end, regression 
analysis was performed to investigate the relationships between the physico-chemical 
properties and the Papp values. No statistically significant correlations were found in 
this analysis. This is in contrast with the results of an earlier study on the transport 
characteristics of adenosine A1 receptor agonists.  Here it has been found that the dynamic 
polar surface area (non-linear) and logBB as calculated by the Abraham equation (linear) 
were significantly related to the in vitro BBB clearance values of a set of 11 structurally 







Alfentanil + - Very high
Fentanyl ++ - Very high
Sufentanil ++ - Very high
Morphine +/- + Low
Butorphanol - - Very high
Nalbuphine - + Moderate
M3G - n.d. n.d.
M6G - n.d. n.d.
Loperamide ++ ++ moderate
Table 1: Results of the biophase distribution studies in vitro
Inhibition/Substrate: ++ strong, + moderate, +/- weak, - none
Permeability: very high > 400 nm/sec, high 250-400 nm/sec, moderate 50-250 nm/sec, low <50 nm/sec
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factor with the opioids tested here is that three clusters exist: four compounds with a 
very high passive permeability (alfentanil, fentanyl, sufentanil and butorphanol), two 
compounds with an intermediate permeability (nalbuphine and loperamide) and one 
with a low permeability (morphine).  It is therefore expected that the in silico-in vitro 
correlations may improve upon inclusion of more opioids representing a more equal 
distribution of passive permeabilities.
3. MODELLING OF THE BIOPHASE DISTRIBUTION KINETICS OF 
MORPHINE IN VIVO
For morphine, the role of biophase distribution kinetics in the PK-PD correlation 
was investigated using a novel combined EEG/microdialysis technique that allows 
simultaneous characterisation of both the brain extracellular fluid (ECF) distribution 
and the EEG effect. In these investigations a wide dose range was investigated (4 to 
40 mg/kg). The influence of Pgp was investigated by co-infusion of the Pgp blocker 
GF120918. In these investigations, the pharmacokinetics of morphine was investigated 
by non-linear mixed effect modelling (NONMEM). 
The pharmacokinetics of morphine in blood was best described by a three-compartment 
model, whereas in previous studies plasma pharmacokinetics was described with a two-
compartment model (Bouw et al., 2000; Tunblad et al., 2004). A possible explanation of this 
difference is that in the current investigations samples were collected for a much longer 
period of time (up to 350 minutes after the end of the infusion), whereas in previous 
studies samples were only collected up to 180 minutes. The blood pharmacokinetics of 
morphine was further shown to be independent of the dose administered. Moreover, co-
administration of GF120918 did not influence the blood pharmacokinetic parameters.
3.1 Non-linear brain distribution model
To study BBB transport characteristics, intracerebral microdialysis is a valuable tool, 
since its allows the determination of detailed profiles of the free drug concentrations 
in the ECF as a function of time, which can be related to the (free) concentration-time 
profile in blood. However, the dialysate concentrations do not directly equal the real 
extracellular fluid (ECF) concentrations, because of the existence of a constant flow 
of the perfusion fluid. This results in a recovery value below 100%. The recovery can 
be determined in vitro, but to account for periprobe tissue processes, the recovery of 
the microdialysis should also be determined in vivo (Bungay et al., 1990). For example, 
co-infusion of GF120918 can alter the elimination of morphine from the ECF and in 
addition, the in vivo recovery can also be changed by GF120918. It is therefore crucial the 
determine the in vivo recovery in the presence and absence of this Pgp efflux blocker.
For morphine, the in vivo recovery is typically determined using the retrodialysis-by-
drug method (Bouw et al. 2000; Hyafil et al. 1993; Tunblad et al. 2004). In the current 
investigation, the in vivo recovery was determined with the retro-DNNF method (Bouw 
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& Hammarlund-Udenaes, 1998; Olson & Justice, Jr., 1993) in order to obtain concentration- 
as well as time-dependent recovery values of morphine. The retro-DNNF method 
consists of a retrodialysis period before intravenous administration of morphine to 
determine whether the loss of morphine from the probe was concentration dependent 
or influenced by GF120918. These perfusion concentrations were maintained until the 
end of the experiment, according to the DNNF principle (Olson & Justice, Jr., 1993). In 
vivo recovery was calculated from the retrodialysis period, in order to determine time-
dependent values for in vivo recovery after iv administration of morphine. However, in 
contradiction to previous results for morphine in mice (Xie et al. 1999), in this case no 
conclusions could be drawn from the microdialysis data obtained for the DNNF rats 
after iv administration of morphine. Therefore these data were omitted from further 
analysis. 
Upon administration of morphine, a rapid increase in morphine concentrations in the 
brain ECF was observed. A non-linearity was observed between the two dose groups 
as reflected in a reduction of the dose normalized AUC with increasing dose (chapter 
5). Moreover,  for the 4 mg/kg dose group a characteristic relatively stable plateau of the 
morphine concentration was reached in the brain ECF which was not observed for the 
40 mg/kg dose group for which a clear decline was observed in time. To describe this 
non-linearity, a transport model was proposed which consisted of a passive diffusion, 
an active saturable influx and an active efflux component (figure 2). The active efflux 
was influenced by GF120918. This model is based on earlier indications for active uptake 
of morphine into the brain (Xie et al., 1999), simulations of the influence of different 
transport processes on the ECF concentration-time profiles (Hammarlund-Udenaes et 
al. 1997) and the models proposed by Upton and Geldof for the brain distribution of 
fluvoxamine (Upton et al. 2000; Xie et al. 1999; Geldof et al., 2007). The value of the passive 
diffusion rate constant was 0.0014 min-1 and the values of the active efflux rate constant 
were 0.0113 min-1 and 0.0195 min-1 in the presence and absence of GF120918, respectively. 
The active influx has a low capacity as indicated by the maximum transport rate of 0.66 
ng.min-1.ml-1 and was readily saturated at low concentrations of morphine (C50 = 9.9 ng/
ml).  The active influx was not influenced by GF120918. Interestingly, the active efflux 
component could not be blocked completely with GF120918 indicating that BBB efflux 
of morphine is also mediated by transporters other than Pgp. Tunblad and co-workers 
showed that morphine is also substrate for the probenecid-sensitive transporters at the 
BBB. Specifically, co-administration of probenecid was found to result in a decrease 
in efflux clearance of morphine from the brain (Tunblad et al. 2004). Taken together, it 
can be concluded that the distribution of morphine is dependent by multiple transport 
mechanisms.
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3.2 Biophase distribution model
In the current investigations, EEG monitoring was used as a pharmacodynamic endpoint. 
Quantitative analysis of drug effects on the electroencephalogram (EEG) yields an 
attractive biomarker, which is continuous, sensitive and reproducible (Dingemanse et 
al. 1988). It has been shown that the synthetic opioid alfentanil, which is frequently used 
in anesthesia produces a progressive slowing of the EEG with a pre-dominant increase 
in the delta frequency band (0.5-4.5 Hz) of the EEG power spectrum in both animals 
(Cox et al. 1997; Mandema & Wada 1995; Wauquier et al. 1988; Young & Khazan 1984) and 
humans (Scott et al. 1985; Wauquier et al. 1984; Young & Khazan 1984). Meanwhile the 
increase in the delta frequency band of the EEG has been widely used as a biomarker in 
numerous studies on the PK-PD correlations of synthetic opioids. In preclinical studies 
evidence has been obtained that the increase in the delta frequency band of the EEG 
reflect μ-opioid receptor activation (Cox et al. 1997; 1998; 1999). However, it remains to be 
elucidated whether changes in the delta frequency band are solely caused by μ-opioid 
receptor activation or whether more complex interactions at multiple receptor subtypes 
are involved.
After the start of the morphine infusion, a gradual increase in the EEG effect, expressed 
as the absolute amplitude in the 0.5-4.5 Hz frequency range, was observed. After the 
start of the morphine infusion, a gradual increase in the EEG effect was observed. The 
maximal effect was 60 μV and was observed around 20 minutes after the end of the 
morphine infusion. The duration of the effect (from the start of the infusion until the 




return to baseline values) was dependent on dose and co-infusion of GF120918 and 
around 180 minutes following the infusion of 4 and 10 mg/kg morphine whereas after 
a dose of 4 mg/kg combined with GF120918 or 40 mg/kg morphine the duration of 
the effect was around 360 minutes. It was found that the derived blood concentration-
EEG effect relationships showed profound hysteresis for all experimental groups. To 
describe this hysteresis, a biophase distribution model was developed. Initially, the 
biophase equilibration kinetics was fitted according to the one-compartment biophase 
distribution model. The utility of both a symmetrical (with identical values of the rate 
constants k1e and keo) and an asymmetrical (with different values for k1e and keo) effect 
compartment distribution model to describe the data was tested. However, neither the 
symmetrical nor the asymmetrical effect compartment model was able to estimate 
the biophase concentrations accurately. Therefore, the extended-catenary biophase 
distribution model was proposed, consisting of two sequential effect compartments; 
a transfer and an effect compartment (figure 2). The structure of this model is similar 
to the two-compartment “tank in series” model described by Upton and co-workers 
and provides a simple method to account for dispersion of drug in transit through 
the brain (Upton et al. 2000). The value of the rate constant for transport through the 
transfer compartment (k1e) was 0.038 min-1 and was unaffected by the co-administration 
of GF120918. The values for transport rate constants for the loss from the effect 
compartment (keo) in the presence and absence of GF120918 were 0.0015 min-1 and 0.043 
min-1, respectively. Interestingly, the observation of the involvement of Pgp-mediated 
efflux in the brain distribution of morphine as observed on the basis of the EEG effect 
is consistent with observations on the basis of the brain ECF concentrations as obtained 
with intracerebral microdialysis. 
3.3 Evaluation of the brain and biophase distribution models
In the investigations on the brain distribution kinetics and the PK-PD correlations, 
two structurally different models are proposed for characterization of the biophase 
distribution. The brain distribution model consisted of one brain ECF compartment with 
distinction between passive diffusion, active saturable influx and active efflux whereas 
the biophase distribution model consisted of two sequential biophase compartments 
with two rate constants for transport through the transfer compartment and efflux 
from the effect compartment . A schematic diagram of both models is shown in figure 2. 
When comparing the concentration-time profiles in brain ECF and biophase, it could 
be noted that they were distinctly different (figure 3). The concentration in brain ECF 
peaked early, whereas the maximum biophase concentration showed a profound 
delay. In addition, at the low dose of morphine a “plateau” was observed in brain ECF 
whereas in the biophase concentrations a clear decline over time was observed. These 
observations indicate that the brain ECF cannot be used to explain the hysteresis. This 
is in contrast with the observation by Bouw and co-workers where 85% of the observed 
hysteresis for the anti-nociceptive effect could be explained by distribution into the 
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brain ECF (2000). In addition, Bouw and co-workers did not identify the active uptake of 
morphine in the brain ECF. This indicates that the site of action for the anti-nociceptive 
effects is different from that for the EEG effect. 
A discrepancy between the predicted biophase concentration and the measured CNS 
concentration-time course has also been observed for the EEG effects of amobarbital and 
baclofen, where the biophase concentrations did not reflect the measured cerebrospinal 
fluid concentrations (Mandema et al. 1991; 1992). In addition, Chenel and co-workers 
showed that the extensive time delay between EEG effect and plasma concentrations of 
norfloxacin, best described with an effect-compartment model, could not be explained 
by slow distribution to the biophase (Chenel et al. 2004). For norfloxacin the brain ECF 
concentrations peaked very early, whereas the EEG effect was delayed, which was also 
seen for morphine. For norfloxacin the brain ECF profiles were parallel to the plasma 
profiles whereas for morphine a non-linearity was observed at the low dose (4 mg/kg). 
Chenel and co-workers showed that the keo did not decrease when the ECF data were 
included in the PK-PD analysis, whereas for morphine the brain ECF and EEG effects 
could not be analysed simultaneously.
A number of possibilities can explain these observations. First, from a pharmacokinetic 
perspective it may be that the biophase distribution of morphine is not mainly 
determined by BBB transport but also to a significant extent by distribution and 
elimination processes in relation to the regional distribution of the target (de Lange 
& Danhof 2002). The location of the microdialysis probe in the specific area of the 
brain, and the concentrations measured in that region, may differ from the biophase 
as determined by receptor density (Mansour et al. 1988). In addition, while the free 
concentrations in the brain ECF are quantified by intracerebral microdialysis, also 
intracellular concentrations of morphine may contribute to the EEG effects. 
Figure 3:	 Comparison	 of	 the	 population	 predicted	 biophase	 concentration-time	 profiles	 (black	 lines)	 and	 the	
population	predicted	brain	ECF	fluid	concentration-time	profiles	(grey	lines)	as	obtained	previously.	It	 is	shown	
that the time-course of the biophase concentrations differs substantially from the time-course of the brain ECF 
concentrations indicating that biophase distribution is slower than transport to the brain ECF.
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Alternatively, from a pharmacodynamic perspective, it could be that morphine does not 
exclusively exerts its EEG effects by binding to the μ-opioid receptor. It is known that 
morphine has affinity for both the μ and κ receptor (Chen et al. 1993; Kilpatrick & Smith 
2005; Ulens et al. 2001) and therefore it is possible that although the EEG is considered 
to be a biomarker for μ-opioid receptor activation, the other receptor subtypes can 
influence the EEG effect of morphine. 
In addition, the observed discrepancy could also be explained by the influence of 
receptor association-dissociation kinetics. Recently it has been shown that the onset 
and offset of the anti-nociceptive and respiratory depressant effects of buprenorphine 
are determined by both biophase distribution and receptor association-dissociation 
kinetics, although the major determinant was the biophase distribution kinetics 
(Yassen et al. 2005; 2006). Buprenorphine is an opioid which is structurally related to 
morphine and kinetics of binding to and dissociation from the μ-opioid receptor is 
slow (Boas & Villiger 1985; Cowan et al. 1977). In contrast, for fentanyl it was shown that 
the hysteresis could be completely explained by biophase distribution kinetics. Since 
buprenorphine is structurally related to morphine, it may be possible that receptor 
association-dissociation kinetics also influence the onset and offset of the EEG effect. 
Finally, transduction processes can also influence the time-course of the EEG effect. 
In the current investigations, the biophase concentration-effect relationships were 
described with the sigmoidal Emax model. However, in theory, the transduction function 
may take any shape. Depending on the behaviour of the drug in the biological system, a 
hyperbolic or linear transduction is chosen (Black & Leff 1983). The receptor theory by 
Clark states that for partial agonists, the pharmacological response is directly related to 
the number of receptors occupied (Clark 1937). So, when information is available in the 
in vivo receptor binding, a linear transduction function is able to describe the receptor 
occupancy-effect relationship.
4. PK-PD MODELLING OF THE EEG EFFECTS OF OPIOIDS
In addition to morphine, the EEG effects of the opioids alfentanil, fentanyl, sufentanil, 
nalbuphine and butorphanol have been investigated. The data for alfentanil, fentanyl 
and sufentanil have been collected and published previously (Cox et al. 1998). The blood 
pharmacokinetics of all opioids could be successfully described using population 
PK analysis. For fentanyl, sufentanil and butorphanol, a two-compartment model 
best described the data whereas for alfentanil, morphine and nalbuphine a three-
compartment model was most suitable.
4.1	Role	of	complex	biophase	distribution	kinetics
From the previous studies it can be concluded that the modelling of complex biophase 
distribution kinetics of opioids is important, given the potential interaction with active 
transporters and the wide range in lipophilicity. It was shown the biophase distribution 
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kinetics of morphine could be best described with the extended-catenary biophase 
distribution model which consists of two sequential compartments (chapter 6). To 
describe the time-course of the EEG effect of fentanyl, sufentanil, butorphanol and 
nalbuphine two structurally different biophase distribution models were investigated: 
1) the one-compartment biophase distribution model (the effect-compartment model) 
and 2) the extended-catenary biophase distribution model. For alfentanil, a direct 
relationship between the blood concentrations and the EEG effect was observed. 
For fentanyl, sufentanil and butorphanol, the one-compartment distribution model, 
with identical values of the distribution rate constants k1e and keo yielded the most 
accurate description of the pharmacodynamics. This was expected since the delay in 
pharmacodynamic effect was relatively short, as is confirmed by the k1e values of 0.47 
min-1, 0.17 min-1 and 0.21 min-1 for fentanyl, sufentanil and butorphanol, respectively. 
The biophase distribution kinetics of nalbuphine could be equally well described with 
both distribution models. However, since the accuracy of the parameter estimates did 
not change when the model was simplified from the extended-catenary to the one-
compartment distribution model, the latter model was accepted as the most appropriate 
model to describe the biophase distribution kinetics of nalbuphine. In addition, 
asymmetrical distribution could not be identified for nalbuphine and the estimated k1e 
(and keo) value was 0.20 min-1.
Interestingly, a statistically significant correlation was observed between the values 
of the in vivo k1e and the in vitro Papp as determined in the in vitro assays (chapter 4). 
However, it should be taken into consideration that for biophase distribution processes, 
apart from BBB transport, also distribution within the brain can influence the hysteresis 
(Liu et al. 2005). An important question is whether the estimates of the biophase 
concentrations that have been obtained with this PK-PD modelling approach indeed 
reflect the true biophase concentrations. In this respect, it is important that the role of 
active transporters at the BBB other than Pgp has not been taken into considerations. 
The findings on the effect of the Pgp blocker GF120918 on the biophase distribution and 
the EEG effect of morphine indicate that such an effect might be significant. Whether 
this also applies to the other opioids will be discussed in a subsequent paragraph. 
4.2	 Identification	of	the	kinetics	of	target	binding	and	activation
As the first step in the pharmacodynamic analysis, the unbound biophase concentration 
effect relationships were analysed with the Hill equation. This analysis showed that 
alfentanil is the opioid with the highest intrinsic activity (123 ± 13 μV). This analysis 
was performed in order to enable a ranking in intrinsic activity for the set of opioids. 
The relative intrinsic activity of the various opioids (α) ranged from 0.81 to 0.10 for 
sufentanil and butorphanol, respectively which corresponds to an Emax value of 100 μV 
for sufentanil and 12 μV for butorphanol. In addition, the EC50,u ranged from 0.21 nM for 
sufentanil to 1223 nM for morphine. Thus, a wide range of both Emax and EC50,u values 
was observed (figure 4). 
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A limitation of the Hill equation is that, although very useful for descriptive purposes, 
it is only of limited value to understand factors which determine the shape and location 
of the concentration-effect relationship. Specifically, the pharmacodynamic parameters 
of the Hill equation are mixed parameters which depend on both the properties of the 
drug and the biological system (van der Graaf et al. 1997; van der Graaf & Danhof 1997). 
As a result, observed values of the Emax may depend on the drug or the biological system. 
Moreover, values of the EC50 depend on both the target affinity and the intrinsic efficacy. 
Recently, the concepts of receptor theory have been used to make a strict distinction 
between drug-specific and biological-system specific factors as determinants of in vivo 
concentration-effect relationships. Especially, the operational model of agonism (Black 
& Leff 1983;) has been successfully applied for explaining and predicting the effects of 
differential expression of agonism in vivo (Black & Leff 1983; van der Graaf et al. 1997; 
Zuideveld et al. 2004). 
The comparative method (Black & Leff 1983; Leff et al. 1990; van der Graaf et al. 1997) 
was applied for analysis of the concentration-effect relationships by the operational 
model of agonism with the values of Emax (123 μV) and n (1.44) constrained to the values 
of alfentanil which displays the highest intrinsic activity in vivo. In addition, the pKA 
of sufentanil, as the opioid with the highest receptor affinity, was fixed to the in vitro 
pKi (9.15). The constraint of the in vivo pKA to the in vitro pKi has also been applied in 
previous analyses of concentration-effect relationships (Black & Leff 1983; Jonker et al. 
2005; van der Graaf et al. 1997; Zuideveld et al. 2004). When analyzing the concentration-
effect relationships of the opioids, the efficacy parameter τ ranged from 0.452 for 
nalbuphine to 2.618 for alfentanil. In addition, the KA ranged from 4.3*10-10 to 2.3*10-6 
M for sufentanil and morphine, indicating that large differences existed in the set of 
opioids. 
Figure 4: Unbound biophase concentration-EEG effect relationships of opioids as obtained by simultaneous 
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When taking all compounds together, the correlations between the in vivo pKA and the in 
vitro pKi determined in the presence of 1 mM GTP or 100 mM NaCl were not statistically 
significant (P>0.05). However, there were clear indications for two (sub-)populations of 
opioids. The estimated in vivo pKA for alfentanil, fentanyl and sufentanil were similar 
to the values obtained in vitro, whereas for morphine, butorphanol and nalbuphine, 
the pKa was higher. For these opioids, this may be explained by biophase distribution 
processes, including BBB transport, as has been specifically addressed for morphine. 
Another explanation may be that these opioids interact not only with a specific μ-opioid 
receptor subtype, but also with other μ, κ and δ-opioid receptor subtypes.
a) Biophase distribution processes
As discussed in section 3, for morphine it has been shown that biophase distribution is 
influenced by the functionality of Pgp at the BBB. Specifically, co-infusion of GF120918 
reduced the rate constant for efflux of morphine from the effect compartment with 
60%. As a result, in the absence of Pgp blockers the free drug concentrations in the 
brain ECF are substantially lower than the corresponding free blood concentrations. 
This could well explain the observed discrepancy between the in vitro and in vivo KA 
values. However, it is important to note that morphine is not only transported by Pgp, 
but also by other transporters like the probenecid-sensitive transporter which is also 
present at the BBB (Tunblad et al. 2004). The influence of active transport mechanisms 
as a confounder of the analysis of the in vitro-in vivo corrlations of pKA values has also 
been identified for 5-HT1A receptor agonists in particular with regard to flesinoxan 
(Zuideveld et al. 2004). In addition, regional differences in brain kinetics can also 
explains the differences between the local pharmacokinetic in the brain ECF and the 
overall kinetics responsible for the EEG effect.
b) Interaction with μ opioid receptor subtypes and κ and δ opioid receptors
Another possible explanation of the existence of two (sub-)populations is the interaction 
with different μ-opioid receptor subtypes or the interaction with κ and δ opioid receptors. 
Upon reducing the number of available μ-opioid receptors by irreversible binding by β-
funaltrexamine (β-FNA), it has been found that the Hill factor of alfentanil is increased 
to 2.75 (Garrido et al. 2000). It has been speculated that antagonist-induced curve-
steepening could be indicative for receptor heterogeneity (van der Graaf et al. 1996) and 
that the EEG effect of alfentanil is mediated via multiple receptor types which differ 
in their sensitivity to β-FNA (Garrido et al.,2000). Recently, several spliced μ-opioid 
receptor isoforms have been identified, which might be involved with different aspects 
of the pharmacology of opioids (Pasternak 2005; Zernig et al. 1994). Specifically, for the 
opioids morphine, butorphanol and nalbuphine it is known that they have affinity 
for both the μ- and κ-opioid receptor, whereas fentanyl is a specific μ-opioid receptor 
agonist (Chen et al. 1993). In literature, little is known about the receptor affinity of 
alfentanil and sufentanil, but they have been specifically designed to bind exclusively 
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to the μ-opioid receptor (Chen et al. 1993; Yeadon & Kitchen 1988). Furthermore, it is 
known that heterodimerisation of opioid receptors can potentiate the effects of opioids 
(Gomes et al. 2000).
5. CONCLUSIONS AND PERSPECTIVES
The objective of the research described in this thesis was to develop a PK-PD model 
for the EEG effects of opioids, to get insight into the mechanisms that determine the 
pharmacological effects of opioids. The results described in this thesis indicate that the 
major determinants of the EEG effects of opioids are biophase distribution processes 
and kinetics of target binding. This illustrates that the biophase distribution kinetics 
should be explicitly addressed in great detail as an integral part of the investigations 
into the pharmacodynamics of opioids.
Biophase distribution kinetics
In the current investigations, the biophase distribution kinetics has been studied 
with emphasis on BBB transport and the influence of Pgp. However, multiple (efflux) 
transporters are present at the BBB which could influence biophase distribution. 
These transporters include the multidrug resistance proteins (MRP) (Zhang et al. 2000) 
and other probenicid-sensitive transporters, which have shown to be involved in the 
transport of morphine and morphine-3-glucuronide (Tunblad et al. 2004; Xie et al. 2000). 
In addition, modelling of the BBB transport of morphine has revealed the influence of a 
yet unknown influx transporter (chapter 5). Active influx was also found for oxycodone 
(Bostrom et al. 2006). In addition, other yet unknown transporters could also play a 
role in the BBB transport of opioids. In order to be able to exclude the influence of such 
transporters a cocktail of different selective blockers could be administered in each 
experiment or single or multiple transporter knock-out animals (e.g. mdr1a/1b(-/-), 
mrp1(-/-) mice (Johnson et al. 2001)). As an alternative, detailed information on the brain 
concentrations should be obtained, for example including intracerebral microdialysis 
combined with EEG monitoring (chapter 5 and 6), though the location of the biophase 
does not need to be represented by that of the ECF surrounding the microdialysis probe 
as shown for morphine in relation to the EEG effect. 
Other in vivo techniques could be considered as well. For example, Positron Emission 
Tomography (PET) would be very useful to study the distribution of a (radio 
labelled) opioid across the brain thereby enabling detailed information on total brain 
concentration distribution of the radiolabel and its specific binding within the brain 
as a function of time and location. Recently, Liefaard and co-workers have established 
a population pharmacokinetic model to describe and predict these processes for 11C-
flumazenil (2005). Important disadvantages of PET are that it requires radioisotopes 
which are often instable resulting in a very short half-life and that it cannot distinguish 
between parent compound and metabolites. 
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Simultaneous analysis of biophase distribution and kinetics of target binding
Biophase distribution models were proposed for all opioids and biophase concentration-
effect relationships were derived. Subsequently, the estimated biophase concentration-
effect relationships were analysed according to the operational model of agonism to 
get insight into the kinetics of target binding and activation. As an alternative to this 
sequential approach, simultaneous analysis of the biophase distribution and kinetics 
of target binding could be performed. Recently, Yassen and co-workers have presented 
a mechanism-based PK-PD model that is based on receptor theory and aims at the 
separate characterisation of biophase distribution and receptor association/dissociation 
kinetics as determinants of hysteresis between plasma concentrations and effect 
(Yassen et al. 2005; 2006). It was shown that for the anti-nociceptive and respiratory 
depressant effects of opioids, reliable parameter estimates could be obtained for both 
biophase distribution and receptor association/dissociation. However, for fentanyl, no 
reasonable values could be obtained for the receptor association/dissociation kinetics, 
indicating that receptor binding for fentanyl is instantaneous and therefore does not 
contribute to the hysteresis. A prerequisite for this approach is that receptor binding is 
not instantaneous. On that basis it is expected that this approach cannot be applied for 
fentanyl-like opioids. Since buprenorphine is structurally related to morphine, it may 
be possible that receptor association-dissociation kinetics also influence the onset and 
offset of the EEG effect of morphine, butorphanol and nalbuphine.
Specificity of EEG as biomarker of μ-opioid receptor activation
In this thesis, EEG is used as a biomarker for μ-opioid receptor activation. EEG is an 
attractive biomarker because it can be monitored continuously. However, it remains to 
be elucidated whether changes in the δ-frequency band are solely caused by μ-opioid 
receptor activation. In order to investigate this, EEG experiments should be performed 
with specific agonists for the different receptor subtypes. A list of specific agonists and 
antagonists as derived from available literature is shown in table 2. See (Alexander et al. 
2000; Baker & Meert 2002; Chen et al. 1993) for additional references. 
Receptor subtype Agonists Antagonists







[dAla2]deltorphine I or II Naltriben (d2)
SNC80
Table 2: Selective agonists and antagonists for the different opioid receptor subtypes
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Influence of other μ-opioid receptor subtypes
It is known from literature that opioids bind to different opioid-receptor subtypes. First, 
the receptor binding characteristics at these receptor subtypes should be investigated 
in vitro using radioligand binding studies as described in section 3 of this discussion 
and by Chen and co-workers (1993). 
Next, the influence of the different receptor subtypes should be investigated by co-
administration of selective blockers for each receptor subtype (table 3). Recently, a 
study has been described which investigates the roles of peripheral and central μ, δ and 
κ receptors and their subtypes in opioid-induced hypothermia in mice (Baker & Meert 
2002). The effects of morphine and selective agonists for the opioid receptor subtypes, 
(fentanyl, SNC80, U50,488H and loperamide), on the body temperature were assessed 
directly. All selected opioids produced hypothermia, which was (partly) counteracted 
by a selection of receptor specific antagonist (naloxone, β-funaltrexamine, naloxonazine, 
naltrindole, BNTX, naltriben, nor-binaltorphine and DIPPA). For morphine and 
fentanyl, the hypothermia was shown to involve a composite action on μ, κ and possible 
δ receptors after initial activation. Such findings indicate that for the development of 
a mechanistic PK-PD model also the influence of the interaction between different 
receptor subtypes has to be considered.
Other pharmacodynamic end-points
In the current investigations, EEG was used as a pharmacodynamic endpoint. It has 
the advantages of being continuous and subjective. However, for opioids to produce 
changes in the EEG effect, relatively high concentrations are required, often resulting 
in the occurrence of respiratory depression. In addition, for example for buprenorphine, 
no clear effect on the EEG could be observed (Yassen, personal communication), while 
also for butorphanol and nalbuphine, the EEG effect was difficult to quantify. The high 
dose group of nalbuphine had to be excluded because of severe systemic side effects 
during and after the opioid infusion. Another disadvantage of EEG in rats is that it 
is a rather invasive technique involving the implantation of cortical electrodes. For 
research of opioids, antinociception is often used as a pharmacodynamic endpoint. 
Antinociception can be investigated using the tailflick latency test (Letrent et al. 1998; 
1999; Yassen et al. 2005) or the electrical stimulation-vocalisation test (Bouw et al. 2000; 
2001; Ekblom et al. 1993). Disadvantages of these tests are censoring of the data (values 
above cut-off value), possible interference between measurement and the limited 
number of observations that can be obtained in one animal. 
All opioids produce respiratory depression to some extent. Respiratory depression is 
often measured using arterial carbon dioxide tension (PACO2) as a surrogate biomarker 
of minute ventilation (Vi) (Megarbane et al. 2006; Ohtani et al. 1997). Recently, Yassen 
and co-workers have developed a more sensitive method in which minute ventilation 
is measured by whole body plethysmography at a fixed inspired CO2 concentration of 
6.5% (Yassen et al. 2006).
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Conclusions
The effects of opioids are mainly determined by biophase distribution kinetics and 
kinetics of target binding. For the development of a mechanism-based PK-PD model 
which also has predictive value, these processes should be investigated in great detail. 
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SAMENVATTING IN HET NEDERLANDS
1. ALGEMENE INLEIDING EN DOEL VAN HET ONDERZOEK
Het onderzoek in dit proefschrift heeft betrekking op de relaties tussen farmacokinetiek 
(PK) en farmacodynamiek (PD) van opiaten, met speciale aandacht voor de distributie 
vanuit het bloed naar de plaats van werking (de biofase) in het centrale zenuwstelsel 
en de interactie met de µ-opiaat receptor. In hoofdstuk 1 wordt een inleiding gegeven 
over de achtergronden van de PK-PD modellering in het algemeen en van opiaten in 
het bijzonder.
1.1 Farmacokinetisch-farmacodynamische modellering
Het doel van farmacokinetisch-farmacodynamische (PK-PD) modellering is de 
beschrijving en voorspelling van het tijdsverloop van geneesmiddel effecten in vivo in 
gezonde en zieke toestand. Klassieke PK-PD modellen bestaan uit drie componenten: 
1) een farmacokinetisch model, 2) een farmacodynamisch model en 3) een link model. 
Het farmacokinetische model beschrijft het verloop van de concentratie van het 
geneesmiddel in bloed/plasma in de tijd. In deze modellen wordt de farmacokinetiek 
vaak beschreven met hypothetische compartimentele modellen die de processen van 
absorptie, distributie en eliminatie nabootsen. Het farmacodynamische model beschrijft 
de relatie tussen de geschatte biofase concentratie en het farmacologische effect. Het 
meest bekende farmacodynamische model is het sigmoidale Emax model dat de relatie 
tussen concentratie en effect beschrijft met een s-vormige curve, de zogenaamde Hill 
vergelijking. Een beperking van dit model is dat het geen mechanistisch model is. Dat 
wil zeggen dat er geen onderscheid gemaakt wordt tussen stof-specifieke en systeem-
specifieke eigenschappen die de vorm en de ligging van de concentratie-werkingsrelatie 
bepalen. Het link model tenslotte wordt gebruikt voor het beschrijven van de vertraging 
tussen het verloop van de concentratie in bloed/plasma en het effect (hysterese). 
Hysterese wordt vaak beschreven op basis van distributie naar een hypothetisch 
effect-compartiment, waarbij de intensiteit van het effect wordt gerelateerd aan de 
concentratie in het hypothetische effect compartiment (de biofase). 
1.2 Mechanistische PK-PD modellering: onderscheid tussen de verschillende 
processen die het verloop van het farmacologische effect bepalen
Er is een duidelijke trend in de richting van de ontwikkeling van mechanistische PK-PD 
modellen waarbij onderscheid wordt gemaakt tussen de verschillende (deel-) processen 
die bepalend zijn voor het verloop van het farmacologische effect. Deze modellen 
bevatten beschrijvingen van 1) het verloop van de concentratie in bloed/plasma, 2) de 
biofase distributie, 3) de binding en activatie van het doeleiwit op de plaats van werking, 
4) de transductie en 5) de homeostatische terugkoppelings mechanismen. Het onderzoek 
dat in dit proefschrift wordt beschreven richt zich met name op 1) de rol van biofase 
distributie, dat de concentratie op de plaats van werking bepaalt, en 2) de beschrijving 




Biofase distributie is afhankelijk van de bloedperfusiesnelheid van het weefsel waarin 
zich het doeleiwit bevindt en weefseldistributie processen waarbij de laatste kunnen 
worden onderverdeeld in passieve diffusie en transporter-gemedieerd transport. Voor 
stoffen met een werking binnen het centrale zenuwstelsel, wordt de biofase distributie 
in belangrijke mate bepaald door het transport over de bloed-hersen barriere (BBB). 
De BBB bevindt zich in de wanden van de bloedvaten in de hersenen en onderscheidt 
zich van andere vaatwanden in het lichaam onder meer doordat de vaatwanden in 
de hersenen sterk vernauwde ruimtes hebben tussen aangrenzende vaatwandcellen. 
Dit maakt dat het transport van stoffen die niet over celmembranen kunnen 
diffunderen in hoge mate beperkt wordt. Daarnaast bezit de BBB een diversiteit aan 
actieve transporter-eiwitten waaronder P-glycoproteine (Pgp), een efflux-transporter 
die stoffen vanuit de hersenen terug naar het bloed pompt.  Experimenten in vitro, in 
cellijnen die getransfecteerd waren met het MDR1 gen, dat codeert voor het humane 
Pgp, hebben inzicht gegeven in de functionele rol van Pgp op het transport van veel 
stoffen. Daarnaast hebben in vivo studies waarin specifieke blokkers zijn toegediend, 
inzicht gegeven in de functionele rol van specifieke transporters bij de distributie 
naar de hersenen. Een gevoelige techniek om het transport naar de hersenen in vivo te 
kwantificeren is intracerebrale microdialyse. Hierbij wordt een microdialyse probe in 
een specifiek gedeelte van de hersenen geïmplanteerd. De probe wordt geperfuseerd 
met een artificiële extracellulaire vloeistof (ECF). Moleculen die klein genoeg zijn om 
het semi-permeabele membraan aan de punt van de probe te passeren, zullen de probe 
in diffunderen en worden meegenomen met de perfusiestroom. Vervolgens kunnen ex 
vivo fracties te worden opgevangen om geanalyseerd te worden. Op deze manier wordt 
een afspiegeling van de concentratie van de te meten stof in de hersen ECF verkregen.
Hersen en biofase distributie modellen
Wanneer het verloop van de concentratie in bloed/plasma en in de hersen ECF bepaald 
is, kan een farmacokinetisch model worden opgesteld waarmee het transport naar de 
hersenen beschreven kan worden en waarmee de invloed van transporters kan worden 
gekarakteriseerd. Op die manier kan inzicht worden verkregen in de mechanismen die 
bepalend zijn voor de distributie naar de plaats van werking.
Recent is deze benadering toegepast in PK-PD experimenten waarbij gelijktijdig 
de distributie naar de hersenen, met behulp van microdialyse, en de concentratie-
EEG effect relatie van het geneesmiddel norfloxacin zijn bepaald. Er werd hysterese 
waargenomen, die het beste beschreven kon worden met het effect-compartiment model. 
De waarde van de snelheidsconstante voor distributie naar het effect compartiment 
was verschillend van die voor de distributie over de BBB. Dit geeft aan dat de ECF 
concentratie niet representatief is voor de norfloxacin concentratie op de plaats van 
werking voor het EEG. Echter, voor morfine kon de hysterese die is waargenomen in het 
anti-nociceptieve effect voor 80% verklaard worden door het transport over de BBB. 
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1.3 PK-PD modellering van opiaten
Biofase distributie kinetiek van opiaten
Voor de PK-PD modellering van opiaten is het van belang de biofase distributie in detail 
te karakteriseren vanwege de sterk verschillende fysisch-chemische eigenschappen van 
de opiaten, alsook vanwege de mogelijke interactie met transporters op de BBB. In de 
literatuur zijn verschillende studies beschreven waarin de biofase distributie kinetiek 
van opiaten is bestudeerd in in vitro en in vivo modellen. Daarbij werd voor morfine 
en loperamide aangetoond dat Pgp een functionele rol speelt bij het transport over de 
BBB. Voor alfentanil en sufentanil werd geen interactie gevonden, terwijl voor fentanyl 
de resultaten niet eenduidig waren. De biofase distributie kinetiek van morfine en 
metabolieten is uitvoerig bestudeerd met behulp van intracerebrale microdialyse. PK-
PD studies hebben aangetoond dat onder invloed van de Pgp blokker GF120918 het 
anti-nociceptieve effect van morfine langer duurt door een langere halfwaardetijd in 
de hersenen.
EEG als biomarker voor receptor activatie
Om in PK-PD studies de biofase distributie kinetiek in detail te kunnen bestuderen is 
de keuze van het farmacodynamische eindpunt erg belangrijk. Electroencephalogram 
(EEG) metingen vormen bij uitstek een geschikt farmacodynamisch eindpunt omdat 
het een continu eindpunt is, het effect met hoge resolutie in de tijd kan worden gemeten 
en het effect zowel bij proefdieren als bij de mens kan worden gekwantificeerd. Opiaten 
laten een specifiek effect zien in de delta-band van het EEG; onder invloed van opiaten 
verandert het EEG van een signaal met hoge frequentie en lage amplitude naar een 
signaal met lage frequentie en hoge amplitude.
PK-PD modellering van de EEG effecten van opiaten
In eerdere studies zijn de EEG effecten van de synthetische opiaten alfentanil, fentanyl 
en sufentanil bestudeerd in ratten. Daarbij werd hysterese waargenomen voor fentanyl 
en sufentanil. Deze kon goed beschreven worden met het effect-compartiment 
model. Voor alfentanil werd een directe relatie tussen bloed concentratie en EEG 
effect waargenomen. De biofase concentratie-effect relatie van de drie opiaten kon 
gekarakteriseerd worden met het sigmoidale Emax model. Aanvullend is er ook 
mechanistisch onderzoek verricht naar de factoren die de vorm en de ligging van deze 
concentratie-effect relaties bepalen. Dit had vooral betrekking op de rol van receptor 
binding en activatie. De receptor bindingskarakteristieken werden bepaald met behulp 
van een in vitro model en de PK-PD relaties werden geanalyseerd op basis van het 
zogenaamde “operational model of agonism”. Dit leverde aanwijzingen op voor een 
aanzienlijke receptor reserve, wat inhoudt dat niet alle receptoren bezet hoeven te 
zijn om het maximale effect te bereiken. Dit werd bevestigd in studies naar de invloed 
van voorbehandeling met de irreversibele antagonist b-FNA, wat resulteert in een 
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afname van het aantal functionele receptoren (experimentele receptor “knock-down”). 
Voorbehandeling met  b-FNA resulteerde in een verschuiving van de concentratie-effect 
relatie naar hogere alfentanil concentraties met een gelijkblijvend maximaal effect. De 
verschuiving in de concentratie-effect relatie kwam overeen met een 40-60% afname in 
het aantal beschikbare receptoren.
1.4 Doel van het in dit proefschrift beschreven onderzoek
Het onderzoek in dit proefschrift heeft betrekking op de ontwikkeling van 
mechanistische PK-PD modellen voor de effecten van opiaten, met speciale aandacht 
voor 1) de distributie naar de plaats van werking in de hersenen en 2) de binding en 
activatie van de µ-opiaat receptor. Hiertoe werden de PK-PD relaties van een serie van 
opiaten met sterk verschillende fysisch-chemische en farmacologische eigenschappen 
onderzocht. De opiaten werden voornamelijk gekozen op basis van (partiële) agonistische 
eigenschappen op de µ-opiaat receptor. De veranderingen in de delta-frequentieband 
van het EEG werden gebruikt als farmacodynamisch eindpunt. De volgende opiaten 
zijn bestudeerd: alfentanil, fentanyl, sufentanil, morfine, nalbuphine en butorphanol.
2. KARAKTERISERING VAN DE ROL VAN BIOFASE DISTRIBUTIE
2.1	 Bepaling	 van	 morfine,	 nalbuphine	 en	 butorphanol	 concentraties	 in	 bloed	 en	
hersenmicrodialysaat monsters met behulp van HPLC
Om de PK-PD relaties van morfine, nalbuphine en butorphanol te kunnen karakteriseren 
werd een gevoelige HPLC methode ontwikkeld voor de bepaling van de concentratie 
in bloed en hersen microdialysaat monsters (hoofdstuk 3). Deze methode bestond uit 
een vloeistof-vloeistof extractie van de bloedmonsters met ethylacetaat. Voor de hersen-
microdialysaat monsters was geen monstervoorbewerking nodig. De (voorbewerkte) 
monsters werden geïnjecteerd op een HPLC systeem dat gekoppeld was aan een 
electrochemische detector.  De detectielimiet lag tussen 25 en 50 ng/ml voor de 
bloedmonsters en was 0.5 ng/ml voor morfine in microdialysaat. Voor de analyses kon 
worden volstaan met kleine monster volumina van rond de 50 µl wat de methode zeer 
geschikt maakt voor PK-PD studies in ratten.
2.2 Membraan transport van opiaten in vitro: invloed van P-glycoproteine en passieve 
permeabiliteit.
In hoofdstuk 4 wordt het onderzoek beschreven naar de relatieve bijdrage van het door 
het P-glycoproteine gemedieerde efflux transport en de passieve diffusie aan het totale 
membraan transport van opiaten. De experimenten werden uitgevoerd in MDCKII:
MDR1 en LLC-PK1:MDR1a cellen. Deze cellen zijn getransfecteerd met respectievelijk 
het humane MDR1 gen of het muizen MDR1a gen. De interactie van de opiaten met P-
glycoproteine werd zowel indirect, op basis van de inhibitie van de Pgp-gemedieerde 
efflux van 3H-digoxine,  als direct, op basis van het transport van het betreffende opiaat 
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in aan- en afwezigheid van de Pgp-blokker GF120918 bepaald. De passieve permeabiliteit 
van de opiaten werd bepaald in aanwezigheid van GF120918, waarmee de actieve efflux 
door Pgp werd geblokkeerd. De resultaten zoals verkregen met de digoxine assay lieten 
zien dat alfentanil, fentanyl, sufentanil, morfine en loperamide mogelijk substraten 
zijn voor Pgp omdat zij de actieve efflux van digoxine kunnen remmen. Echter, in de 
transport studies kon niet worden aangetoon dat alfentanil, fentanyl en sufentanil 
substraat zijn voor Pgp. Een mogelijke verklaring hiervoor is dat de bijdrage van Pgp-
gemedieerd transport aan het totale transport van deze opiaten niet significant is door 
de hoge passieve permeabiliteit (>500 nm/sec). Omgekeerd geldt dat Pgp transport een 
belangrijke invloed heeft op het totale BBB transport van morfine en loperamide omdat 
de passieve permeabiliteit van deze opiaten relatief laag is.
De relaties tussen de passieve permeabiliteit en de fysisch chemische eigenschappen 
(LogP, LogBBB, PSA) werden bestudeerd met regressie analyse. Er konden echter 
geen significante verbanden worden geïdentificeerd. Dit betekent dat de fysisch-
chemische eigenschappen geen voorspellende waarde hebben met betrekking tot de 
passieve permeabiliteit. In dit verband is het van belang dat slechts een beperkt aantal 
opiaten is bestudeerd en bovendien dat de bestudeerde opiaten, qua structuur, tot twee 
afzonderlijke groepen behoren. 
 2.3	 Populatie	pharmacokinetische	modellering	van	de	hersen	distributie	van	morfine:	
invloed	van	actieve	verzadigbare	influx	and	Pgp-gemedieerde	efflux
Voor morfine werd de rol van biofase distributie kinetiek bestudeerd in vivo in chronisch 
geïnstrumenteerde ratten. In deze ratten kan simultaan het verloop van de concentratie 
in de ECF en het EEG effect worden bestudeerd. Daartoe werden bij ratten vier corticale 
EEG electroden en een microdialyse probe geïmplanteerd. Voor de toediening van 
morfine, de Pgp blokker GF120918 (of het oplosmiddel) en midazolam en om bloed 
monsters af te kunnen nemen, werden vier permanente arteriële en veneuze cannules 
ingebracht. In elk experiment werd midazolam toegediend via een continu infuus om 
mogelijke opiaat-geïnduceerde convulsies te onderdrukken. In de verschillende studies 
varieerde de morfine dosering van 4 mg/kg tot 40 mg/kg. Om de invloed van Pgp te 
onderzoeken werd bij één serie van ratten ook GF120918 toegediend via een continu 
infuus. In hoofdstuk 5 lag de nadruk op het karakteriseren van het transport over de BBB 
en de invloed van Pgp hierop. De farmacokinetiek van morfine in bloed kon het beste 
beschreven worden met een drie-compartimenten model. De farmacokinetiek van de 
distributie naar de hersenen was niet-lineair over de verschillende doseringsgroepen. 
Bovendien werd een duidelijk effect van Pgp waargenomen. Om de distributie van 
morfine naar de hersenen te beschrijven werd een farmacokinetisch model opgesteld 
met verschillende wiskundige vergelijkingen voor het transport door passieve diffusie 
van en naar de hersenen, een verzadigbare actieve influx en een actieve efflux door Pgp. 
De actieve influx was al bij lage morfine concentraties verzadigd (C50 = 9.9 ng/ml). Er 
is op dit moment nog geen aanwijzing welke transporter betrokken is bij deze actieve 
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influx, maar in andere studies in mdr1a knock-out muizen is hetzelfde waargenomen. 
De actieve efflux door Pgp werd voor 42% geremd door GF120918. Deze resultaten 
laten zien dat de actieve efflux (voor een deel) via Pgp verloopt. Uit deze analyse kon 
geconcludeerd worden dat de kinetiek van distributie naar de hersenen van morfine 
complex is, wat belangrijke gevolgen kan hebben voor het karakteriseren van de PK-PD 
relaties.
2.4	 PK-PD	 modellering	 van	 de	 EEG	 effecten	 van	 morfine:	 invloed	 van	 biofase	
distributie en de interactie met Pgp.
In hoofdstuk 6 werd de invloed van biofase distributie en Pgp op de EEG effecten 
van morfine bestudeerd. Er werd een significante hysterese waargenomen tussen 
het verloop van de bloed concentraties en het verloop van het EEG effect in de tijd. 
Bovendien leidde toediening van GF120918 tot een sterke verlenging van de duur van 
het EEG effect. De hysterese kon niet beschreven worden met een eenvoudig effect 
compartiment model. Uiteindelijk werd een “extended catenary biophase distribution 
model” voor het EEG effect van morfine ontwikkeld. In dit model wordt de distributie 
van morfine van het bloed naar de plaats van werking in de hersenen beschreven op 
basis van twee in serie geschakelde compartimenten; een transfer compartiment en 
een effect compartiment. Daarbij worden twee snelheidsconstantes bepaald , k1e die de 
snelheid van het transport door het transfer compartiment beschrijft en de keo die de 
snelheid van het transport uit het effect compartiment beschrijft. Vervolgens werd de 
relatie tussen de geschatte concentraties in het effect compartiment en het EEG effect 
beschreven met het sigmoidale Emax model. 
Gelijktijdige toediening van GF120918 had alleen invloed op de keo. Deze waarneming 
is geheel in overeenstemming met de bevindingen in het hersendistributie model 
waar GF120918 ook alleen invloed had op de actieve efflux. In tegenstelling tot het 
hersendistributie model kon voor het extended catenary biophase distributie model 
geen actieve influx worden geïdentificeerd. Een opmerkelijke bevinding was verder 
dat de voorspelde biofase concentratie-tijd profielen duidelijk verschilden van de 
ECF concentratie-tijd profielen zoals bepaald met intracerebrale microdialyse. De 
maximale concentratie in ECF werd snel bereikt, terwijl een duidelijke vertraging werd 
waargenomen in de maximale biofase concentratie. Ook werd na toediening van een 
lage dosering van morfine in het ECF concentratie-tijd profiel een plateau waargenomen, 
terwijl dat voor de voorspelde biofase concentratie niet het geval was. Dit betekent 
dat bestudering van de hersendistributiekinetiek met behulp van intracerebrale 
microdialyse weliswaar belangrijke informatie kan opleveren over de mechanismen 
die de verdeling van morfine naar de plaats van werking in de hersenen bepalen, maar 
dat uiteindelijk geïntegreerde PK-PD studies nodig zijn om het concentratieverloop op 
de plaats van werking vast te stellen. 
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3.  PK-PD MODELLERING VAN DE EEG EFFECTEN VAN OPIATEN 
DIE VERSCHILLEN IN FYSISCH-CHEMISCHE EN FARMACOLOGISCHE 
EIGENSCHAPPEN
3.1	 De	rol	van	complexe	biofase	distributie	kinetiek
Het doel van het onderzoek dat wordt beschreven in dit deel van het proefschrift 
is gericht op de ontwikkeling van een mechanistisch PK-PD model voor opiaten. 
Daartoe werden de PK-PD relaties van de gehele set van opiaten, die onderling sterk 
verschillen in fysisch-chemische (lipofilie) en farmacologische (receptor affiniteit en 
intrinsieke effectiviteit) eigenschappen bestudeerd. De EEG effecten van de opiaten 
werden onderzocht in ratten waarbij corticale electrodes waren geïmplanteerd voor 
het monitoren van het EEG en permanente cannules voor de infusie van de opiaten, 
midazolam en vecuronium bromide en voor het afnemen van bloed monsters. Evenals 
in de studies met morfine, werd in alle ratten midazolam toegediend via een continue 
infusie om mogelijke opiaat geïnduceerde convulsies te onderdrukken. Na toediening 
van opiaten kan ademhalingsdepressie optreden. Bij toediening van alfentanil, 
fentanyl, sufentanil en de hoge dosering van morfine (40 mg/kg) moesten de ratten 
beademd worden, waarvoor toediening van de spierverslapper vecuronium bromide 
noodzakelijk was. Eerst werd de invloed van biofase distributie kinetiek in kaart 
gebracht (hoofdstuk 7). Met uitzondering van alfentanil werd voor alle opiaten een 
significante hysterese waargenomen tussen het verloop van de concentratie in bloed en 
het verloop van het EEG effect. Voor deze opiaten werden twee verschillende biofase 
distributie modellen getest om de hysterese te beschrijven, 1) het effect compartiment 
model  en 2) het extended-catenary biophase distributie model zoals beschreven voor 
morfine. Alleen voor morfine was het extended-catenary biophase distributie model 
het beste model wat erop duidt dat alleen morfine een complexe biofase kinetiek laat 
zien.
Regressie analyse liet zien dat er een relatie bestaat tussen de passieve permeabiliteit en 
de waarde van k1e, dat het transport naar het effect compartiment beschrijft.
3.2	 Identificatie	van	het	operational	model	of	agonism	voor	de	EEG	effecten	van	opiaten:	
schatting van de in vivo	affiniteit	en	intrinsieke	activiteit	op	de	µ-opioid	receptor
In hoofdstuk 8 werd de relatie tussen de in vivo concentratie-effect relatie en de interactie 
met de µ-opioid receptor onderzocht. De voorspelde biofase concentratie-effect relaties 
werden eerst simultaan geanalyseerd met het sigmoidaal Emax model. 
De analyse was uitgevoerd om de opiaten te rangschikken op de waarde voor intrinsieke 
activiteit (maximale effect). Alfentanil had de hoogste intrinsieke activiteit (123 ± 13 
µV). Voor de andere opiaten werd de intrinsieke activiteit uitgedruk als een fractie van 
alfentanil en deze fracties lagen tussen 0.81 en 0.10. Echter, om de in vivo concentratie-
effect relaties volledig te begrijpen zijn meer mechanistische modellen noodzakelijk. 
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Hierbij dienen zowel de binding aan de receptor als de daaropvolgende signaal 
transductie processen te worden meegenomen en zal een duidelijk onderscheid gemaakt 
moeten worden tussen specifieke eigenschappen van zowel de stof als het biologische 
systeem. Daarom werden de pharmacodynamische data verder geanalyseerd op basis 
van het “operational model of agonism”. Het daarin te gebruiken systeem maximum 
(oftewel het maximaal bereikbare effect in het biologische systeem) werd gelijk gesteld 
aan de intrinsieke activiteit van alfentanil, terwijl ook de helling van de concentratie-
effect relatie van alfentanil werd gebruikt. Op basis van het operational model of 
agonism werden grote verschillen gevonden tussen de opiaten in zowel in vivo affiniteit 
als intrinsieke effectiviteit. 
Het verband tussen de in vivo affiniteit (pKA) en de in vitro affiniteit (pKi) was een 
aanwijzing voor het bestaan van twee subgroepen binnen deze set van opiaten. Ook 
werd het verband tussen de in vivo effectiviteit (log τ) en de in vitro effectiviteit
(Na/GTP-shift) onderzocht, maar er werd voor deze set van opiaten geen duidelijk 
verband gevonden. Mogelijke verklaringen hiervoor zijn het bestaan van meerdere μ-
opiaat receptor subtypes en de mogelijke interactie van de opiaten met andere types 
opiaat receptoren.
4.  CONCLUSIES
Het doel van het onderzoek beschreven in dit proefschrift was om een PK-PD model te 
ontwikkelen voor de EEG effecten van opiaten, waarbij inzicht zou worden verkregen in 
de mechanismen die de farmacologische effecten van opiaten bepalen. Dit proefschrift 
laat zien dat zowel biofase distributie als receptor interactie van invloed zijn op deze 
PK-PD relaties. Om een mechanistisch model te ontwikkelen dat ook nog voorspellende 
waarde heeft, moeten deze processen in detail bestudeerd worden. Daarnaast zijn 
ondersteunende data (bijv in vitro bindings data) essentieel voor de validatie en 








αH2 Hydrogen bond acidity
A Area of the monolayer
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b→a	 Basolateral	to	apical
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Cd Concentration of the displacer added
CD(t), CR(t) Drug concentration in the donor/receiver chamber
Ce Effect-site concentration
Cecf ECF concentration
Cet Concentration in the transfer compartment
Cf Free ligand (3H-naloxone)	concentration
Cl Clearance of the drug from the body
(c)LogP	 (calculated)	octanol/water	patitioning	coefficient
Cmax	 Maximum	concentration
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k1e Rate constant for transport to the effect-site
KA Agonist dissociation equilibrium constant
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Aan het einde van lang promotietraject is mijn proefschrift dan eindelijk afgerond. 
Echter, dit was niet mogelijk geweest zonder de bijdragen van een groot aantal mensen 
die ik hier graag even wil noemen.
In de eerste plaats natuurlijk Jan Freijer. Eindeloze discussies hebben we gevoerd over 
de verschillende modellen, maar het resultaat mag er wezen. Ik heb er heel veel van 
geleerd en ben het modelleren echt leuk gaan vinden. En nu gaan we als collega’s 
gewoon verder met onze discussies.
Om de data te verkrijgen waren er een heleboel experimenten nodig, die ik op 
verschillende afdelingen heb uitgevoerd. Allereerst de EEG en microdialyse 
experimenten die zonder de expertise van Erika Tukker, Susanne Bos-van Maastricht 
en Pieter Looijmans niet mogelijk waren geweest. Ook mijn stagestudenten Andrea 
Rosier en Dennis de Mik hebben veel uurtjes doorgebracht bij de experimenten. Ik heb 
het erg leuk gevonden om samen met jullie aan het project te werken en hoop dat ik 
jullie wat heb kunnen leren.
During my research project, I have performed a series of in vitro experiments at 
GlaxoSmithKline, Drug Metabolism and Pharmacokinetics in Ware, United Kingdom, 
together with Dennis de Mik. I think we have made quite an impression there and it 
was a really good experience. I would especially like to mention Glynis Nicholls and 
Andy Ayrton who made it possible for me to do the research and guide me through the 
processes. But also the help of Nipa Shah and Caroline Brough with the cell-cultures 
and Rebecca Scott and Phil Deniff from the World-wide bioanalysis department with 
the analysis of all the samples is highly appreciated.
In mijn laatste jaar heb ik ook een serie in vitro experimenten uitgevoerd bij de afdeling 
farmacochemie van het LACDR onder begeleiding van professor IJzerman en Jacobien 
von Frijtag-Drabbe Kunzel. Jacobien, helaas kun je dit niet meer meemaken, maar 
zonder jou waren de experimenten nooit zo succesvol verlopen. Ik zal je nooit vergeten. 
Daarnaast ben ik professor IJzerman zeer erkentelijk dat mij de mogelijkheid geboden 
is om de experimenten uit te voeren. Al de verschillende technieken hebben mijn 
promotie juist zo aantrekkelijk gemaakt.
Maar natuurlijk mag ik mijn collega-aio’s ook niet vergeten, het was een echte 
vrouwenclub met Corine, Lia, Tamara, Dymphy, Paulien en Marian, af en toe echt een 
kippenhok, maar zo gezellig. Wat zullen jullie mannen, Hugo, Ashraf, Gijs, weleens 
gedacht hebben.
En dan mijn paranimfen, Margret en Paulien. Margret, zonder jouw steun en hulp had 
ik die HPLC allang het raam uitgegooid. Hoeveel monsters we samen we niet gemeten 
hebben?! Het heeft ook onze persoonlijke band sterk gemaakt en ben heel blij dat 
jij als paranimf aan mijn zijde wilt staan. Paulien, we zijn al vriendinnen vanaf het 
introductieweekend in Leiden en ook al was het soms lastig om collega’s te zijn, ik had 
het niet willen missen en ben blij dat ik ook nu weer op je steun kan rekenen.
Mijn vrienden en familie hebben mijn promotie van dichtbij meegemaakt. Ik ben niet 
altijd even sociaal geweest, maar jullie hadden altijd er altijd begrip voor en waren 
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altijd geïnteresseerd in hoe het ging. In het bijzonder wil ik graag mijn ouders, Bas 
en mijn schoonouders noemen die me altijd hebben gesteund en op wie ik altijd kon 
rekenen voor een luisterend oor. Roel, zonder jouw hulp had mijn proefschrift er nu 
niet zo mooi uitgezien. 
En tot slot, lieve Michiel, zonder jouw onvoorwaardelijke liefde, steun en hulp had ik 
het nooit gered. Hoe vaak ging je niet met me mee naar het lab om te pipetteren of 
moest je mijn frustraties aanhoren? Ik hoop dat ik voor jou nu hetzelfde kan doen. Een 






Dorien Groenendaal werd geboren op 11 april 1978 te Velsen. Na het behalen van 
het diploma Gymnasium in 1996 aan het Augustinus College te Beverwijk, begon zij 
de studie Bio-Farmaceutische Wetenschappen aan de Universiteit Leiden, waar zij 
in 1998 het propedeutisch diploma verkreeg. Tijdens de doctoraal fase heeft zij haar 
hoofdvakstage gedaan op de afdeling Farmacologie van het Leiden/Amsterdam Center 
for Drug Research, onder begeleiding van Dr. M.P. Schaddelee, Dr. A.G. de Boer en Prof. 
Dr. M. Danhof. Het verslag van het stage project was getiteld: The Blood-brain barrier 
transport of the adenosine A1 receptor agonists CPA, MCPA and 2’dCPA. Aansluitend 
volgde zij een tweede onderzoeksstage bij Pfizer Global Research and Development, 
Discovery Biology, Sexual Health Group te Sandwich, United Kingdom. Dit project 
werd begeleid door Dr. P.H. van der Graaf, Dr. C. Wayman and Prof. Dr. M. Danhof 
en het stageverslag was getiteld: In vitro studies to investigate novel targets for the 
treatment of Male Erectile Dysfunction. In december 2000 behaalde zij haar doctoraal 
diploma Bio-Farmaceutische Wetenschappen.
Van december 2000 tot en met juli 2005 was zij als assistent in opleiding verbonden 
aan de afdeling Farmacologie van het Leiden/Amsterdam Center for Drug Research 
onder begeleiding van Dr. E.C.M. de Lange en Prof. Dr. M. Danhof, alwaar het in dit 
proefschrift beschreven onderzoek werd uitgevoerd. In het kader van dit onderzoek 
werd samengewerkt met de afdeling Farmacochemie van het Leiden/Amsterdam Center 
for Drug Research en de afdelingen Drug Metabolism and Pharmacokinetics en Clinical 
Pharmacokinetics Neurology van GlaxoSmithKline in het Verenigd Koninkrijk.
Sinds augustus 2005 is zij werkzaam als Clinical Pharmacokineticist bij Astellas Pharma 







Groenendaal D,	 Freijer	 J,	Rosier	 A,	 de	Mik	D,	Nicholls	G,	Hersey	A,	 Ayrton	AD,	Danhof	M,	 de	 Lange	ECM	
(2007).	Pharmacokinetic-pharmacodynamic	modelling	of	the	EEG	effects	of	opioids:	the	role	of	complex	biophase	
distribution kinetics. Eur. J. Pharm. Sci., Submitted 
Groenendaal D,	Freijer	J,	de	Mik	D,	Bouw	MR,	Danhof	M,	de	Lange	ECM	(2007).	Population	pharmacokinetic	
modelling	 of	 non-linear	 brain	 distribution	 of	 morphine:	 influence	 of	 active	 saturable	 influx	 and	 P-glycoprotein	
mediated	efflux.	Br J Pharmacol.  515: 701-712
Groenendaal D,	Freijer	J,	de	Mik	D,	Bouw	MR,	Danhof	M,	de	Lange	ECM	(2007).		Influence	of	biophase	distribution	
and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the 
EEG. Br J Pharmacol. 515: 713-720
de	Lange	ECM,	Ravenstijn	PGM,	Groenendaal D, van Steeg TJ (2005).  Toward the prediction of CNS drug-effect 
profiles	in	physiological	and	pathological	conditions	using	microdialysis	and	mechanism-based	pharmacokinetic-
pharmacodynamic modeling. AAPS Journal 7: E532-E543
Groenendaal D, Blom-Roosemalen MC, Danhof M, de Lange ECM (2005). High-performance liquid 
chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application 
to pharmacokinetic/pharmacodynamic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 822: 230-
237
Schaddelee MP, Groenendaal D, DeJongh J, Cleypool CG, IJzerman AP, De Boer AG,
Danhof M (2004).  Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 
receptor agonists. J Pharmacol Exp Ther. 311: 1138-1146
Schaddelee MP, Voorwinden HL, Groenendaal D,	Hersey	A,	Ijzerman	AP,	Danhof	M,
De Boer AG (2003).  Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure 
transport relationships. Eur J Pharm Sci. 20: 347-356
240
